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SUMMARY 
 
Programmed cell death (PCD) is an intrinsically regulated cellular suicide 
process that can be categorized into apoptosis and necrosis based on their distinct 
morphological characteristics. Autophagy refers to an evolutionarily conserved 
process that sequesters and targets bulk cellular constituents for lysosomal 
degradation. Autophagy has been found to be implicated in regulation of PCD under 
various cellular settings. At present, the role of autophagy on PCD is highly 
controversial. Although autophagy generally serves as a cell survival mechanism 
under stress conditions such as starvation, there are reports showing that autophagy 
executes caspase-independent cell death, known as autophagic cell death. However, 
in many cases the evidence supporting autophagy as a cell death mechanism is 
frequently circumstantial and appears inadequate. zVAD, a pan-caspase inhibitor, has 
been shown to induce robust necrosis in L929 cells, and such necrosis has been 
reported as autophagic cell death. However, the molecular mechanism underlying 
such cell death has not been fully elucidated. Therefore, the main objective of this 
study is to investigate the regulatory role of autophagy in necrosis and to elucidate the 
underlying molecular mechanisms using in vitro mammalian cell models. The 
following investigations have been conducted: (i) examining the role of autophagy in 
zVAD-induced necrosis by modulation of autophagy via either pharmacological or 
genetic approaches; (ii) studying the regulatory role of class I PI3K-Akt-mTOR 
signaling axis in modulation of autophagy and necrosis; and (iii) elucidating the 
molecular mechanism underlying zVAD-induced necrosis.  
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In this study, we first demonstrated that autophagy played a cytoprotective role 
during zVAD-induced necrosis. Moreover, zVAD was able to suppress autophagy via 
suppression of lysosome function via inhibition of cathepsin enzyme activity. One 
surprising finding of this study was that growth factors such as insulin and IGF-1 and 
nutrients such as amino acids were able to enhance zVAD-induced necrosis via 
activation of the PI3K-Akt-mTOR pathway and subsequent suppression of autophagy. 
Moreover, the pro-death function of insulin/amino acids was also observed in other 
two necrosis models, including MNNG-induced necrosis in L929 cells and 
H2O2-induced necrosis in Bax/Bak double knockout cells, where autophagy acted as a 
pro-survival mechanism. Finally, we identified that zVAD-induced necrosis was 
RIP1- and RIP3-mediated necroptosis that depended on the autocrine production of 
TNFα. zVAD promoted the autocrine production of TNFα at the transcription level, 
which was required for induction of cell death. We also demonstrated that zVAD 
promoted TNFα production via the PKC-MAPKs-AP-1 pathway. Moreover, we 
presented evidence showing that defects in autophagy might promote zVAD-induced 
cell death by enhancing AP-1 activity.  
In conclusion, data from this study demonstrate that (i) autophagy plays a cell 
survival strategy in the three necrosis models tested in this study; (ii) growth factors 
and amino acids promote necrosis in these models via activation of the 
PI3K-Akt-mTOR pathway and subsequent suppression of autophagy; and (iii) 
zVAD-induced necroptosis depends on autocrine production of TNFα that is mediated 
via the PKC-MAPKs-AP-1 signaling pathway. Taken together, results from the 
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above-described studies provide novel insights for a better understanding of the role 
of autophagy in necrosis.  
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INTRODUCTION 
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1.1 Programmed cell death: apoptosis versus necrosis 
Cell death was observed and reported as early as in 1842 by Carl Vogt, however, 
it had not been recognized as a physiological process until 1960’s (Clarke and Clarke, 
1995). When studying the disappearance of muscles in the large American silkmoths, 
Lockshin and Williams revealed that cell death was executed by a biological scheme. 
They first coined the term, “programmed cell death (PCD)”, to appreciate that the cell 
death is triggered by intrinsic cellular signaling (Lockshin and Williams, 1965). Due 
to its crucial implications in a broad array of physiological and pathological processes, 
PCD has been extensively studied. To date, PCD has been well-documented to be 
essential in all metazoans during embryonic development for organogenesis. In adult 
organisms, PCD also functions to maintain the tissue homeostasis. On the other hand, 
abnormality of PCD is involved in various pathological conditions. Defects in PCD 
can manifest cancer, autoimmunity, whereas accelerated PCD is evident in acute and 
chronic degenerative diseases, and immunodeficiency (Danial and Korsmeyer, 2004).  
Based on morphological characteristics, PCD can be categorized into apoptosis 
and non-apoptotic cell death, among which the former is the most studied and 
elucidated (Kroemer et al., 2009). However, in disagreement to the original view that 
only apoptosis is programmed, accumulative evidence has suggested that necrosis, a 
non-apoptotic cell death, is also tightly disciplined by intrinsic signals. Necrosis can 
occur under certain cellular contexts in vitro as well as in vivo. In particular, when 
apoptotic pathways are impaired, necrosis may take place as the alternative route to 
maintain tissue homeostasis (Zong and Thompson, 2006). Therefore, apoptosis and 
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necrosis are two major forms of PCD playing diverse essential biological roles. 
1.1.1 Apoptosis 
1.1.1.1 General introduction 
In 1972, when Kerr J.F. and his colleagues were trying to explore the 
morphologic features of the “physiological cell death”, they found that the dying cells 
in various tissues of different origins displayed resembled morphology: rounded and 
dense, with blebs, with rounded or fragmented nuclei, and the chromatin was 
condensed. Moreover, the cell death manifesting such unique “shrinkage” 
morphological characteristics was found to be conserved throughout metazoans. They 
proposed to name such cell death as “apoptosis” (Kerr et al., 1972). Wherefrom, 
apoptosis has entered the research spotlight and fueled numerous studies. One 
breakthrough in understanding the mechanism of apoptosis was achieved by Horvitz 
H.R. and his colleagues who described a handful of genes, ceds, which controlled 
apoptosis in C. elegans (Ellis and Horvitz, 1986; Greenwald et al., 1983). Shortly 
thereafter, it was unveiled that the ced-3-encoded protein acts as a cysteine protease 
to initiate apoptosis (Yuan et al., 1993). This study eventually led to the discovery that 
a group of cysteine proteases conserved from worms to mammals execute apoptosis, 
which are now known as caspases (Zakeri and Lockshin, 2008). In addition to the 
core execution pathway of apoptosis, other critical proteins involved in apoptosis 
regulations were also rapidly identified. For instance, the Bcl-2 was recognized to 
regulate apoptosis in 1988 (Vaux et al., 1988), while the pro-apoptosis function of 
p53 was demonstrated in 1991 (Yonish-Rouach et al., 1991). With the rapid 
                                                            4 
expansion of our understanding of its regulations, apoptosis has been appreciated as 
an outcome derived from a complex signaling network.  
1.1.1.2 Machinery 
Caspases 
Caspases are a group of cysteine proteases that specifically recognize a four 
contiguous amino acid consensus within their substrate and cleave the substrate after 
the C-terminal residue of the consensus, usually an Asp residue (Li and Yuan, 2008). 
To date, a number of caspases has been identified in various organisms. Although 
caspases also play non-apoptotic roles such as to regulate inflammatory responses, 
cell proliferation, and cell differentiation, many of them have been clearly 
demonstrated to function in apoptosis (Kumar, 2007). 
Caspases are synthesized as inactive zymogens containing prodomains. Upon 
receiving apoptotic signals, the zymogens will undergo a proteolytic process to 
remove the prodomains, which thereby activates caspases (Fuentes-Prior and 
Salvesen, 2004). Interestingly, activation of caspases can be achieved via a signaling 
cascade in which certain caspases are cleaved by the upstream caspases to gain the 
proteolytic activity towards their substrates (Li and Yuan, 2008). According to the 
length of their prodomains and the positions in the apoptotic signaling cascade, 
caspases can be classified into two groups, the initiator caspases (caspase-1, -2, -4, -5, 
-8, -9, -10, -11, -12) and the effector caspases (caspase-3, -6, -7). Initiator caspases 
harbor long prodomains containing a protein-protein interaction motif, the death 
effector domain (DED) or the caspase recruitment domain (CARD). The DED or 
                                                            5 
CARD domain can direct the interaction of the initiator caspases with the upstream 
adaptor molecules, whereby the initiator caspases are activated. Upon activation, the 
initiator caspases will cleave and activate the downstream effector caspases. The 
effector caspases harbor short prodomains that can be removed by the initiator 
caspases. Activated effector caspases perform the execution steps of apoptosis by 
cleaving a variety of cellular substrates such as poly(ADP-ribose) polymerase (PARP), 
nuclear lamins, and inhibitor of caspase activated DNase or DNA fragmentation 
factor (ICAD) 45 (Danial and Korsmeyer, 2004). 
Extrinsic versus intrinsic caspase cascade 
Despite their diverse nature, various apoptosis inducers usually utilize common 
core machineries for apoptosis execution. Two such machineries have been 
established, the extrinsic and the intrinsic pathways. The extrinsic apoptotic pathway 
is classically initiated by the cell death receptors, such as TNF receptor 1 (TNFR1), 
Fas, and death receptor (DR) 4/5. The engagement of the cell death ligands with their 
respective receptors induces the formation of intracellular death-inducing signaling 
complexes (DISCs) consisting of multiple adaptor molecules, such as TNFα 
receptor-associated factor 2 (TRAF2) and Fas-associated death domain (FADD). The 
adaptor proteins in turn recruit initiator caspases, usually caspase-8, onto the DISCs 
through their DED domain. Whereby, the caspase-8 undergoes oligomerization and 
autocatalytic activation. Activated caspase-8 subsequently activates the downstream 
effector caspases, such as caspase-3 or caspase-7, to execute apoptosis.  
In contrast, the intrinsic apoptotic pathway is initiated from the mitochondria. 
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Diverse stimuli, such as cytotoxic drugs, DNA damage and growth factor withdrawal, 
have been found to induce mitochondria permeabilization, leading to the release of 
cytochrome c into cytosol. With the assistance of dATP, the cytosolic cytochrome c 
promotes the assembly of a complex called apoptosome, consisting of apoptotic 
peptidase activating factor 1(Apaf-1), cytochrome c and procaspase-9. Apaf-1 carries 
an N-terminal CARD domain that recruits the initiator caspase, caspase-9. The 
proteolytic activity of caspase-9 will be evoked within the apoptosome, which first 
activates caspase-9 itself. The matured, activated caspase-9 in turn cleaves and 
activates the effector caspases (Green, 2005).  
Interestingly, the extrinsic and intrinsic apoptotic machineries are not absolutely 
separated, instead, they are interlinked. In certain cell types, the DISC-induced 
caspase-8 activation may not be sufficient for proceeding apoptosis execution; the 
extrinsic cascade thus can be amplified by the intrinsic machinery. In this case, 
caspase-8 cleaves a cytosolic BH3-only Bcl-2 family member, Bid, and the truncated 
Bid (tBid) will translocate to mitochondria. The mitochondrion located tBid in turn 
facilitate the oligomerization of Bax and Bak to form pores on the mitochondrial 
outer membrane, which thus leads to the cytochrome c release and triggers the 
intrinsic caspase cascade (Li et al., 1998). The extrinsic and intrinsic apoptotic 
pathways and their crosstalk are briefly illustrated in Figure 1.1 (Li and Yuan, 2008). 
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                                          Oncogene. Li and Yuan (2008) 
Figure 1.1 Extrinsic versus intrinsic apoptotic pathways 
1.1.1.3 Regulatory mechanisms  
Apoptosis is finely regulated within an extremely complex signaling network. 
Depending on the nature of apoptotic stimuli, different pathways will be utilized as 
the upstream signals to trigger the apoptotic machineries. For instance, IAP 
antagonist or Smac-mimetic can promote TNFα transcription and autocrine 
production and subsequently lead to the activation of the extrinsic apoptotic cascade 
(Petersen et al., 2007; Vince et al., 2007). On the other hand, misfolded protein 
aggregates can elicit the intrinsic apoptotic cascade via the endoplasmic reticulum 
(ER) stress pathway (Kaufman, 1999; Zong et al., 2003). In addition, the apoptotic 
machineries per se are also influenced by diverse signaling pathways, among which 
the Bcl-2 family members, NF-κB pathway, p53 pathway, and Akt pathway are the 
major ones.  
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Bcl-2 family members 
The Bcl-2 family members can be divided into three groups. The anti-apoptosis 
members, such as Bcl-2, Bcl-xL, and Mcl-1, and the pro-apoptotic members, such as 
Bax and Bak, which are all multidomain proteins sharing sequence homology within 
three to four Bcl-2 homology (BH) domains. Whereas another group of members, 
including Bad, Bid, Bim, Noxa, Bik, and Puma, which contain only one BH3 domain, 
can bind to and antagonize functions of the anti-apoptosis Bcl-2 proteins to promote 
apoptosis (Danial, 2007).  
The Bcl-2 family members are predominantly involved in regulation of the 
intrinsic apoptotic pathway. The fundamental underlying mechanism is that the Bax 
and Bak are able to induce the mitochondrial outer membrane permeabilization 
(MOMP) and the release of cytochrome c for initiating the intrinsic apoptotic cascade 
(Kuwana et al., 2002). Such MOMP-inducing function of Bax and Bak can be 
suppressed by the anti-apoptosis proteins, classically Bcl-2, Bcl-xL, and Mcl-1. The 
anti-apoptosis Bcl-2 members prevent Bax or Bak from perturbing the integrity of the 
mitochondrial outer membrane (Adams and Cory, 2007). More importantly, the 
balance between Bax, Bak and Bcl-2, Bcl-xL, and Mcl-1 is tightly regulated by the 
BH3-only Bcl-2 family members. The BH3-only Bcl-2 members are able to bind to 
the anti-apoptosis Bcl-2 members and neutralize their inhibitory effects on Bax and 
Bak (Chen et al., 2005). In addition to acting as “derepressors”, certain BH3-only 
proteins including Bid and Bim also function as “activators” by binding to and 
activating Bax (Kuwana et al., 2005).  
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The Bcl-2 family members are subjected to regulations by various signaling 
pathways at the transcriptional and the post-translational level, which integrate those 
pathways into apoptosis regulation. For example, Bcl-xL can be transcriptionally 
induced by growth factors via Janus kinase–signal transducer and activator of 
transcription (JAK–STAT) pathway (Grad et al., 2000), while Noxa and Puma are 
induced by p53 in response to DNA damage (Nakano and Vousden, 2001; Oda et al., 
2000a). There are numerous examples illustrating the significance of 
post-translational modification in regulation of Bcl-2 protein. One prominent example 
would be the activation of Bid by caspase-8-mediated cleavage (Li et al., 1998; Luo 
et al., 1998). Others include that Bim is inactivated by ERK-mediated 
phosphorylation (Akiyama et al., 2003; Ley et al., 2005); Mcl-1 is rapidly degraded 
by the ubiquitin-proteasome pathway in response to cytokine deprivation (Cuconati et 
al., 2003).  
NF-κB pathway 
The transcription factor, “NF-κB”, refers to a heterogeneous collection of 
dimeric transcription factors consisting of members of the NF-κB/Rel family 
including NF-κB1 (p50), NF-κB2 (p52), c-Rel, RelA (p65), and RelB (Hayden and 
Ghosh, 2004). The c-Rel, RelA and RelB are synthesized in their mature form and are 
held in cytoplasm by IκB proteins, whereas p50 and p52 are derived from their 
precursors, p105 and p100 respectively. Processing of p105 appears to be constitutive 
that provides a pool of matured p50; in contrast, p100 can be processed to generate 
p52 via limited proteolysis upon proper stimulations. While c-Rel, RelA and RelB 
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contain transactivation domains that are capable of driving gene transcription, p52 
and p50 only serve for dimerization and as DNA-binding partners (Hayden and 
Ghosh, 2004).  
A variety of stimuli, such as TNFα and IL-6, are able to activate NF-κB via 
rapid degradation of IκB proteins, classically the IκBα, which is called the canonical 
NF-κB pathway. Degradation of IκBα frees the RelA:p50 NF-κB heterodimers for 
their entry to nucleus to regulate the expression of target genes. A subset of TNF 
family members, such as lymphotoxin-α and B-cell activating factor (BAFF), are able 
to activate NF-κB through an alternative pathway, also named non-canonical NF-κB 
pathway (Hacker and Karin, 2006). In this scenario, the essential signaling event is to 
generate matured p52 from its precursor. Processing of p100 to p52 requires IKKα 
and NF-κB-inducing kinase (NIK). p52 can bind to RelB and the p52:RelB dimer will 
translocate to the nucleus and drive gene transcription (Dejardin, 2006).  
As one of the rapid-responsive transcription factors, NF-κB regulates the 
expression of a wide range of genes that are involved in immune response, 
inflammation, cell survival, cancer, and apoptotic regulations. For example, NF-κB 
upregulates various anti-apoptosis proteins such as Bcl-2, Bcl-xL, Mcl-1 and c-FLIP 
and IAP1/2 (Rayet and Gelinas, 1999). Intriguingly, NF-κB has also been found to 
promote apoptosis under certain cellular context. For example, NF-κB can enhance 
the expression of death receptors such as DR5 and Fas to promote apoptosis (Kuhnel 
et al., 2000; Ravi et al., 2001; Shetty et al., 2005). Recently, several studies reported 
that both canonical and non-canonical NF-κB precede apoptosis through promoting 
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transcription and secretion of TNFα in response to Smac-mimetic and IAP 
antagonists (Petersen et al., 2007; Varfolomeev et al., 2007; Vince et al., 2007) 
p53 pathway 
p53 is a transcription factor that resides at the hub of numerous signaling 
pathways triggered by various cellular cues including DNA damage, hypoxia, and 
oncogene activation. p53 is able to promote apoptosis via both 
transcription-dependent and -independent manners. A wide range of apoptotic genes 
are p53-targeted such as Apaf-1, Bax, Caspase-1, Caspase-6, Noxa, and Puma (Riley 
et al., 2008). Among these pro-apoptotic proteins, two BH3-only Bcl-2 family 
members, Noxa and Puma, deserve more attentions. The importance of Puma during 
p53-dependent apoptosis was underscored by the observation that the cells from the 
developing nervous system derived from the Puma knockout mice were almost 
completely resistant to p53-directed apoptosis (Jeffers et al., 2003). On the other hand, 
in some other cell types, where apoptosis is only partially impaired upon Puma 
deletion, Noxa appears to be critical, as the p53-dependent apoptosis can be well 
protected in these cell types by compound disruption of Noxa and Puma (Michalak et 
al., 2008).  
Several lines of evidence suggest that p53 can signal to apoptosis independent 
of its transcriptional activity. For example, deletion or mutation of the p53 
transactivation domain (TAD) does not eliminate the ability of p53 to induce 
apoptosis (Haupt et al., 1995). It is now known that, in response to genotoxic stress, 
p53 is able to translocate to mitochondria and the mitochondria-located p53 will 
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induce apoptosis by interacting with various Bcl-2 family members, such as Bak, 
Bcl-2 and Bcl-xL (Green and Kroemer, 2009). 
The pro-apoptotic activity of p53 is finely regulated by various signaling 
pathways. For example, p53 is negatively regulated by Mdm2 and MdmX. In the 
absence of stress signals, p53 is usually undetectable in most embryonic and adult 
tissues because it is constitutively targeted for poly-ubiquitination and rapid 
proteasomal degradation majorly mediated by the E3/4 ligases, Mdm2/X. In response 
to DNA damage, Mdm2/X will be phosphorylated by ATM that targets Mdm2/X for 
destruction. Removal of Mdm2/X thus stabilizes p53 and facilitates its functions 
(Wahl, 2006). Besides, activation of p53 is governed by a variety of post-translational 
modifications (PTMs) including acetylation, phosphorylation, methylation, 
poly(ADP-ribosyl)ation et al. For example, aceylation of lysine 373 of p53 by p300 
and/or CBP markedly increases its transactivities toward the lower affinity-binding 
target genes (Knights et al., 2006). Phosphorylation of p53 at Ser46 is critical for 
transcription of the p53-targeted pro-apoptotic genes (Oda et al., 2000b). Moreover, a 
number of molecules, acting as p53-binding partners, have been identified capable of 
influencing the transcription activity of p53 such as Hzf proteins, Brn3 family 
proteins (Pietsch et al., 2008).  
Akt pathway 
Akt, also called protein kinase B (PKB), is a serine/threonine kinase that has 
been known as a central node navigating metabolism responses downstream of many 
cellular stimuli such as growth factors (Manning and Cantley, 2007). In response to 
                                                            13 
growth factors such as insulin, the class I phosphatidylinositol-3 kinase (PI3K) will 
be activated and generate PtdIn(3,4,5)P3 (PIP3) from PtdIn. PIP3 in turn recruits Akt 
onto plasma membrane through its pleckstrin homology (PH) domain, whereby Akt is 
phosphorylated at threonine 308 by phosphoinositide-dependent kinase 1 (PDK1). 
Full activation of Akt will be achieved by an additional phosphorylation at serine 473 
catalyzed by the mammalian target of rapamycin (mTOR) complex 2 (Jacinto et al., 
2006; Sarbassov et al., 2005). The activated Akt turns on the mTOR complex 1 via 
tuberous sclerosis complex (TSC) complex and Rheb to coordinate protein synthesis, 
cell growth and proliferation (Inoki et al., 2003a; Inoki et al., 2002).  
In addition to its essential roles in controlling cellular metabolism, Akt has been 
found to protect cells against apoptosis under various cellular contexts (Downward, 
2004). One approach that is utilized by Akt to block apoptosis is to directly modify 
the pro-apoptotic proteins. For example, Akt phosphorylates Bad at serine 136, 
resulting in its sequestration in cytosol by binding to 14-3-3 and loss of its 
pro-apoptotic function (Datta et al., 1997; Zha et al., 1996). Likewise, caspase-9 also 
has been reported to be phosphorylated by Akt, which attenuates its activity (Cardone 
et al., 1998). Another powerful means for Akt to regulate apoptosis is to modulate the 
activity of various transcription factors that control the expression of 
apoptosis-related proteins. For instance, Akt can phosphorylate and inactivate the 
Forkhead transcription factors (FoxOs) (Brunet et al., 1999), which are able to 
promote the expression of a variety of pro-apoptotic proteins, such as Fas ligand and 
Bim (Brunet et al., 1999; Dijkers et al., 2000). Besides, Akt has been found to 
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modulate other important apoptosis-regulatory transcription factors such as NF-κB 
and p53 via phosphorylation of IKK and Mdm2 respectively (Kane et al., 1999; Mayo 
and Donner, 2001).  
1.1.2 Necrosis 
1.1.2.1 General introduction 
Before the discovery of apoptosis, all types of cell death were called “necrosis”. 
While apoptosis morphologically is characterized as the “shrinkage” cell death, 
necrosis is defined by electron-lucent cytoplasm, swelling of cellular organelles, and 
loss of plasma membrane integrity. In contrast to apoptosis that is an ATP-consuming 
process, the necrotic events can be reproduced experimentally by inhibiting cellular 
ATP production. These observations appear to suggest that, while apoptosis is 
intrinsically triggered, necrosis is a form of cell death that is accidentally imposed 
and unprogrammed. However, accumulative evidence has suggested that necrosis, in 
response to given stimuli, represents an alternative form of PCD. Moreover, the 
programmed necrosis has been shown to possess great biological significances under 
various physiological, pathological, and pharmacological circumstances (Zong and 
Thompson, 2006). For instance, in central nervous system (CNS), persistent neuronal 
excitation will lead to cell death in mature neurons that resembles necrosis (Lindsten 
et al., 2003). The necrotic cell death induced by excitotoxicity plays an important role 
in many CNS disorders, including seizures, trauma, and possibly neurodegenerative 
disorders such as Alzheimer’s and Huntington’s diseases (Zong and Thompson, 2006). 
It is known that the development of resistance to apoptosis by gene mutations or by 
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virus-encoded caspase inhibitors such as CrmA is a critical step in tumorigenesis. 
Under such scenarios, to induce necrosis in cancer cells is an effective strategy for 
cancer therapy (Bai et al., 2003; Salomon et al., 2000). Thus far, our understanding of 
programmed necrosis is still quite limited. 
1.1.2.2 Different forms of necrosis  
Necroptosis 
Necroptosis refers to a form of programmed necrosis that is elicited from the 
death-receptor signaling. It has been observed that the classic apoptotic stimuli, such 
as TNFα and FasL, are capable of inducing necrotic cell death when apoptotic 
pathway is blocked by caspase inhibitors (Khwaja and Tatton, 1999; Matsumura et al., 
2000) or by mutations of caspase-8 or FADD (Chan et al., 2003; Degterev et al., 2005; 
Holler et al., 2000). Interestingly, in certain cell types, such as murine fibrosarcoma 
cells, L929 cells, TNFα alone is sufficient to induce massive necrotic cell death, 
suggesting that the necroptosis pathway could be the default cell demise route in 
given cellular settings. Such a notion is supported by the in vivo observation that 
necroptosis is the major form of cell death in cerulein-induced mouse acute 
pancreatitis model (He et al., 2009).  
Although the underline mechanisms are still elusive, it has been known that 
receptor interacting protein 1 (RIP1) plays a critical role in necroptosis (Zheng et al., 
2006); Moreover, the RIP1 kinase activity is required for initiating necroptosis while 
it is dispensable for eliciting apoptosis and NF-κB activation (Holler et al., 2000). In 
appreciation of this, a RIP1 kinase inhibitor, necrostatin-1, has been developed as a 
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specific necroptosis inhibitor (Degterev et al., 2008; Degterev et al., 2005). Recently, 
three groups provided compelling evidence showing that RIP3, another RIP family 
member, in association with RIP1, contributes essentially to necroptosis (Cho et al., 
2009; He et al., 2009; Zhang et al., 2009).  
Downstream of RIP proteins, it has been well-known that endogenous reactive 
oxygen species (ROS) production is required for induction of necroptosis since the 
ROS scavenger, BHA, is able to abrogate TNFα- or Fas-induced necroptosis (Lin et 
al., 2004; Vercammen et al., 1998b; Vercammen et al., 1995). ROS refers to a set of 
intracellular products that harbor free oxygen radicals with high oxidative activity, 
such as superoxide anion (O2
·-
), hydroxyl radicals (
·
OH), and hydrogen peroxide 
(H2O2). ROS perform multiple biological functions by reacting with a wide range of 
cellular targets including DNA, proteins, and lipids (Shen and Liu, 2006). One 
connection linking RIP1 and ROS production during induction of necroptosis has 
been reported to rely on Nox1 NADPH oxidase which functions within a complex 
with RIP1, TRADD, and Rac1 upon TNFα treatment (Kim et al., 2007b). 
Interestingly, it was also found that, as a critical switch between TNFα-induced 
necroptosis and survival, RIP3 facilitated ROS production through directly 
modulation of metabolic enzymes, including glycogen phosphorylase (PYGL), 
glutamate ammoniavligase (GLUL), and glutamate dehydrogenase 1 (GLUD1) 
(Zhang et al., 2009). Of note, it appears that ROS production is not always the critical 
step for induction of necroptosis evidenced by the observation that RIP3-mediated 
necroptosis in HT29 cells cannot be blocked by ROS quenching (He et al., 2009). 
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How endogenous ROS triggers necroptosis is still a mystery. Several lines of 
evidence indicate that the activation of c-Jun N-terminal kinase (JNK) is important. 
JNK, also known as stress activated protein kinases, is an important subgroup of the 
mitogen-activated protein kinase (MAPK) superfamily. It is well-known that ROS are 
potent JNK activators and the activation of JNK has been found to mediate oxidative 
stress-induced necrotic cell death (Shen et al., 2004; Wu et al., 2008b). Moreover, the 
crucial involvement of JNK activation in necroptosis has been demonstrated (Kim et 
al., 2007b; Schulze-Osthoff et al., 1992). So far, the mechanisms underlying the key 
role of JNK in necroptosis are largely unknown. 
PARP-1-mediated necrosis 
PARP-1 is a nuclear enzyme that has a key role in maintaining genome stability. 
PARP-1 is rapidly activated by DNA-strand breaks and recruits DNA-repair factors 
by attaching ADP–ribose units to chromatin-associated proteins. Interestingly, in 
certain scenarios, especially when caspase activation is blocked, overactivation of 
PARP-1 is able to induce necrotic cell death, which can be protected by the PARP-1 
chemical inhibitor or genetic deletion of PARP-1 (Pieper et al., 1999).  
Two models have been proposed to explain the molecular mechanisms 
underlying PARP-1-mediated necrosis. (i) Activated PARP-1 catalyzes 
poly(ADP-ribosyl)ation on β-nicotinamide adenine dinucleotide (NAD), leading to 
depletion of cellular NAD+ (Pieper et al., 1999). As the cytosolic NAD+ is essentially 
required for glycolysis and ATP production, its depletion will result in “energy 
collapse” and necrotic cell death in glycolytic cells (Zong et al., 2004). (ii) Activated 
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PARP-1 catalyzes the formation of poly(ADP-ribose) (PAR) polymer. Cytosolic 
translocation of PAR polymer leads to redistribution of apoptosis-inducing factor 
(AIF) from mitochondria into nuclei, where it triggers necrotic cell death (Andrabi et 
al., 2006; Yu et al., 2006b). Interestingly, the activation of JNK appears also 
contributing to PARP-1-mediated necrosis (Xu et al., 2006a), indicating that this 
process may share common signaling pathways with necroptosis. However, whether 
PARP-1-mediated necrosis requires the kinase activity of RIP1 for the downstream 
JNK activation is still unclear. Furthermore, TRAF2 is required for PARP-1-mediated 
JNK activation and necrosis but not for necroptosis (Kim et al., 2007b; Xu et al., 
2006a), implying that these two types of necrosis may utilize distinct routes for JNK 
activation and the consequent cell demise. Interestingly, JNK has also been found to 
act upstream of PARP-1 and contributes to sustained PARP-1 activation, leading to 
necrosis in response to oxidative stress (Zhang et al., 2007). Therefore, the 
relationship and potential crosstalk between these two types of necrosis remain to be 
elucidated.  
Autophagy-mediated necrosis  
Autophagy is an evolutionarily conserved intracellular catabolic process that 
targets bulk cytosolic constituents for lysosomal degradation for energy and protein 
recycling (Klionsky and Emr, 2000). Although autophagy has long been regarded as a 
cell survival mechanism against nutrient deprivation conditions, some evidence has 
suggested that it may also execute necrotic cell death under given cellular settings 
(Levine and Yuan, 2005). However, this type of cell death is far from being 
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well-characterized, which will be discussed in details in Section 1.3. The different 
forms of necrosis has been briefly summarized and illustrated elsewhere as shown in 
Figure 1.2 (Degterev and Yuan, 2008). 
 
                          Nat. Rev. Mol. Cell. Biol. Degterev and Yuan (2008) 
Figure 1.2 Three forms of non-apoptotic cell death 
1.1.3 Crosstalk between apoptosis and necrosis 
Many studies have demonstrated that apoptosis and necrosis often occur 
simultaneously. Many insults induce apoptosis at lower doses and necrosis at higher 
doses. Even in response to a certain dose of death-inducing agent, both apoptosis and 
necrosis may coexist in the same cell type. In addition, apoptotic cells may present 
necrotic features at the late stage due to the loss of cellular energy and plasma 
membrane integrity (Zong and Thompson, 2006). All these observations thus suggest 
that apoptosis and necrosis are mechanistically interlinked. 
To facilitate necrosis, inhibition of apoptotic pathway is usually employed. For 
instance, the pan-caspase inhibitor such as zVAD was applied to switch Fas-mediated 
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apoptosis into necroptosis in L929 cells (Vercammen et al., 1998b). Such a strategy is 
also valid for PARP-1-mediated necrosis, for example, the DNA alkylating agent, 
MNNG, induces PARP-1-dependent necrosis in Bax-/-Bak-/- MEF cells while 
induces apoptosis in WT MEF cells (Zong et al., 2004). Therefore, it appears that 
caspases behave as a switcher between apoptosis and necrosis in response to certain 
cellular milieu. It seems straightforward and understandable that blocking caspase 
activity is required for PARP-1-mediated necrosis because PARP-1 will be cleaved by 
effector caspases during apoptosis, which eliminates PARP-1 protein and terminates 
the necrotic pathway (Zong and Thompson, 2006). On the other hand, RIP1 has been 
reported to be a substrate of caspase-8 and caspase-8 can cleave RIP1 to promote 
apoptosis (Lin et al., 1999). Therefore, blockage of caspase activation may facilitate 
necroptosis through stabilization of RIP1.  
As mentioned above, RIP3 has been identified as a crucial player in necroptosis 
(Cho et al., 2009; He et al., 2009; Zhang et al., 2009). In these studies, RIP3 was 
found to act as a key switcher between apoptosis and necrosis. The cells lacking RIP3 
or with knockdown of RIP3 are resistant to necroptosis while undergo apoptosis 
normally (He et al., 2009), and the RIP3 deficient cells will become susceptible to 
necroptosis when engineered with RIP3 (Zhang et al., 2009). However, whether RIP3 
also performs similar functions in PARP-1-mediated necrosis is not known. These 
findings may provide novel insights and directions for us to further investigate the 
key role of caspase in necrotic cell death. 
Interestingly, in addition to being capable of switching apoptosis into necrosis, 
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inhibition of caspase is able to promote necroptosis. The pan-caspase inhibitor, zVAD, 
and CrmA, a viral protein acting as a natural caspase-8 inhibitor, were shown to 
greatly promoting TNFα- induced necrosis by 1000 folds in L929 cells (Vercammen 
et al., 1998a). The stabilization of RIP1 upon caspase inhibition is unlikely the reason 
because TNFα alone triggers necroptosis in L929 cells without caspase activation 
(Vercammen et al., 1997). Another interesting model was proposed in which zVAD 
could bind to the adenine nucleotide translocase (ANT) in a RIP1-dependent manner. 
Such an interaction thereby perturbed the ATP/ADP exchange in mitochondria, 
leading to rapid energy collapse and promoting necrosis (Temkin et al., 2006). 
However, this model fails to explain why CrmA displays similar sensitization effect 
as zVAD (Vercammen et al., 1998a). It is thus possible that multiple mechanisms are 
involved to enable such an amazing sensitization. 
 
1.2 Autophagy 
1.2.1 General introduction 
Normal cell growth and development requires a well-controlled balance 
between protein synthesis and organelle biogenesis versus protein degradation and 
organelle turnover. The major pathway for degradation of bulk cellular constituents is 
autophagy and for cytosolic protein turnover is the proteasome pathway (Klionsky 
and Emr, 2000). The term “autophagy” was first coined by Christian de Duve in 1963 
to illustrate a cellular process of cells’ self (auto) eating (phage). In contrast to 
proteasomal degradation pathway that turns over short-lived proteins with proteases, 
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autophagy utilizes lysosome and hydrolases for digestion. Moreover, autophagy is 
able to target bulk cytoplasmic contents for destruction including long-lived proteins, 
lipids, nucleic acid, as well as organelles such as mitochondria (Klionsky, 2007).  
There are three types of autophagy, macroautophagy, microautophagy, and 
chaperon-mediated autophagy, among which the macroautophagy is the most studied. 
Macroautophagy (hereafter refer to as autophagy) is evolutionarily conserved from 
yeast to mammal and ubiquitously takes place in all eukaryotic cells and is 
morphologically featured by the formation of the double-membrane vesicles, named 
autophagosome (Klionsky and Emr, 2000).  
1.2.2 Dynamic process of autophagy 
Autophagy is a dynamic process that can be broken down into at least four 
sequential steps: induction, formation of autophagosome, docking and fusion of 
autophagosome with lysosome, and autophagic body breakdown (Kim and Klionsky, 
2000). The formation of autophagosome can be further divided into several stages 
including initiation, nucleation, elongation, and completion (Xie and Klionsky, 2007). 
The dynamic process of autophagy is illustrated briefly in Figure 1.3 (He and 
Klionsky, 2009). 
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Figure 1.3 The dynamic process of autophagy 
Induction of autophagy is tightly regulated by various cellular cues such as 
amino acid deprivation, growth factor withdrawal, and hypoxia. Upon receiving 
autophagy-inducing signals, the autophagic process will be triggered to initiate 
autophagosome formation. Autophagosome is de novo generated that it does not 
appear to be derived by budding from a pre-existing organelle (Yorimitsu and 
Klionsky, 2005). After initiation by the Atg1 complex machinery, a precursor 
membrane sac, the phagophore, also named pre-autophagosome structure (PAS) in 
mammalian system, forms via the nucleation machinery (Xie et al., 2008). 
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Autophagosome then can be built and expanded from the PAS by the membrane 
elongation machinery. After maturation, the double-membrane autophagosome can 
dock to and fuse with lysosome, becoming the autolysosome. Eventually, the 
autophagosome together with those enclosed contents will be degraded in 
autolysosome by lysosomal enzymes (Yorimitsu and Klionsky, 2005). Various 
autophagy-related proteins coordinate the autophagosome formation process, which 
will be discussed in details. 
1.2.3 Machinery for autophagosome formation 
1.2.3.1 Atg genes 
It has been well-known that autophagy is tightly controlled by an array of 
autophagy-related (Atg) genes. Since the first discovery of Atg gene in yeast, Atg1 
(Matsuura et al., 1997), thus far 31 Atg genes have been identified and many of them 
have orthologs in mammals (He and Klionsky, 2009). As all studies in this thesis 
were performed in mammalian cells, the mammalian Atg proteins and their functions 
are summarized and listed in Table 1.1  
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Table 1.1 Functions of mammalian Atg genes in autophagy 
Atg Other Name Function Reference 
1 ULK control autophagy initiation within a 
complex with Atg 13 and Atg 17  
(Chan et al., 2007; Hara 
et al., 2008; Young et al., 
2006) 
3 - E2-like enzyme involved in Atg8-PE 
conjugation 
(Tanida et al., 2002) 
4 - Cysteine protease for Atg8 processing and 
deubiquitinating-like enzyme for 
removing PE from Atg8 
(Marino et al., 2003; 
Scherz-Shouval et al., 
2003; Tanida et al., 2004) 
5 - Conjugate with Atg12, leading to 
oligomerization with Atg16 to form a 
complex acting as a E3-like enzyme 
involved in Atg8 lipidation 
(Mizushima et al., 1998a; 
Mizushima et al., 2001) 
6 Beclin  Interact with PI3K class III required for 
membrane nucleation  
(Liang et al., 1999) 
7 - E1-like enzyme involved in Atg5-Atg12 
conjugation and Atg8 lipidation 
(Tanida et al., 2001) 
8 LC3 Undergo lipidation with PE involved in 
autophagosome formation 
(Kabeya et al., 2000) 
9 - Transmembrane protein involved in 
autophagosome formation 
(Yamada et al., 2005; 
Young et al., 2006) 
10 - E2-like enzyme mediating Atg5-Atg12 
conjugation 
(Mizushima et al., 2002) 
12 - Conjugate with Atg5, leading to 
oligomerization with Atg16 to form a 
complex acting as a E3-like enzyme 
involved in Atg8 lipidation 
(Mizushima et al., 
1998b) 
13 - Regulatory component in Atg1 complex 
controlling autophagy initiation  
(Hosokawa et al., 2009; 
Meijer et al., 2007) 
14 Barkor Bind with Beclin 1-PI3K class III (Vps34) 
complex involved in membrane 
nucleation 
(Itakura et al., 2008) 
16 - Interact with Atg5-Atg12 to form 
complex acting as a E3-like enzyme 
involved in Atg8 lipidation 
(Mizushima et al., 2003) 
17 FIP200 Form a complex with Atg1 and Atg13 
controlling autophagy initiation 
(Ganley et al., 2009; 
Hara et al., 2008; Jung et 
al., 2009) 
18 WIPI-1α Bind with PI3P involved in phagophor 
nucleation 
(Proikas-Cezanne et al., 
2004) 
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Currently, Atg proteins involved in autophagosome formation have been divided into 
four groups that coordinately function in different sequential steps including initiation, 
membrane nucleation, membrane elongation, and autophagosome maturation. 
1.2.3.2 Atg1 (ULK1) complex in autophagy initiation 
In yeast, one of the earliest autophagy-specific events is believed to be carried 
out by the Atg1 complex, consisting of Atg1, Atg13, and Atg17, downstream of the 
target of rapamycin (TOR) and cAMP-dependent kinase (PKA) pathways (Matsuura 
et al., 1997). The Atg1 kinase activity is enhanced in response to nutrient deprivation, 
which is required for initiating autophagosome biogenesis (Kamada et al., 2000). 
Likewise, the mammalian Atg1 orthologue, ULK1, has been found to form a complex 
with mammalian orthologue of Atg13 and Atg17 (FIP200), regulating autophagy 
downstream of mammalian TOR (mTOR) pathway.  
The ULK1-Atg13-FIP200 complex (ULK1 complex) interacts with mTOR 
complex 1 (mTORC1) in a nutrient-dependent manner, through the binding between 
ULK1 and raptor, one of the mTORC1 components (Ganley et al., 2009; Jung et al., 
2009). Under nutrient rich conditions, the mTORC1 is activated and associates with 
the ULK1 complex, whereby the mTOR kinase phosphorylates ULK1 and Atg13 at 
the inhibitory sites and consequently suppresses the ULK1 kinase activity. Nutrient 
withdrawal inactivates mTORC1 and frees ULK1 complex, leading to 
dephosphorylation of ULK1 and Atg13 at those inhibitory sites, by which ULK1 
gains its kinase activity and promote autophagy (Hara et al., 2008; Hosokawa et al., 
2009). Notably, Atg13 and FIP200 are required for maximizing Atg1 kinase activity 
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(Ganley et al., 2009; Hosokawa et al., 2009; Jung et al., 2009). To date, the direct 
substrate of ULK1 complex for autophagy induction is elusive; however, it is 
believed that the rapid translocation of activated ULK1 complex from a diffuse 
cytoplasmic pool to PAS is critical for initiating autophagosome biogenesis (Hara et 
al., 2008; Hosokawa et al., 2009). 
1.2.3.3 Atg6 (Beclin 1) complex in PAS nucleation 
Beclin 1was originally discovered as a novel Bcl-2-interacting protein by yeast 
two-hybrid (Liang et al., 1998); due to its structural similarity to the yeast Atg6, 
further studies found that Beclin 1 is the mammalian homolog of Atg6 that is 
indispensible for autophagy in mammals (Liang et al., 1999). In yeast, Atg6, together 
with Atg14 and Vps15, acts as an obligatory allosteric activator of the class III PI3K 
(Vps34), an enzyme that produces PI3P from PI. The PI3P is important for nucleation 
of the phagophore assembly as well as for the retrieval of additional membranes to 
the extending isolation membrane (Obara et al., 2008a; Obara et al., 2008b). It is 
noteworthy that, in yeast, the Atg6-Vps34 can constitute another complex with Vps15 
and Vps38, which is involved in vacuolar sorting, but not autophagy (Kihara et al., 
2001). These two functional complexes appear to be conserved in mammals. 
There exists at least two Beclin 1-hVps34 complexes in mammalian cells 
sharing several common components including Beclin 1, hVps34, hVps15 (formerly 
called p150), and possibly a mammalian specific Beclin 1-interacting WD40 domain 
protein, Ambra1 (Fimia et al., 2007). The assembly of these common components is 
designated as the “core complex”. The core complex can bind with Atg14, also called 
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Barkor (Sun et al., 2008), to form one Beclin 1-hVps34 complex, which is believed to 
participate predominantly in autophagy regulation (Itakura et al., 2008; Matsunaga et 
al., 2009; Zhong et al., 2009). Another Beclin 1-hVps34 complex comprises the core 
complex and the mammalian homolog of Vps38 and the UV irradiation 
resistance-associated gene (UVRAG) protein, whose functions in autophagy are still 
controversial. While UVRAG was reported to activate Beclin 1-hVps34 complex and 
promote autophagosome formation (Liang et al., 2006; Takahashi et al., 2007), other 
studies found that the UVRAG-incorporated Beclin 1-hVps34 complex was not 
involved in autophagosome formation (Itakura et al., 2008; Sun et al., 2008). 
Interestingly, it was recently reported that the Beclin 1-bound UVRAG is able to 
regulate autophagosome maturation and endocytotic trafficking via targeting the class 
c Vps complex (Liang et al., 2008).  
The detailed molecular mechanisms for Beclin 1-hVps34 complex to regulate 
autophagy are not well understood. It is believed that this complex can facilitate 
membrane trafficking and nucleation during autophagosome biogenesis process via 
providing PI3P (Axe et al., 2008; Petiot et al., 2000; Taguchi-Atarashi et al., 2010). 
Several studies have shown that PI3P can recruit PI3P-binding proteins, such as 
WIPI-1α (the mammalian homolog of yeast Atg18), onto PAS through the FYVE 
domain; the later thus precede autophagosome formation (Axe et al., 2008; 
Proikas-Cezanne et al., 2004). In yeast, the activity of Vps34 is tightly regulated by 
Vps15 (Stack et al., 1995). Notably, in mammalian systems, the hVps34 activity is 
also modulated by hVps15 and more importantly, Beclin 1 can activate hVps34 by 
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enhancing the interaction between hVps34 and hVps15 (Yan et al., 2009). In contrast, 
the Atg14 and Ambra1 may assist the translocation of Beclin 1-hVps34 complex to 
PAS (Itakura et al., 2008; Matsunaga et al., 2009; Sun et al., 2008). Collectively, these 
studies appear to suggest that Beclin 1 is involved in autophagy at probably both 
membrane nucleation and autophagosome maturation steps upon interacting with 
different binding partners. 
1.2.3.4 Ubiquitin-like systems in membrane elongation 
Ubiquitin is a small protein with 76 amino acid residues that is highly conserved 
from yeast to human (Pickart, 2004). Ubiquitin is best known for targeting protein 
destruction by 26S proteasome; however, its nonproteolytic functions have been 
uncovered at a rapid pace in the past few years (Chen and Sun, 2009). The enzymatic 
cascade of ubiquitination begins from ubiquitin activation by an E1 
(ubiquitin-activating enzyme), followed by transferring of the activated ubiquitin to 
an E2 (ubiquitin-conjugating enzyme), and ends with conjugation of ubiquitin to a 
target protein by an E3 (ubiquitin-protein ligase) (Pickart, 2004). Remarkably, 
proteins can be subjected to such a post-translational modification with other small 
molecules, such as phosphate groups, methyl groups, or acetyl groups. Due to the 
similarity of the enzymatic cascade as ubiquitination, these reactions are called 
ubiquitin-like systems (UBL) (Hochstrasser, 2009).  
During induction of autophagy, two UBL systems have been conserved from 
yeast to mammals, playing essential roles in autophagosome biogenesis, including (i) 
Atg8 (LC3) system and (ii) Atg5-Atg12 system. It is known that elongation of 
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autophagic membrane requires phosphatidylethanolamine (PE) conjugated LC3 (LC3 
II). The newly synthesized LC3 (pre-LC3) will be processed by Atg4 to remove 
C-terminal 22 amino acids to generate LC3 I, which resides in cytosol in resting cells; 
during induction of autophagy, LC3 I can be further processed into LC3 II by 
lipidation with PE by UBL reactions (Satoo et al., 2009). In this system, the LC3 is 
the UBL protein that is attached to the substrate lipid molecule, PE. The ligation of 
LC3 with PE is catalyzed by the E3 ligase, Atg5-Atg12 complex (Ichimura et al., 
2000), which per se is a product of the other autophagic-specific UBL system (Suzuki 
et al., 2005; Tanida et al., 2001). A number of Atg proteins participate into these two 
UBL systems acting as E1, E2, and E3, which are summarized in Table 1.2. 
 
Table 1.2 Mammalian Autophagy-Specific UBL Systems 
System Substrate UBLs* E1 E2 E3 DUB* Product 
Atg8 (LC3) PE LC3 I Atg7 Atg3 Atg5-Atg12 Atg4 PE-LC3 I  
Atg5-Atg12 Atg5 Atg12 Atg7 Atg10 - - Atg5-Atg12 
*UBLs, ubiquitin-like proteins; DUB, deubiquitinating enzyme 
 
In mammalian cells, the LC3 II, as the final product of these two UBL systems, 
is required for autophagosome formation. Upon lipidation, LC3 II will translocate 
onto PAS at both outer and inner membrane to facilitate the elongation of PAS 
(Kabeya et al., 2000). After the completion of autophagosome formation, the outer 
membrane anchored LC3 II will be released and processed into LC3 I by the DUB 
Atg4 for recycling (Satoo et al., 2009), while the inner membrane-resided LC3 II will 
remain in autophagosome and be degraded within autolysosome (Mizushima et al., 
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2003). However, what the LC3 II exactly does is not clear. 
1.2.3.5 Atg9 in membrane cycling 
    Atg9 is the only conserved transmembrane protein in the core machineries of 
autophagy. Atg9 is able to anchor in membranes via its six transmembrane domains. 
In mammals, a population of Atg9 is localized to the PAS, while the remained Atg9 
anchors in non-PAS membranes including trans-Golgi network and endosomes. It has 
been shown that Atg9 can move bidirectionally between the PAS and non-PAS 
membranes (Young et al., 2006). Such a shuttling movement of Atg9 is believed to 
contribute to delivery of membrane to PAS for autophagosome formation and is 
defined as the membrane cycling machinery (Reggiori et al., 2005; Reggiori et al., 
2004). The delivery of yeast Atg9 to phagophore is assisted by Atg23 and Atg27, 
however, no apparent homologs of these two proteins have currently been identified 
in mammalian systems. The retrieval of Atg9 from the phagophore/PAS is regulated 
by Atg1/ULK1 complex. In human cells, short interfering RNA (siRNA) depletion of 
ULK1 inhibits the starvation-induced redistribution of Atg9 from the trans-Golgi 
network to endosomes (Young et al., 2006). In addition, Atg9 can interact with Atg18, 
which bridges the membrane cycling machinery with the nucleation machinery 
(Reggiori et al., 2004).  
1.2.4 Regulatory pathways 
1.2.4.1 mTOR pathway 
In 1970s, a bacterial metabolite was found to potently kill fungi, named 
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rapamycin. In exploring the mechanisms of the antifungal function of rapamycin, two 
genes were identified as encoding the target of rapamycin proteins in yeast, called the 
target of rapamycin (TOR-1 and TOR-2). Subsequently, the mammalian homolog of 
TOR, mammalian TOR (mTOR) was determined, which, unlike that in yeast, is 
encoded by only one gene (Wullschleger et al., 2006). To date, it is clear that mTOR 
resides in the central node integrating various signals into regulation of cell growth, 
metabolism, as well as autophagy (Yang and Guan, 2007).  
mTOR complexes 
In mammals, mTOR constitutes two complexes, mTOR complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2). mTORC1 comprises mTOR, raptor, and mLST8 
(also known as GβL), which is sensitive to rapamycin. In contrast, mTORC2 consists 
of mTOR, rictor, Sin 1, and mLST8, which is much less responsive to rapamycin 
(Yang and Guan, 2007).  
mTORC1 has been well-recognized as the major molecule, by sensing 
environmental nutrients, growth factors, energy balance, and stresses, to regulate cell 
growth, metabolisms and autophagy (Schmelzle and Hall, 2000). Upon activation, 
mTORC1 phosphorylates S6K1 and 4E-BP1 to promote protein translation. mTORC1 
also activates ribosome biogenesis via regulating the TIF1A signaling. Besides, 
mTORC1 controls transcriptions of many genes via modulating the activities of URI 
(unconventional prefoldin RPB5 interactor) and transcription factors such as STAT1 
and STAT3 (Wullschleger et al., 2006). More importantly, mTORC1 regulates the 
induction of autophagy at the initiation step by modulating the ULK1 complex 
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activity as discussed in Section 1.2.3.2. Activation of mTORC1 phosphorylates ULK1 
and Atg13 at the inhibitory sites, leading to suppression of autophagy. 
The biological functions of mTORC2 are less understood. It is known that 
mTORC2 signals to the actin cytoskeleton regulation (Jacinto et al., 2004; Sarbassov 
et al., 2004), and controls the stability of proteins such as PKC and Akt by 
phosphorylating their turn motif (Facchinetti et al., 2008; Ikenoue et al., 2008). 
Remarkably, mTORC2 has been identified as the PDK2 that phosphorylates Akt at 
the hydrophobic motif (Ser473) (Jacinto et al., 2006; Sarbassov et al., 2005). So far, 
there is no apparent evidence showing that mTORC2 directly participates in 
autophagy regulation. 
Growth factors signal to mTORC1 
mTORC1 is one of the major molecule that respond to growth factors such as 
insulin for regulation of cell growth and proliferation. Ligation of insulin with its 
receptor leads to activation of PI3K class I, which produces PIP3 to recruit Akt onto 
the cytoplasmic membrane, whereby the Akt is activated by PDK1 at the activation 
loop (Thr308). Akt can be further phosphorylated at the hydrophobic motif (Ser473) 
by mTORC2 and becomes fully activated (Jacinto et al., 2006; Sarbassov et al., 2005). 
The activated Akt in turn phosphorylates TSC2 and disrupts the TSC1-TSC2 complex. 
Dissociation of TSC1-TSC2 complex subsequently maintains the Rheb in its 
GTP-bound form (Inoki et al., 2002; Tee et al., 2002; Tee et al., 2003). The 
GTP-Rheb then activates mTORC1 (Inoki et al., 2003a; Li et al., 2004; Long et al., 
2005a). However, the importance of TSC2 as an Akt substrate in mTORC1 activation 
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may not be the only route (Dong and Pan, 2004; Hahn-Windgassen et al., 2005). 
Alternatively, Akt has been demonstrated to directly phosphorylate PRAS40 
(proline-rich Akt/ PKB substrate 40 kDa), an mTOR binding partner that inhibit 
mTOR kinase activity. Phosphorylation of PRAS40 by Akt targets it for association 
with 14-3-3 and dissociate from the mTORC1, which thus allows mTORC1 
activation (Vander Haar et al., 2007). 
Nutrients signal to mTORC1 
Nutrients, especially essential amino acids (EAA), are able to activate mTORC1. 
It was proposed that amino acids activate mTORC1 also via TSC1-TSC2 complex 
(Gao et al., 2002) or Rheb (Long et al., 2005b; Saucedo et al., 2003). Recent studies 
revealed that amino acid-mediated mTORC1 activation is dependent on the Rag 
GTPase (Kim et al., 2008; Sancak et al., 2008). Moreover, it was found that the Rag 
GTPase per se does not directly activate mTOR kinase, but localizes mTORC1 to the 
compartment whereby it is activated by Rheb (Sancak et al., 2008).  
The signaling pathways upstream of Rag protein remain mysterious. It has been 
identified that the transportation of essential amino acids into cells is carried out by 
the bidirectional transporter, SLC1A5, which simultaneously facilitates the efflux of 
L-glutamine out of cells and the influx of L-leucine/EAA into cells (Nicklin et al., 
2009). This important finding explains why single amino acid fails to activate 
mTORC1 (Hara et al., 1998). As for the signaling downstream of the transporter, the 
PI3K class III (hVps34) has been reported as a mediator (Byfield et al., 2005; 
Nobukuni et al., 2005). In addition, it has been found that amino acid can activate 
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hVps34 via Ca2+/calmodulin (Gulati et al., 2008). However, a recent study suggested 
that the hVps34 activity is not regulated by calmodulin, but rather dependent on 
hVps15 (Yan et al., 2009). Nevertheless, it is intriguing that hVps34 activity is 
required for amino acid withdrawal-induced autophagy while also precedes amino 
acid-induced mTORC1 activation and subsequent suppression of autophagy. On the 
other hand, a number of studies have shown that the hVps34 is constitutively 
activated in a nutrient-independent manner (Petiot et al., 2000; Takahashi et al., 2007; 
Tassa et al., 2003); moreover, the activity of Vps34 has been shown to be essential for 
autophagy but not for activation of TOR in drosophila (Juhasz et al., 2008), 
suggesting that the activity of hVps34 may not be the key molecule mediating amino 
acid-stimulated mTORC1 activation. At present, there is no plausible explanation 
answering such an apparent discrepancy.  
Energy balance signals to mTORC1 
As the central machinery controlling metabolism in response to metabolic cues, 
mTORC1 can sense the balance of cellular energy and adjust energy consuming plans 
accordingly. The key molecule bridging the balance of energy and mTORC1 activity 
is AMP-activated protein kinase (AMPK). AMPK is activated by LKB1 when the 
AMP/ATP ratio increases, which is resulted from short of energy supply or excessive 
energy consuming (Corradetti et al., 2004; Hardie et al., 1998; Shaw et al., 2004). 
Activated AMPK directly phosphorylates TSC2, leading to stabilization of the 
TSC1-TSC2 complex. The TSC1-TSC2 complex thus catalyses the GTP-Rheb into 
GDP-Rheb and eventually suppresses mTORC1 (Inoki et al., 2003b). In addition, 
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AMPK also directly phosphorylates raptor, targeting raptor for sequestration by 
14-3-3, thereby suppresses mTORC1 activity (Gwinn et al., 2008). Collectively, 
depletion of ATP can be sensed by LKB1-AMPK pathway that signals to mTORC1, 
which consequently downregulates energy demands by reducing cellular anabolic 
process and upregulates energy supply by accelerating catabolic process such as 
autophagy. 
In Figure 1.4, the major signaling pathways, which sense growth factors, amino 
acids, and energy balance and signal to mTOR for regulation of autophagy, are 
illustrated. 
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Figure 1.4 Major signaling pathways control autophagy via mTOR 
 
Other pathways signal to mTORC1 
In addition to the classical signaling pathways described above, various other 
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pathways have been shown capable of modulating mTORC1 activity. Hypoxia is able 
to inhibit mTORC1 via REDD. Hypoxia upregulates the expression of REDD by 
activating the transcription factor, hypoxia-induced factor 1 (HIF1). The REDD then 
liberates TSC2 from 14-3-3 to form the TSC1-TSC2 complex, leading to inhibition of 
mTOR (DeYoung et al., 2008).  
ERK has emerged as one of the regulatory factors of mTORC1. Activated ERK 
has been reported to phosphorylate TSC2, resulting in activation of mTORC1 
(Distefano et al., 2009; Ma et al., 2005). Alternatively, ERK activates RSK, which in 
turn phosphorylates raptor, thereby activating mTORC1 (Carriere et al., 2008). 
In response to genotoxic stresses, p53 will be activated to inhibit cell 
proliferation, stop cell cycle progression, induce cell death, and modulate autophagy. 
Some of these functions are believed to be fulfilled via regulation of mTORC1 
activity. In addition to upregulation of various negative regulators in mTOR pathway 
including PTEN, TSC2, activation of p53 results in activation of AMPK, thereby 
suppresses mTORC1 activity (Feng et al., 2005). Such a pathway has been extended 
by a recent study that p53 is able to inhibit mTORC1 and induce autophagy by 
promoting transcription of sestrin1 and sestrin2, which are required for p53-induced 
AMPK activation (Budanov and Karin, 2008). However, it has also been reported that 
deletion, silencing, or inhibition of p53 can activate AMPK and inhibit mTORC1 and 
induce autophagy (Tasdemir et al., 2008b), apparently being controversial to the 
previous studies. It is thus proposed that the cytosolic p53 is an autophagy-suppressor 
whereas the nucleus-located p53 promotes autophagy (Green and Kroemer, 2009; 
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Tasdemir et al., 2008a). 
1.2.4.2 Beclin 1-hVps34 pathway 
In Section 1.2.3.3, we have discussed the essential role of Beclin 1-hVps34 
complex in autophagy at the nucleation step; thus, many signaling pathways can 
influence autophagy via modulating either hVps34 activity or Beclin 1 functions. The 
regulation of hVps34 activity is unclear and controversial. As discussed above, 
several studies proposed that the hVps34 activity can be stimulated by amino acid 
input (Byfield et al., 2005; Nobukuni et al., 2005). However, other evidence showed 
that the hVps34 appears constitutively active independent of nutrient milieu (Petiot et 
al., 2000; Takahashi et al., 2007; Tassa et al., 2003). Nevertheless, it has been reported 
that hVps34 activity can be regulated by an Endophilin B member, Bif-1 (also known 
as Endophilin B1). Bif-1 can interact with the Beclin 1-hVps34 complex via UVRAG 
and acts as a positive modulator of hVps34 in its kinase activity to promote 
autophagy (Takahashi et al., 2007).  
The function of the Beclin 1-hVps34 complex in autophagy can be alternatively 
regulated by modulation of Beclin 1 activity. Beclin 1 contains a BH3 domain that 
facilitates its interaction with various Bcl-2 family members. In normal conditions, 
Beclin 1 is bound to and inhibited by Bcl-2 or Bcl-xL (Maiuri et al., 2007b). Upon 
receiving appropriate signals, Beclin 1 dissociates from Bcl-2 and Bcl-xL and 
facilitates induction of autophagy (Levine et al., 2008). The interaction between Bcl-2 
and Beclin 1 is subjected to regulation by extracellular nutrients availability 
(Pattingre et al., 2005). Further study identified the JNK1 as the upstream molecule 
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that phosphorylates Bcl-2 at multiple sites, leading to the dissociation of Bcl-2 from 
Beclin 1 and induction of autophagy, although how starvation activates JNK1 is 
unclear (Wei et al., 2008). Similarly, disruption of the interaction between Beclin 1 
and Bcl-2 can also take place in vitro via phosphorylation of Beclin 1 at its BH3 
domain by the death-associated protein kinase (DAPK) (Zalckvar et al., 2009). 
However, whether DAPK functions as such under physiological conditions requires 
further studies (He and Levine, 2010). 
As the interaction between Beclin 1 and Bcl-2, Bcl-xL is mediated by the BH3 
domain, one can speculate that other BH3-only domain-containing protein may 
competitively displace Beclin 1 from Bcl-2. This has been supported by the study that 
a BH3-mimetic compound, ABT-737, is able to disrupt the interaction and induce 
autophagy (Oltersdorf et al., 2005). More recently, Bad, Bnip3, and Bax have also 
been reported to induce autophagy via such a competitive binding mechanism in 
response to various stimuli such as hypoxia, growth factor withdrawal (Bellot et al., 
2009; Maiuri et al., 2007a; Mammucari et al., 2007; Yee et al., 2009). The regulations 
of Beclin 1 by Bcl-2 family members are illustrated in Figure 1.5 (He and Levine, 
2010).  
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Figure 1.5 Regulation of Beclin 1 by Bcl-2 family members 
1.2.4.3 Other regulatory pathways 
Autophagy can be regulated through several other approaches such as 
manipulation of Atg protein transcription. For example, growth factor withdrawal 
inactivates Akt, leading to activation of the forkhead box O (FoxO) transcription 
factors 3 (FoxO3). FoxO3 then amplifies a variety of autophagy-related genes 
including LC3, Bnip3, Atg4, and hVps34, which are essential for induction of 
autophagy during muscle atrophy (Mammucari et al., 2007; Zhao et al., 2007). As 
another example, in response to ER-stress, the eucaryotic translation initiation factor 
2α (eIF2α) can be activated by PERK, leading to selective translation of specific 
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transcription factors, which augments transcription of Atg12 and promotes autophagy 
(Kouroku et al., 2007).  
Since autophagy is a dynamic process consisting of multiple steps, it can be 
regulated by modulations at the late stages other than at the induction step. For 
instance, it has been reported that the membrane cycling machinery could be 
regulated by p38α MAPK via modulating the interaction between Atg9 and its 
inhibitory binding partner, p38IP (Webber and Tooze, 2009). The autophagosome 
maturation has been shown to be disrupted by sustained ERK activation induced by 
carcinogen (Corcelle et al., 2006). DRAM, a lysosome protein downstream of p53, 
has been demonstrated as an essential player in DNA damage-induced autophagy, 
presumably through modulating lysosome functions (Crighton et al., 2006).  
1.2.4.4 Conclusion remarks 
Taken together, autophagy can be regulated by multiple pathways in response to 
various cellular cues. Importantly, one stimulus may regulate autophagy via multiple 
means in an orchestrated fashion. For example, growth factor withdrawal can induce 
autophagy by suppressing PI3K class I-Akt-mTOR pathway; in addition, it also 
activates FoxO3 to upregulate the transcription of Atg proteins to promote autophagy. 
Growth factor withdrawal will decrease nutrient uptake such as glucose, which 
eventually results in ATP depletion and AMPK activation, further increasing 
autophagy (Lum et al., 2005a). Of note, the molecules that are essential for autophagy 
regulation are usually subjected to regulations by numerous other signaling networks. 
For example, the JNK1, AMPK can be activated by IKK (Criollo et al., 2009) and 
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p53 (Jones et al., 2005), which thus integrates the cytokine responses and 
DNA-damage signals into autophagy regulation. Therefore, regulation of autophagy 
is governed by an extremely complex cell signaling network. 
1.2.5 Autophagy functions and implications in diseases 
Autophagy has been shown to possess diverse biological functions under both 
physiological and pathological conditions, through which autophagy is implicated 
into organismal survival, development, and various diseases including cancer, 
neurodegeneration diseases, immunodeficiency diseases, and infection diseases. 
1.2.5.1 Biological functions of autophagy 
As one of major catabolic processes, autophagy has been shown by 
overwhelming evidence to provide the essential energy and nutrient recycling for 
organisms to survive starvation and this function has been proven conserved from 
yeast to mammals: if there is no food available in the surroundings, a cell is forced to 
break down part of its own reserves to stay alive until the situation improves 
(Mizushima et al., 2008). However, autophagy has also been implicated in cell death 
mechanisms. It is believed that excessive autophagy can destroy essential cellular 
components that are required for survival, leading to cell death.  
Although autophagy was originally recognized as a non-selective process, 
accumulative evidence has emerged suggesting it may selectively degrade certain 
cellular components such as damaged organelles, protein aggregates (Klionsky and 
Emr, 2000). For example, the mitophagy, referring to the autophagy that selectively 
targets mitochondria for degradation, has been extensively studied and proposed to be 
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an important quality control system by removing the defective mitochondria (Kim et 
al., 2007a; Lemasters, 2005). In addition to degradation of mitochondria, autophagy 
can turnover other organelles including peroxisome (Kim and Klionsky, 2000) and 
ER (Bernales et al., 2006). More importantly, autophagy is able to remove protein 
aggregates. During ER stress, newly synthesized proteins cannot be properly folded 
in ER; the misfolded proteins are poorly dissolved and form insoluble protein 
aggregates, which is cytotoxic (Kruse et al., 2006). The misfolded protein aggregates 
can be selectively disposed via autophagy mainly mediated by p62 (Bjorkoy et al., 
2005; Ding et al., 2007b; Kruse et al., 2006; Pankiv et al., 2007). In addition, 
autophagy has been shown capable of recognizing certain invasive bacteria and 
specifically delivering them to lysosome for degradation. Therefore, selective 
autophagy plays housekeeping roles for disposal of the cellular wastes as well as 
invaders. 
1.2.5.2 Implications of autophagy in human diseases 
A large body of evidence has indicated a strong connection between autophagy 
and cancers. It was found that allelic loss of Beclin 1 resulted in increased 
tumorigenesis in mice and enforced expression of Beclin 1 inhibited tumor growth 
(Liang et al., 1999; Qu et al., 2003; Yue et al., 2003); moreover, net deletions of 
several autophagy-specific genes are commonly found in human malignancies 
(Levine, 2007), suggesting a tumor-suppressor function of autophagy. Consistent with 
this theory, tumor-suppressor genes such as p53 and PTEN turn autophagy on, and 
genes that are frequently activated in cancer, such as class I PI3K and Akt, turn it off 
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(Levine, 2007). Several models have been proposed to explain the anti-cancer 
function of autophagy. For example, it has been established that autophagy can 
protect genome stability by removing damaged mitochondria and eliminating 
overproduced ROS (Karantza-Wadsworth et al., 2007; Mathew et al., 2007). 
Alternatively, autophagy can prevent inflammation response, which is a 
pro-tumorigenesis factor, by suppressing metabolic stress-induced necrotic cell death 
in tumors (Degenhardt et al., 2006). It is also possible that autophagy can negatively 
regulate cell growth and other pro-tumorigenesis signaling (Mathew et al., 2009). On 
the other hand, autophagy may also promote tumor growth by maintaining tumor 
cell’s viability under nutrient deprivation conditions that could happen when a tumor 
grows too fast to get enough blood supply (Levine, 2007). 
Emerging evidence suggests a pivotal role of autophagy in neurodegenerative 
diseases. The constitutive basal level of autophagy is believed to be essential for 
normal neuronal function. For example, mice with neuron-specific deletion of Atg5 or 
Atg7 display severe neurodegeneration and a massive accumulation of protein 
aggregates (Hara et al., 2006; Komatsu et al., 2006), indicating autophagy can rescue 
neuronal cells via removing the cytotoxic protein aggregates. Consistently, in the 
human neurodegenerative diseases, such as Huntington’s, Alzheimer’s, and 
Parkinson’s, which are caused by accumulation and aggregation of defective 
misfolded cytosolic proteins, autophagy has been seen upregulated trying to protect 
neuronal cells (Meijer and Codogno, 2009). Moreover, the mutant huntingtin protein 
has been found to be degraded via autophagy (Jeong et al., 2009).  
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Because of its very nature, the gastrointestinal tract is potentially subject to 
inflammation and infection. Crohn’s disease is an inflammatory disease affecting the 
small intestine. Recently, several genomewide association studies revealed a 
connection of Atg16L1 mutation with Crohn’s disease, implying a potential key role 
of autophagy in this disease (Cadwell et al., 2008; Kuballa et al., 2008). In these 
studies, the mutant form of Atg16L1 associated with Crohn’s disease (T300A) has 
been found to induce multiple defects in Paneth cells that result from autophagy 
deficiency (Cadwell et al., 2008). These defects are also reproduced in mice lacking 
either Atg5 or Atg7 (Cadwell et al., 2008; Cadwell et al., 2009). Thus far, how these 
defects of Paneth cells contribute to Crohn’s disease is unclear. One possible 
explanation is that the autophagy-deficient Paneth cells produce more 
pro-inflammatory cytokines such as IL-1 that facilitate the development of this 
inflammatory disease (Saitoh et al., 2008). 
In addition to the diseases listed above, autophagy has been implicated in 
various other human diseases including aging, liver diseases, heart diseases, infection 
diseases. The role of autophagy in human diseases has been extensively discussed and 
reviewed elsewhere (Huang and Klionsky, 2007; Meijer and Codogno, 2009; 
Mizushima et al., 2008) and a brief summary is presented below in Figure 1.6 
(Mizushima et al., 2008). 
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Figure 1.6 The role of autophagy in human diseases 
 
1.3 Crosstalk between autophagy and PCD 
It has long been observed that autophagosomes are usually presented in dying 
cells, suggesting a close link between cell death and autophagy (Bursch, 2001; 
Schweichel and Merker, 1973). However, it is unclear whether autophagy is an 
innocent bystander, or a death execution machinery, or a defensive mechanism that 
eventually fails to preserve cell viability (Levine and Yuan, 2005). In the past several 
years, tremendous efforts have been dedicated to explore the crosstalk between 
autophagy and PCD. Accumulating evidence suggests that autophagy may play 
distinct roles in the course of PCD under different biological settings (Fimia and 
Piacentini, 2009).  
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1.3.1 Autophagy in apoptosis 
Apoptosis is the best-characterized pathway for “self-killing” while autophagy is 
the well-established mechanism for “self-eating”. Thus, apoptosis and autophagy 
constitutes two processes maintaining organismal and cellular homeostasis by 
eliminating damaged and aged cells or malfunctioned organelles and misfolded 
proteins. A number of studies revealed that apoptosis and autophagy can be 
simultaneously activated by various inducers including etoposide (Feng et al., 2005) 
and ceramide (Pattingre et al., 2009). These lead to the speculation that these two 
processes may take place concomitantly. However, a large body of evidence appears 
to suggest a complex relationship between apoptosis and autophagy. Under certain 
scenarios, autophagy acts to promote or is required for induction of apoptosis, while 
under other certain scenarios, autophagy serves as a pro-survival mechanism to 
prevent apoptosis. 
1.3.1.1 Pro-death function of autophagy in apoptosis 
It has been reported that suppression of autophagy by 3-methyladenine (3-MA) 
attenuates arsenic trioxide-induced apoptosis in leukemia cell lines. In CD4+ T 
lymphocytes, blocking autophagy by either 3-MA or knockdown of Atg7 and Beclin 
1 abolished apoptosis induced by transfection of HIV-1 envelope glycoproteins 
(Espert et al., 2006). Salazar, M. and colleagues reported that cannabinoid is able to 
induce autophagy via ER-stress response, which is the upstream signal of 
cannabinoid-induced apoptosis in human and mouse cancer cells (Salazar et al., 
2009a, b). These results thus imply the pro-death function of autophagy towards 
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apoptosis. Several models have been established at the molecular level to explain the 
pro-death function of autophagy.  
Akt and ERK 
As described in Section 1.2.4.1, the mTORC1 is the central molecules regulating 
autophagy downstream of the PI3K-Akt-TSC and Raf-MEK1/2-ERK-RSK pathways. 
The Akt and ERK pathways are by no means specific to autophagy but have a wide 
range of activities in the cell, particularly in the context of apoptosis (McCubrey et al., 
2007; Song et al., 2005). Akt is able to inhibit apoptosis via phosphorylation of Bad 
and suppression of FoxO transcription factors as introduced in Section 1.1.1.3 
(Brunet et al., 1999; Datta et al., 1997; Zha et al., 1996). Likewise, ERK and RSK 
activation also ablates apoptosis via phosphorylation of Bad and activation of the 
transcription factor CREB that amplifies anti-apoptosis proteins (Ballif and Blenis, 
2001). In this regards, the apoptosis may be promoted by suppression of the Akt and 
ERK/RSK pathways, which probably leads to concomitant induction of autophagy. 
Of note, this mechanism illustrates that apoptosis may be influenced by the signaling 
pathways that are shared by autophagy. 
Atg5 
Atg5 is one of the key components participate in autophagy at the membrane 
expansion step as described in Section 1.2.3.4. Targeting Atg5 by knockdown or 
knockout has been widely applied to investigate the function of autophagy. 
Interestingly, Atg5 has been found to be cleaved by calpains and the truncated Atg5 
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could translocate from cytosol to mitochondria to promote cytochrome c release and 
caspase activation (Yousefi et al., 2006). This is the first finding that demonstrated an 
autophagy-independent function of Atg5. Interestingly, one can assume that this 
cross-talk probably is a mechanism by which apoptosis suppresses autophagy, 
perhaps under circumstances when the latter’s pro-survival functions would counter 
cell death (Eisenberg-Lerner et al., 2009).  
Bcl-2 family members 
In Section 1.1.1.3 and 1.2.4.2, the essential implications of Bcl-2 proteins in 
regulation of apoptosis and autophagy have been discussed respectively. In general, 
the anti-apoptosis proteins such as Bcl-2, Bcl-xL, and Mcl-1 can inhibit autophagy by 
interacting with and suppressing Beclin 1. Conversely, pro-apoptotic BH3-only 
proteins such as BNIP3, Bad, Noxa, Puma, and Bik can induce autophagy by 
liberating Beclin 1 (Levine et al., 2008). Thus, it appears that the Bcl-2 proteins could 
bridge the pro-death function of autophagy in apoptosis. It appears that autophagy 
could inhibit apoptosis by sequestering Bcl-2 proteins via Beclin 1. However, this has 
been shown not the truth that the Beclin 1-bound Bcl-2 and Bcl-xL still maintain full 
anti-apoptosis functions (Ciechomska et al., 2009). This can be further supported by 
the observation that overexpression of Beclin 1 does not exert detectable apoptogenic 
effects while induces autophagy (Levine et al., 2008). Thus, the dual role of Bcl-2 
proteins in apoptosis and autophagy largely manifests a pathway that the apoptotic 
stimuli can concomitantly trigger autophagy, but not the direct impact of autophagy 
on apoptosis. 
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p53 
p53 is a well-know activator of apoptosis and also displays complex functions in 
autophagy (see Section 1.1.1.3 and 1.2.4.1). By facilitating the transcription of a 
variety of BH3-only proteins, such as Bad, Noxa and Puma, p53 is able to promote 
apoptosis as well as autophagy (Fridman and Lowe, 2003; Levine et al., 2008). 
Beside, in response to DNA damage, p53 can promote autophagy via transcription of 
DRAM, a lysosomal protein, which is required for the sequential apoptosis (Crighton 
et al., 2006). Therefore, p53 may be another link mediating the crosstalk between 
autophagy and apoptosis. Similarly, the effect of autophagy per se on apoptosis is not 
investigated in this context. 
Providing energy for suicide 
It is interesting to note that apoptosis, albeit a movement of cellular cease, still 
requires energy for completion. Thus, one can hypothesize that, under certain 
circumstances when cellular energy is extremely scarce, autophagy may fuel 
apoptosis by providing the energy. It was reported that autophagy was required for 
cells in embryoid bodies to expose phosphatidylserine on the cell surface, which is a 
typical apoptotic marker (Qu et al., 2007). However, in the same study, the authors 
also found that the apoptosis proceeded normally in the embryoid bodyies with 
defects of autophagy but the corps could not be engulfed by neighbor cells because 
lacking of the exposed phosphatidylserine signal (Qu et al., 2007). Therefore, it is 
clear that induction of apoptosis does not require autophagy pathway but the late 
apoptotic events may need it for energy supply (Kroemer and Levine, 2008). 
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1.3.1.2 Pro-survival function of autophagy in apoptosis 
Autophagy has long been proposed to be a cell survival strategy, especially for 
overcoming nutrient deprivation conditions, by providing energy and amino acid 
recycling (Boya et al., 2005; Levine and Yuan, 2005). Thus far, the protective role of 
autophagy against apoptosis has been witnessed under various cellular settings. For 
example, induction of autophagy can mitigate ER stress-induced apoptosis (Bernales 
et al., 2006; Ding et al., 2007a; Ogata et al., 2006). Autophagy was shown to protect 
non-transformed epithelial cells from anoikis, the loss of matrix attachment that 
induces apoptotic cell death (Fung et al., 2008). Autophagy also displays protective 
role against DNA damage-induced apoptosis (Ito et al., 2005; Paglin et al., 2001). A 
number of models have been proposed to explain the pro-survival function of 
autophagy in apoptosis. 
Energy and nutrients recycling 
Under starvation conditions, depletion of energy and nutrients will activate 
autophagy in attempt to adapt to starvation. By engulfing and digesting bulk cytosolic 
contents, autophagy provides a critical energy and metabolite supply to favor cell 
survive (Lum et al., 2005b). In response to DNA-damage agents, the intracellular ATP 
production can be maintained via autophagy and serves to promote cell survival 
(Katayama et al., 2007). Remarkably, such a notion is well-supported by a in vivo 
study that the mice lacking Atg5 or Atg7 cannot survive during neonatal period, when 
the placental blood supply is interrupted and they undergo a form of starvation 
(Komatsu et al., 2005; Kuma et al., 2004).  
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Although depletion of energy and nutrients might be the triggers for induction of 
apoptosis, In vitro studies found that the drop of ATP usually occurs at the late stage 
of apoptosis (Bossy-Wetzel et al., 1998), moreover, intracellular ATP production was 
only required for downstream events in apoptosis (Eguchi et al., 1997), indicating that 
depletion of energy may not be true mechanism for induction of apoptosis (Green and 
Reed, 1998). Therefore, how autophagy, by supplying energy and nutrient recycling, 
prevents or delays the onset of apoptotic machinery is still elusive. 
Cellular “housekeeper” 
    Despite that autophagy has been predominantly regarded to degrade cytosolic 
contents non-discriminately, accumulative evidence suggests it also possesses 
selectivity towards its targets such as harmful organelles (Mizushima et al., 2008). 
For example, autophagy can target damaged mitochondria for disposal thereby reduce 
the susceptibility of cells to MOMP-dependent apoptotic stimuli (Lemasters, 2005; 
Ravikumar et al., 2006). More importantly, autophagy is able to remove protein 
aggregates that are cytotoxic cellular waste. This anti-apoptosis function of autophagy 
has been supported by in vitro as well as in vivo studies. For example, autophagy 
mitigates unfolded protein response (UPR)-induced apoptosis by removing the 
misfolded protein aggregates (Ding et al., 2007b; Zhou et al., 2009). The basal level 
of autophagy in neuronal cells is believed to function essentially as a housekeeper for 
disposal of protein aggregates; therefore, mice with impaired autophagy function via 
deletion of Atg5, Atg7 or Ambra1 are prone to develop neurodegenerative diseases 
(Fimia et al., 2007; Hara et al., 2006; Komatsu et al., 2006).  
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1.3.2 Autophagy in necrosis 
    In contrast to apoptosis that requires energy for its completion, necrosis is 
believed to be caused by bioenergetic catastrophe as it can be experimentally 
reproduced in vitro by disrupting the cell’s ability to produce ATP (Zong and 
Thompson, 2006). In this regard, it appears that autophagy, as a catabolic process 
capable of generating energy, should act as a pro-survival strategy against necrosis. 
It’s true that the pro-survival function of autophagy in necrosis under various cellular 
contexts has been shown in numerous studies. However, accumulative evidence also 
links autophagy to the execution of necrosis as a cell death mechanism, which has 
been widely regarded as the autophagic cell death.  
1.3.2.1 Pro-survival function of autophagy in necrosis 
Lum and his colleagues found that, upon growth factor withdrawal, the 
Bax/Bak-/- double knockout MEF cells (DKO MEF) underwent progressive atrophy 
which was caused by the cell’s inability to utilize extracellular glucose. Interestingly, 
disruption of autophagy pathway by knockdown of Atg5 led to rapid necrosis under 
such a cellular context, indicating that the cells can avoid necrosis and stay alive on 
the nutrients and energy provided by autophagy (Lum et al., 2005a). This notion is 
supported by another study in which GAPDH-mediated upregulation of glycolysis 
and autophagy protected cells from necrosis (Colell et al., 2007).  
The anti-necrosis function of autophagy has also been observed in numerous 
other models. For example, inhibition of autophagy by activation of Akt or allelic 
disruption of Beclin 1 sensitizes tumor cells to necrosis in response to metabolic 
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stress (Degenhardt et al., 2006). In the follow up studies, the same group revealed that 
defective autophagy mitigates metabolic stress-induced necrosis via limiting 
DNA-damage and maintaining genome integrity (Karantza-Wadsworth et al., 2007; 
Mathew et al., 2007).  
1.3.2.2 Autophagic cell death 
Definition of autophagic cell death 
Thus far, the concept “autophagic cell death” is still a subject of confusion. Is it 
introduced to morphologically describe a form of cell death that manifests large-scale 
of autophagosomes in the dying cells (Galluzzi et al., 2008; Kroemer et al., 2009; 
Yoshimori, 2007) or to mechanistically describe a cell death whose execution 
depends on autophagy (Kroemer et al., 2009; Kroemer and Levine, 2008; Levine and 
Yuan, 2005)? The former expression indeed describes that cells die with autophagy 
whereas the latter means by autophagy. Nevertheless, autophagic cell death has been 
predominantly adopted throughout the literature as the autophagy-dependent 
non-apoptotic cell death. Therefore, we decide to introduce autophagic cell death here 
under the category of necrosis. 
Although autophagy has been unequivocally shown as a cell survival strategy, 
particularly under starvation conditions, evidence from both in vivo and in vitro 
studies has emerged showing that it may participate in cell death execution, leading to 
autophagy-dependent but caspase-independent cell death. Here we revisit several 
widely-accepted autophagic cell death models carefully with newly gained 
knowledge of autophagy. 
                                                            55 
Autophagic cell death in vivo in Drosophila 
Berry and Baehrecke found that autophagy was induced and preceded 
developmental degradation in Drosophila salivary glands (Berry and Baehrecke, 2007) 
and such an observation was believed to represent the first in vivo evidence of 
autophagic cell death (Berry and Baehrecke, 2008). Interestingly, in this model, 
inhibition of autophagy via various approaches caused massive apoptosis in the 
glands and a delayed histolysis, indicating that both autophagy and apoptosis are 
involved in salivary gland developmental regression (Berry and Baehrecke, 2007).  
However, compound inhibition of autophagy and apoptotic pathways still cannot 
block the eventual regression of salivary gland, which suggests that both processes 
are dispensable for cell death to occur in this model (Berry and Baehrecke, 2007). 
Furthermore, in a study by another group, DARK, the D. melanogaster APAF1 
orthologue, was shown to be essential for salivary gland histolysis but dispensable for 
autophagy, suggesting that autophagy per se is not the death mechanism (Akdemir et 
al., 2006). This discrepancy might be well explained if autophagy is induced to 
precede phosphatidylserine exposure in the apoptotic cells for their efficient clearance 
by neighbors (Qu et al., 2007). Thus, autophagy may facilitate developmental 
degradation of the salivary glands by promoting clearance of apoptotic cells while is 
dispensable for cell death per se.  
Autophagic cell death in vivo in D. discoideum 
Another in vivo autophagic cell death model is established in Dictyostelium 
discoideum, a soil amoeba that lacks Bcl-2 and caspases, and hence is an ideal model 
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for studying non-apoptotic death pathways (Tresse et al., 2007). In a D. discoideum 
monolayer system, starvation induced autophagy but no cell death; on the other hand, 
addition of differentiation-inducing factor (DIF) in full media did not kill cells either; 
compound treatment with starvation and DIF induced caspase-independent cell death 
with autophagic structures (Levraud et al., 2003; Roisin-Bouffay et al., 2004). It was 
found that disruption of atg1 abrogated autophagy vacuolization, but the cells 
nevertheless died with a necrotic morphology in response to starvation plus DIF 
(Kosta et al., 2004); The authors believed that the necrosis resulted from abrogation 
of autophagy just similar to the fact that necrosis could be induced upon caspase 
inhibition; therefore, such observations were interpreted as evidence supporting that 
autophagy is cell death mechanism (Kosta et al., 2004; Tresse et al., 2007).  
However, such an analog appears not appropriate. It is true that, under particular 
circumstances, necrosis can take over when caspase activation is inhibited; this 
indeed by no means can serve as a piece of proof to support caspase as a cell death 
mechanism. The conclusion that apoptotic pathway is a death mechanism stems from 
the numerous observations that blockage of apoptotic pathway abolishes cell death. 
Therefore, based on the data in this study, we only can conclude a cell death with 
autophagy but not by autophagy. Moreover, providing no plausible biochemical 
markers available to further distinguish necrosis from other non-apoptotic cell death 
(Kroemer et al., 2009), it is possible that the “autophagic cell death” described in this 
model could be indeed necrosis with vacuoles that renders the cells a 
non-necrotic-like morphology. Furthermore, it is still possible that, via providing 
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energy, autophagy functions to prevent the occurrence of the late events of necrosis 
that manifest the “central condensation” and “membrane rupture” morphology, 
similar to the role of autophagy in apoptosis for preceding exposure of 
phosphatidylserine (Qu et al., 2007). In short, the evidence supporting the autophagic 
cell death in this model is still not convincing. 
Autophagic cell death in vitro in DNA-damage agent–treated DKO MEF 
In 2004, two studies provided in vitro examples for autophagic cell death. In one 
study, the MEF cells deficient in both Bax and Bak (DKO MEFs) were employed as a 
model for studying non-apoptotic cell death (Shimizu et al., 2004). In response to 
DNA damage agents such as etoposide and staurosporine, the DKO MEFs underwent 
a non-apoptotic cell death manifesting autophagic morphology. Interestingly, such 
non-apoptotic cell death was dependent on autophagy as targeting Atg5 and Beclin 1 
was able to preserve cell viability. Moreover, the etoposide-induced increase of 
Atg5-Atg12 was believed to be essential for upregulation of autophagy. They also 
showed that the etoposide-induced autophagy was enhanced by overexpression of 
Bcl-2 and blocked by knockdown of Bcl-xL and Beclin 1 (Shimizu et al., 2004).  
However, a number of issues deserve to be carefully considered here. First, in 
this study, the Atg5 expression or Atg5-Atg12 conjugation was shown to be 
controlled by Beclin 1 (Shimizu et al., 2004). It is now known that the Atg5-Atg12 
conjugation is performed in a UBL reaction controlled by Atg7 (E1) and Atg10 (E2), 
which is constitutively activated and appears to be independent of Beclin 1 (Suzuki et 
al., 2005; Tanida et al., 2001). Second, in this study, Bcl-2 and Bcl-xL were found to 
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upreguate Atg5-Atg12 and consequently promote autophagy. However, it has been 
well-established that Bcl-2 and Bcl-xL can suppress autophagy by binding to and 
inhibiting Beclin 1 (Pattingre et al., 2005).  
It is noteworthy that the Atg5-Atg12 appeared to be the crucial molecules in 
controlling both autophagy and cell death (Shimizu et al., 2004). It is thus possible 
that the cell death is dependent on Atg5 but not autophagy per se since Atg5 has been 
known to be cleaved by calpain in response to staurosporine and the truncated Atg5 
can precede cell death (Yousefi et al., 2006). Such a hypothesis also plausibly 
explains why silencing Atg5 and Beclin 1 (suppresses Atg5 expression) protects cell 
death and why overexpression of Bcl-2 and Bcl-xL (increases Atg5 expression) 
enhances cell death while, as we know now, inhibits autophagy (Yousefi et al., 2006). 
Autophagic cell death in vitro in zVAD-treated L929 cells 
During the same year, the Lenardo group form NIH reported that zVAD, a 
pan-caspase inhibitor, induced non-apoptotic cell death in several cell lines, 
particularly in fibrosarcoma L929 cells (Yu et al., 2004). They found that a large 
number of autophagosome accumulated in the dying cells, and the cell death could be 
ablated by silencing Beclin 1 and Atg7, suggesting that such cell death is 
autophagy-dependent. On the other hand, the activation of the 
RIP1-MKK7-JNK-c-Jun pathway and de novo protein synthesis were found to be 
required for zVAD-induced autophagy and cell death. The authors also found that this 
signaling pathway was triggered due to zVAD-mediated caspase-8 inhibition, which 
stabilized RIP1 (Yu et al., 2004). Based on these observations, it was proposed that 
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zVAD can induce autophagy by activating the RIP1-JNK-c-Jun pathway and the 
excessive autophagy executes the non-apoptotic cell death (Yu et al., 2004). 
Remarkably, in the following-up study, the authors found that such autophagic cell 
death depended on intracellular ROS; moreover, the increase of ROS was resulted 
from autophagy because autophagy selectively degraded catalase, a major 
intracellular ROS scavenger (Yu et al., 2006a). This model has been widely cited as 
an in vitro autophagic cell death model in the literatures. 
According to these two studies, ROS was established to execute cell demise 
downstream of autophagy (Yu et al., 2006a). It is interesting to note that ROS has also 
been well-documented to be the upstream molecules controlling autophagy (Azad et 
al., 2009; Bensaad et al., 2009; Chen and Gibson, 2008); more importantly, 
autophagy can be induced to eliminate excessive intracellular ROS (Rouschop et al., 
2009; Tal et al., 2009), most probably via removing the damaged mitochondria, the 
major source of ROS (Lemasters, 2005). Thus, the interplay between autophagy and 
ROS appears to be complex and depends on cellular contexts. 
Intriguingly, in zVAD-treated L929 cells, the RIP1-JNK-c-Jun signaling 
pathway was shown to be required for induction of autophagy and the consequent cell 
death; but the detailed mechanism was not investigated (Yu et al., 2004; Yu et al., 
2006a). It is thus interesting to further explore the molecular mechanism underlying 
the regulatory role of RIP1 and c-Jun in autophagy and cell death. 
Conclusion remarks 
In addition to the studies listed above, a number of other studies has provided 
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evidence to propose autophagy as a cell death mechanism in vitro as well as in vivo, 
which have been extensively discussed and reviewed elsewhere (Baehrecke, 2005; 
Debnath et al., 2005; Gozuacik and Kimchi, 2007; Levine and Yuan, 2005; Scarlatti et 
al., 2009). It is believed that autophagy may trigger cell death when it is over-induced 
and destroys essential cellular components that are required for maintaining cell 
viability (Kroemer and Levine, 2008; Scarlatti et al., 2009). This hypothesis appears 
to be supported by several studies. For example, in D. melanogaster larvae, 
transgenic expression of a highly active atg1 mutant induces excessive autophagy and 
premature degradation of salivary glands (Scott et al., 2007), which can be prevented 
by atg12 knockdown but not overexpression of CrmA (Berry and Baehrecke, 2007). 
In cultured mammalian cells, constitutively active Beclin 1 mutants induce excessive 
levels of autophagy and non-apoptotic cell death that can be inhibited by siRNA 
against Atg5 (Pattingre et al., 2005). However, thus far, there is no in vivo mammalian 
model convincingly shows that physiological (or even pathological) cell loss is 
executed by autophagy (Kroemer and Levine, 2008). 
 
1.4 Objectives 
To elucidate the regulatory role of autophagy in PCD is important for the 
understanding of the biological functions of autophagy and its implications in various 
human diseases. Thus far, no consensus has been achieved regarding the 
cytoprotective versus the pro-death role of autophagy in cell death; particularly, the 
interplay between autophagy and necrosis is a subject of great controversy. Therefore, 
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the main objective of this study is to investigate the regulatory role of autophagy in 
necrosis and to elucidate the underlying molecular mechanisms using in vitro 
mammalian cell models. The specific aims of this study are: 
1. To examine the role of autophagy in zVAD-induced necrosis via modulation 
of autophagy by either pharmacological or genetic approaches. 
2. To study the regulatory role of class I PI3K-Akt-mTOR signaling axis in 
modulation of autophagy and necrotic cell death  
3. To elucidate the molecular mechanism underlying zVAD-induced necrosis. 







CHAPTER 2  
AUTOPHAGY HAS A PROTECTIVE ROLE DURING zVAD-INDUCED 
NECROTIC CELL DEATH 
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2.1 Introduction 
Autophagy, in particular macroautophagy, refers to an evolutionarily conserved 
process in which intracellular membrane structures sequester proteins and organelles 
for lysosomal degradation (Klionsky and Emr, 2000). In the last decade, the 
autophagic process as well as its molecular machinery has been increasingly 
elucidated, in particular with the identification of autophagy-related (Atg) genes 
(Klionsky, 2007). One characteristic of autophagy is the formation of 
autophagosomes, a dynamic process consisting of several sequential stages: (i) 
induction/initiation, referring to the formation of a membrane sac termed the 
phagophore, (ii) nucleation and expansion, referring to a series of processes leading 
to the formation of the double-membrane-bound autophagosomes containing 
sequestered cellular contents, and (iii) maturation, including lysosomal fusion and 
degradation. It is known that these processes are functionally controlled by distinct 
members of the Atg proteins and their respective upstream signaling pathways 
(Maiuri et al., 2007c; Xie and Klionsky, 2007). For instance, mammalian target of 
rapamycin (mTOR) is thought to act by inhibiting the Atg1 kinase complex (Atg1, 
Atg13, Atg17) which is mainly involved in the induction and initiation stage of 
autophagosome formation, while Atg6/Beclin 1, together with the class III 
phosphoinositide-3 kinase (PI3K), mainly mediates the vesicle nucleation step.  
In recent years, the importance of autophagy in human diseases, including cancer, 
neurodegenerative diseases, immunity and defense has been progressively 
appreciated based on the increasing understanding of the diverse biological functions 
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of autophagy (Huang and Klionsky, 2007; Meijer and Codogno, 2006). Among the 
various functions of autophagy studied, one particularly important and highly 
debatable aspect is its role in cell death and cell survival. On one hand, autophagy has 
been well established as a mechanism for cell survival under stress conditions such as 
starvation, either at the cellular level (Lum et al., 2005a), or for the whole organism 
(Kuma et al., 2004). In addition, autophagy is activated as a defense mechanism in 
response to a number of cancer therapeutics and therefore, suppression of autophagy 
sensitizes cell death in cancer therapy (Abedin et al., 2007; Amaravadi et al., 2007; 
Carew et al., 2007). On the other hand, there is emerging evidence supporting the 
notion that autophagy is an important cell death mechanism (Gozuacik and Kimchi, 
2007; Kondo et al., 2005; Levine and Yuan, 2005). Autophagic cell death is 
characterized by the formation of autophagosomes in the cytoplasm in dying cells and 
has been defined as type II programmed cell death, in conjunction with apoptosis 
(type I programmed cell death) and necrosis (type III cell death) (Debnath et al., 
2005).  
In this study we further explored the role of autophagy in necrotic cell death by 
utilizing a well established system in which zVAD was known to promote necrotic 
cell death induced by cell death ligands or lipopolysaccharide (LPS) (Holler et al., 
2000; Vercammen et al., 1998a; Vercammen et al., 1998b; Xu et al., 2006b). In 
addition, zVAD has been reported to induce cell death in L929 cells via autophagy 
(Yu et al., 2004); which has been well cited as an example to support the concept of 
autophagic cell death. In this study, to our surprise, we found that autophagy played a 
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pro-survival function in zVAD-induced necrotic cell death in L929 cells, based on the 
following two key observations: activation of autophagy via serum starvation or 
inhibition of mTOR protected against zVAD-induced cell death, whereas suppression 
of autophagy by a lysosomal enzyme inhibitor or knockdown of Atg genes greatly 
sensitized zVAD-induced cell death. In addition, we provided evidence showing that 
zVAD was able to block autophagy via its inhibitory effect on lysosomal cathepsin 
enzyme activity. At present, the relationship between autophagy and necrosis has not 
been well elucidated. Data from this study help to dissect these two processes and 
advance our understanding of the intricate relationship between autophagy and 
necrotic cell death. 
2.2 Materials and Methods 
2.2.1 Reagents and antibodies  
    Pan-caspase inhibitor zVAD-FMK, caspase-8 inhibitor zIETD-CHO, and 
caspase-3 inhibitor zDEVD-CHO were purchased from BioMol (Plymouth, PA). 
Cathepsin B substrate (z-ARR.AFC), cathepsin inhibitors, E-64d (E64d) and 
pepstatin A, were purchased from Calbiochem (San Diego, CA). Antibody against 
microtubule-associated protein 1 light chain 3 (LC3) was obtained from Abgent (San 
Diego, CA). Anti-Atg5 antibody was purchased from Cosmo Bio Co (Tokyo, Japan). 
Anti-Atg7 antibody was purchased from ProSci (San Diego, CA). Anti-p62 LCK 
Ligand and anti-Beclin 1 were purchased from Pharmingen (San Jose, CA). Mouse 
recombinant tumor necrosis factor-α (TNFα) was from R&D system. Rapamycin, 
chloroquine, cycloheximide (CHX) and anti-α-tubulin were from Sigma-Aldrich (St. 
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Louis, USA). 
2.2.2 Cell culture and treatments  
    Mouse fibrosarcoma cell line L929 and human lymphoma cell line U937 cells 
were purchased from ATCC, and maintained in Dulbecco’s modified Eagle’s medium 
(Sigma) and RPMI-1640 medium (Sigma) respectively, both containing 10% fetal 
bovine serum (FBS, from HyClone) and 1% penicillin-streptomycin (Invitrogen) in a 
rs were dissolved in DMSO as 
stock solution (10 mM) before treatment. For starvation, cells were cultured in phenol 
and FBS-free DMEM for 2 hrs prior to the designated treatments. 
2.2.3 Detection of cell death  
    In this study, several approaches were used to detect cell death quantitatively and 
qualitatively, including (i) morphological changes under phase-contrast microscopy, 
(ii) Hoechst-sytox staining as described previously (Wu et al., 2008b), (iii) the 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) test as 
described elsewhere (Yang et al., 1999), and (iv) the propidium iodide (PI) exclusion 
assay using flow cytometry (Yu et al., 2006a). Briefly, after designated treatments, 
cells were collected and resuspended in PBS containing PI (2 μg/ml) for incubation at 
37℃  for 10 min. Ten thousand cells from each sample were then analyzed with 
FACSCalibur flow cytometry (BD Bioscience).  
2.2.4 Transient transfection and confocal microscopy analysis  
    The tandem fluorescent-tagged LC3 construct (tfLC3), which has been described 
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previously (Kimura et al., 2007), is a generous gift from Dr. T Yoshimori. The 
transient transfection was performed using Lipofectamine Plus reagents (Invitrogen) 
according to the manufacturer’s protocol. The transfected cells were examined by a 
confocal microscopy (Olympus Fluoview 2000).  
2.2.5 Electron microscopy analysis  
    EM analysis was performed as described previously with modifications (Ding et 
al., 2007a). Briefly, cells were fixed in 3% glutaraldehyde and 2% paraformaldehyde 
in 0.1 M PBS buffer (pH 7.4) for 30 min, post-fixed in 1% osmium tetraoxide for 40 
min then dehydrated in an ascending series of ethanol and acetone, and embedded in 
Araldite. Sections of 100 μm were obtained and mounted on copper grids coated with 
Formvar, and double stained with uranyl acetate and lead citrate. Images were viewed 
and captured using a Philips EM208 electron microscope. 
2.2.6 siRNA  
    The scrambled RNAi oligonucleotides and siRNAs targeting mouse Atg5, Atg7 
and Beclin 1 (ON-TARGETplus SMARTpoolTM RNAi reagents) were obtained 
from Dharmacon (Layfayette, CO). All siRNAs were transfected into L929 cells 
using the DharmaFECT 4 Transfection Reagent (Dharmacon, Layfayette, CO) 
according to the manufacturer’s protocol.  
2.2.7 Measurement of cathepsin B activity  
    Determination of cathepsin B activity in total cell extracts was conducted as 
described previously with modifications (Schotte et al., 1999). Briefly, cells were 
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lysed in M2 buffer and the lysate (25 μg cellular protein) was then incubated with 50 
μM of the fluorogenic cathepsin B substrate z-ARR.AFC in 100 μl cell free system 
buffer (10 mM HEPES-NaOH pH 7.4, 220 mM mannitol, 68 mM sucrose, 2 mM 
NaCl, 2.5 mM KH2PO4, 0.5 mM EGTA, 2 mM MgCl2, 5 mM pyruvate, 0.1 mM 
PMSF and 1 mM dithiothreitol) in a 96-well plate for 1 hr at 37°C. The release of free 
7-amino-4-trifluoromethyl coumarin (AFC) was monitored in a fluorometer (Tecan 
SpectraFluor Plus, Switzerland) at an excitation wavelength of 409 nm and an 
emission wavelength of 505 nm. Data are expressed as percentage of fluorescence 
intensity compared to the control group. 
2.2.8 Western blotting  
    At the end of the designated treatments, cells were lysed in M2 lysis buffer (20 
mM Tris at pH 7, 0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM 
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 20 mM glycerol phosphate, 1 
mM sodium vanadate and proteinase inhibitor cocktail). An equal amount of protein 
was resolved by SDS-PAGE and transferred onto PVDF membrane (Bio-Rad). After 
blocking with 5% non-fat milk, the membrane was probed with designated first and 
second antibodies, developed with the enhanced chemiluminescence method (Pierce) 
and visualized with the Kodak Image Station 440CF (Kodak). The band density was 
quantified using the ImageJ image processing program developed by NIH and 
normalized to that of the control group. 
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2.3 Results 
2.3.1 zVAD induces caspase-independent non-apoptotic cell death with the 
presence of autophagy markers in L929 cells  
    zVAD is a pan-caspase inhibitor and is able to block apoptotic cell death and 
enhance death receptor-mediated necrotic cell death (Vercammen et al., 1998a; 
Vercammen et al., 1998b). Here we re-examined zVAD-induced cell death in L929 
cells. Compared to the typical apoptosis induced by TNFα+CHX, it was found that 
zVAD-induced cell death was much slower. Typically, evident cell death induced by 
zVAD was only observed after 12 h (Figure 2.1A). Moreover, cell death induced by 
zVAD displayed distinctive morphological features from apoptotic cell death induced 
by TNFα+CHX when examined using the Hoechst-Sytox staining method (Figure 
2.1B). Next, we further tested caspase-3 activation and PARP cleavage, two common 
hallmarks for apoptosis. As shown in Figure 2.1C, there is no evident caspase-3 and 
PARP cleavage in zVAD-treated cells in contrast to apoptotic cell death induced by 
TNFα+CHX. Our data also confirmed the effectiveness of zVAD as it was able to 
block caspase-3 and PARP cleavage induced by TNFα+CHX (Figure 2.1C). 
    zVAD has been shown to induce autophagic cell death in L929 cells (Yu et al., 
2004). Here we also examined the presence of autophagic hallmarks in zVAD-treated 
L929 cells. Under electron microscopy, there was significant increase of autophagic 
compartments in cells treated with zVAD (Figure 2.2A). Moreover, there was a 
time-dependent increase of LC3-II in L929 cells treated with zVAD (Figure 2.2B). 
Data from this part of our study are basically consistent with the earlier report that 
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zVAD-induced non-apoptotic cell death with the presence of autophagic features (Yu 
et al., 2004).  
2.3.2 Opposite effects of rapamycin and chloroquine on zVAD-induced cell death  
    Since the presence of such autophagic hallmarks could be the result of either 
increased autophagic flux or blockage of autophagosome lysosomal degradation 
(Klionsky, 2005; Klionsky et al., 2007a), we next tested the effect of rapamycin and 
chloroquine on zVAD-induced cell death. Rapamycin is a specific inhibitor of mTOR 
and has been well established to increase the flux of autophagy (Takeuchi et al., 2005), 
whereas chloroquine is a lysosomal enzyme inhibitor that blocks the lysosomal 
degradation of autophagosomes (Amaravadi et al., 2007). To our surprise, rapamycin 
offered significant protection against zVAD-induced cell death, as determined by cell 
morphology (Figure 2.3A), as well as the MTT assay (Figure 2.3B). The induction of 
autophagy by rapamycin treatment was confirmed by the conversion of LC3-I to 
LC3-II (Figure 2.3C). Here we further confirmed the effectiveness of rapamycin by 
showing the suppression of S6 phosphorylation downstream of the blockage of 
mTOR signaling (Figure 2.3C). In contrast, cells treated with chloroquine markedly 
enhanced zVAD-induced cell death in L929 cells (Figure 2.3A and 2.3B).  
 Previous work by Yu et al (Yu et al., 2004) demonstrated zVAD-induced 
autophagic cell death in other cells including U937 and RAW264.7 cells. Here we 
also found that zVAD treatment was able to induce cell death in U937 cells (Figure 
2.4A). Moreover, zVAD-induced U937 cell death was also suppressed by rapamycin 
and enhanced by chloroquine (Figure 2.4B).  
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2.3.3 Opposite effect of serum starvation and Atg gene knockdown on 
zVAD-induced cell death  
    In order to further elucidate the role of autophagy in zVAD-induced cell death, 
we manipulated the autophagy level by different approaches. First, autophagy was 
induced by serum starvation. As shown in Figure 2.5A and 2.5B, it is evident that 
cells cultured in serum-free medium were very resistant to zVAD-induced cell death. 
Induction of autophagy by serum starvation was confirmed by accumulation of 
LC3-II (Figure 2.5C). Such results are indeed consistent with the protective effect of 
rapamycin as shown earlier (Figure 2.3), suggesting that a high level of autophagy 
may protect against zVAD-induced cell death. 
 Second, we examined the effect of Atg gene knockdown on zVAD-induced cell 
death. Contrary to the earlier report (Yu et al., 2004), here we found that suppression 
of autophagy by knockdown of Atg5, Atg7 or Beclin 1 significantly sensitized cells to 
zVAD-induced cell death (Figure 2.6A and 2.6B). The effect of such knockdowns on 
autophagy was confirmed by reduced LC3-I to II conversion (Figure 2.6A). 
Consistent data were obtained when we used another more quantitative method (PI 
live cell staining and flow cytometry) (Figure 2.6C). In order to validate our Atg gene 
knockdown data, we tested whether Atg gene knockdown would alter the protective 
effect of serum starvation on zVAD-induced cell death. As shown in Figure 2.7, it is 
clear that knockdown of Atg5, Atg7 or Beclin 1 almost completely abolished the 
protective effect of starvation on zVAD-induced cell death. Such unequivocal 
evidence thus implies that: (i) the protective effect of serum starvation on 
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zVAD-induced cell death is mediated by the activation of autophagy; and (ii) Atg 
knockdown enhances zVAD-induced cell death via suppression of autophagy. Hence, 
it is clear that autophagy plays a pro-survival role in zVAD-induced non-apoptotic 
cell death. 
2.3.4 zVAD suppresses lysosomal function via its inhibitory effect on cathepsin 
activity  
    After showing the pro-survival function of autophagy in zVAD-induced cell 
death, one of the remaining questions is why zVAD-induced cell death is 
accompanied by autophagic markers. It is known that zVAD is a broad spectrum 
caspase inhibitor. In addition to caspases, zVAD also inhibits other cysteine proteases 
including cathepsins and calpains (Madden et al., 2007; Scaringi et al., 2004). As 
cathepsins are important lysosomal enzymes and closely related to autophagosomal 
degradation (Bursch, 2001), we decided to examine the effect of zVAD on cathepsin 
activity and lysosomal function. As shown in Figure 2.8A, zVAD was found to be a 
potent cathepsin B inhibitor, although to a lesser extent than that of the two known 
cathepsin inhibitors (E64d and pepstatin A). Next, we further examined whether other 
caspase inhibitors possess similar functions. It is interesting to note that neither IETD 
(a caspase-8 inhibitor), nor DEVD (a caspase-3 inhibitor) showed similar effects on 
cathepsin B enzymatic activity (Figure 2.8A). Consistently, neither IETD nor DEVD 
was able to induce cell death in L929 cells (Figure 2.8B), suggesting that caspase 
inhibition alone was insufficient to induce cell death. Furthermore, although cathepsin 
inhibitors alone were not capable of inducing cell death, addition of cathepsin 
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inhibitors significantly enhanced zVAD-induced cell death, but had no effect on 
treatment with IETD or DEVD (Figure 2.8B). In fact, such results were consistent 
with the effect of chloroquine as shown earlier (Figure 2.3). It is thus believed that 
zVAD-induced cell death requires not only general caspase inhibition, but also 
suppression of cathepsin enzyme activity.  
 In order to further understand the effect of zVAD on autophagy, we assessed the 
effects of zVAD and cathepsin inhibitors on LC3-II accumulation. As expected, 
cathepsin inhibitors alone were able to increase the LC3-II level and zVAD plus 
cathepsin inhibitors had an additive effect on accumulation of LC3-II (Figure 2.8C). 
We also examined the changes in p62, a protein being recently identified to be closely 
associated with LC3 and autophagosomes and to be degraded by lysosomes (Bjorkoy 
et al., 2005; Pankiv et al., 2007). It is interesting to note that the p62 protein level 
increased in a similar pattern as that of LC3-II upon treatment with zVAD and 
cathepsin inhibitors (Figure 2.8C). Taken together, it appears that zVAD is able to 
block autophagy via its inhibitory effect on lysosomal cathepsin enzyme activity. 
2.3.5 zVAD inhibits autophagosome maturation  
    Data from the above experiments demonstrate the possibility that zVAD may 
suppress autophagy via its inhibitory effect on cathepsin enzyme activity and 
lysosomal function. Recently, Kimura et al have established a system using a tfLC3 
construct to dissect the autophagosome maturation process (Kimura et al., 2007). 
Here we utilized this system and first established the pattern of GFP and mRFP 
fluorescence changes in L929 cells under starvation conditions (Figure 2.9A). At the 
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late stage of starvation (cells were cultured in EBSS for 2 hrs), there was significant 
reduction of GFP fluorescence, while the mRFP signal was largely unaffected, 
indicating the completion of autophagosome maturation and lysosomal degradation. 
In contrast, in cells treated with zVAD, there was no significant reduction of GFP 
fluorescence, which was consistent with the effect of cathepsin inhibitors, suggesting 
the blockage of the maturation process of autophagosomes (Figure 2.9B), probably 
via suppression of lysosomal function by inhibition of cathepsin enzyme activity. 
Such observations thus suggest that the presence of various autophagic hallmarks in 
zVAD-treated L929 cells (Figure 2.2B and 2.2C) is most probably due to the 
suppression of autophagy at the late stage of autophagosome maturation and 
lysosomal degradation. 
2.4 Discussion 
    At present, most of the experimental evidence supporting the concept of 
“autophagic cell death” is based on (i) the presence of autophagic hallmarks (most 
commonly autophagosomes and accumulation of LC3-II in dying cells, and (ii) 
rescue of cell death via suppression of autophagy (usually achieved via chemical 
inhibitors or knockdown of Atg genes) (Gozuacik and Kimchi, 2007; Levine and 
Yuan, 2005). Two earlier studies on zVAD-induced cell death in L929 cells (Yu et al., 
2004) and DNA damaging agent-induced cell death in Bax-/- Bak-/- double knockout 
MEFs (Shimizu et al., 2004) have been widely regarded as examples of autophagic 
cell death meeting the above criteria. Here, we present surprising data that directly 
challenge the earlier report in which zVAD induces autophagic cell death in L929 
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cells (Yu et al., 2004). First, we provide compelling evidence that autophagy serves as 
a cell survival mechanism to protect against zVAD-induced necrotic cell death. Our 
conclusion is supported by several important observations: (i) activation of autophagy 
by serum starvation and by mTOR inhibition offered significant protection against 
zVAD-induced cell death; and (ii) suppression of autophagy by blockage of 
lysosomal enzymatic activity (chloroquine) or by knockdown of Atg genes (Atg5, 
Atg7 or Beclin 1) greatly sensitized cells to zVAD-induced cell death. Second, we 
demonstrated that zVAD functioned as a cathepsin inhibitor and was able to block 
autophagy via suppression of autophagosomal maturation. We thus conclude that 
autophagy is a cell survival mechanism and suppression of autophagy via inhibition 
of lysosomal cathepsin enzyme activity contributes to zVAD-induced necrotic cell 
death. We believe that our findings bear important implications for understanding the 
role of autophagy in cell death and cell survival, in particular the intricate relationship 
between autophagy and necrotic cell death.  
 It appears that zVAD, different from other caspase inhibitors, possesses a wide 
spectrum of functions contributing to its apoptosis-inhibiting and necrosis-promoting 
activities. Earlier reports have demonstrated that, in addition to caspases inhibition, 
zVAD also inhibits other cysteine proteases including cathepsins and calpains 
(Madden et al., 2007; Scaringi et al., 2004). Calpain has been proven to be required 
for autophagy in mammalian cells (Demarchi et al., 2007; Demarchi et al., 2006). 
Therefore, the inhibition of caplain activity by zVAD may lead to suppression of 
autophagy. However, it is indeed intriguing that the inhibitory effect of zVAD on 
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calpain was found to be required for zVAD-induced autophagic cell death (Madden et 
al., 2007). As the autophagic cell death in the above-mentioned study was mainly 
defined based on the association between increased autophagic markers (LC3-II 
accumulation) and cell death (Madden et al., 2007), it is likely that inhibition of 
calpain activity may actually block autophagy at a late stage and thus promote 
necrosis. On the other hand, lysosomes are known to contain more than 50 acid 
hydrolases that are capable of digesting all types of macromolecules contained in 
autophagosomes. Among these hydrolases, the group of cathepsins are probably the 
most-studied. The importance of cathepsins including cathepsin B, D and L in 
autophagy has been demonstrated in animal models in which cathepsin deficiency 
leads to accumulation of autophagosomes in neuronal tissues (Felbor et al., 2002; 
Saftig et al., 1995). In this study, we showed that zVAD is capable of inhibiting 
cathepsin B activity, being consistent with an earlier report that zVAD was able to 
suppress cathepsin activity in Jurkat cells (Scaringi et al., 2004). In this regard, it is 
possible that, in addition to caspase inhibition and induction of endogenous ROS, 
which have been reported to be critical for cell death in L929 cells (Yu et al., 2004; 
Yu et al., 2006a), zVAD is also capable of inhibiting autophagy via its direct 
inhibitory effect on cathepsins as well as calpains; and the blockage of pro-survival 
autophagy then eventually also contributes to zVAD-induced necrotic cell death. 
 Another intriguing finding in our study is that knockdown of Atg gene enhanced 
zVAD-induced cell death (Figure 2.6), which is directly contradictory to the earlier 
report in the same system (Yu et al., 2004). The exact reason responsible for such a 
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discrepancy is not known, possibly due to some technical differences such as the 
siRNA reagents and transfection methods used. Here, we would like to highlight two 
important pieces of evidence that strongly support our conclusion. First, Atg gene 
knockdown almost completely abolished the protective effect of serum starvation on 
zVAD-induced cell death (Figure 2.7). Based on the well-established fact that 
starvation activates autophagy (Lum et al., 2005a), it is highly plausible that Atg 
knockdown sensitizes cell death via suppression of autophagy in L929 cells. 
Therefore, it is believed that autophagy is a cell survival mechanism to protect against 
zVAD-induced necrotic cell death in L929 cells, while it still serves as a cell death 
mechanism in Bax-/- Bak-/- MEFs treated with DNA damaging agent. 
 Previously Yu et al proposed a model in which zVAD induces autophagic cell 
death via suppression of caspase-8 activation that subsequently leads to blockage of 
RIP cleavage and the activation of the MKK7-JNK-c-Jun signalling cascade (Yu et al., 
2004). In fact, such a model has already been challenged by a recent report in which 
the caspase-8 inhibitor (IETD) alone failed to induce cell death in L929 cells 
(Madden et al., 2007). In our study, we found similar results that caspase-8 inhibitor 
(IETD) alone, or even in combination with cathepsin inhibitors failed to induce cell 
death in L929 cells (Figure 8B), suggesting that caspase-8 inhibition alone is not 
sufficient for zVAD-induced cell death. Apparently, besides caspase inhibition, 
additional effects of zVAD are required for zVAD-induced cell death, for which both 
calpains and cathepsins may serve as the molecular targets of zVAD. 
 One implication of our study is that we need to be more cautious in the 
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interpretation of experimental evidence supporting autophagic cell death. Based on 
the dynamic process of autophagosome induction, expansion, lysosomal fusion and 
degradation, suppression of autophagy at different stages would lead to different 
consequences in terms of the appearance of those autophagic hallmarks. Therefore, 
the presence of autophagic hallmarks, such as autophagosomes and LC3-II could be 
the results of either increased autophagic flux or decreased autophagosomal 
degradation (Eskelinen, 2005; Klionsky et al., 2007b; Mizushima and Yoshimori, 
2007). In this study, we believe that the presence of autophagic hallmarks in 
zVAD-treated cells is the result of suppression of lysosomal degradation of 
autophagososmes via its inhibitory effect on cathepsin activity. We believe that such 
understanding helps to dissect autophagy from necrotic cell death. 
 At present, the relationship between autophagy and apoptosis has been well 
studied and extensively discussed (Maiuri et al., 2007c), whereas the interaction 
between autophagy and necrosis has been relatively less studied. Necrosis is normally 
regarded as a form of cell death without apoptotic or autophagic features and 
involving early plasma membrane rupture and dilatation of cytoplasmic organelles 
such as mitochondria and ER (Galluzzi et al., 2007; Zong and Thompson, 2006). This 
form of cell death is traditionally considered as passive (without ATP consumption) 
and unregulated. In recent years, however, there is accumulating evidence suggesting 
that necrosis could be another form of programmed cell death which can be 
controlled by specific signalling pathways and regulated by genetic and epigenetic 
factors (Golstein and Kroemer, 2007). Data from this study are consistent with the in 
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vivo studies by White’s group in which they provided convincing evidence showing 
that autophagy is capable of inhibiting necrotic cell death of cancer cells devoid of 
the apoptotic machinery, and that autophagy is able to limit inflammation, mitigate 
metabolic stress, suppress chromosomal instability, and then inhibit tumorigenesis 
(Degenhardt et al., 2006; Karantza-Wadsworth et al., 2007; Mathew et al., 2007). On 
the contrary, some other studies have shown that autophagy is required for ER 
stress-mediated necrosis in Bax-/- Bak-/- MEFs(Ullman et al., 2007) or necrotic cell 
death in neuronal cells in C. Elegans (Samara et al., 2007). Therefore, it appears that 
the exact role of autophagy in necrotic cell death is rather complicated and cellular 
context-dependent. Clearly a better dissection of the regulatory mechanism of 
autophagy in cell survival and cell death, including necrotic/non-apoptotic cell death, 
is critical for understanding the biological significance of autophagy in health and 
disease. 
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Figure 2.1 zVAD induces non-apoptotic cell death in L929 cells. (A) Time-course of 
zVAD-induced cell death. L929 cells were treated with zVAD (10 μM) or DMSO for 
6, 12, 24 and 48 hrs, and the cell viability was determined using the MTT assay, and 
the data were presented as mean ± S.D. from 3 independent experiments. (B) 
Evaluation of zVAD-induced cell death using Hoechst-Sytox staining. L929 cells 
were treated with zVAD (10 μM) for 24 hrs. CHX (10 μg/ml)+TNFα (10 ng/ml × 6 
hrs) and zVAD (10 μM)+CHX (10 μg/ml)+TNFα (10 ng/ml × 4 hrs) were used as the 
positive control to induce typical apoptosis and necrosis, respectively. Representative 
images were taken by a phase-contrast microscope (×400). (C) Absence of caspase-3 
and PARP-1cleavage in zVAD-treated cells. L929 cells were treated with 10 or 20 μM 
zVAD for 24 hrs, other treatments were the same as described in Figure 1B, cleavage 
of caspase-3 and PARP-1 were determined using western blotting. 
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Figure 2.2 Presence of autophagic markers in zVAD-treated L929 cells. (A) 
Accumulation of autophagosomes in zVAD-treated cells. L929 cells were treated with 
zVAD (10 μM) or DMSO for 12 hrs and were examined with TEM, and 
representative images were presented at two different magnifications (×4400 or 
×8900). (B) Accumulation of LC3-II in cells treated with zVAD. L929 cells were 
treated with zVAD (10 μM) for 12 hrs and LC3 proteins were detected by western 
blotting. Quantification of LC3-II was performed using the Image J software and the 
values shown in the panel were the fold increase normalized to the control group. 


















































Figure 2.3 Rapamycin and chloroquine have opposite effects on zVAD-induced cell 
death in L929 cells. (A) Rapamycin protects cells against, whereas chloroquine 
sensitizes cells to, zVAD-induced cell death. L929 cells were treated with media 
containing 10 μM zVAD plus rapamycin (10 nM) or plus chloroquine (10 μM) for 24 
hrs, and cell death was examined by microscopy. Representative images were taken 
by a phase-contrast microscope (×200). (B) Quantification of cell death described in 
panel A. Cell viability was measured using the MTT test and the data were presented 
as the mean ± S.D. from 3 independent experiments (* p<0.05, ** p<0.01; student’s 
t-test). (C) Effectiveness of rapamycin on autophagy and mTOR signaling. L929 cells 
were treated with rapamycin (10 nM) or zVAD (10 μM) or rapamycin+zVAD for 12 
hrs, then cells were lysed and the lysate was subjected to western blotting. 
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Figure 2.4 Effects of rapamycin and chloroquine on zVAD-induced cell death in 
U937 cells. (A) zVAD is able to induce cell death in U937 cells. U937 cells were 
treated with zVAD (100 μM) for 36 hrs, viable cells were determined using the PI 
exclusion assay. The R1 gated cells represent the viable cells. (B) Rapamycin protects 
against, whereas chloroquine sensitizes to zVAD-induced cell death in U937 cells. 
U937 cells were treated with zVAD (100 μM), with or without rapamycin (10 nM) or 
chloroquine (10 μM) for 36 hrs, and cell viability was then determined by the PI 
exclusion assay, and the data were presented as the mean ± S.D. from 3 independent 
experiments (* p<0.05; student’s t-test).  
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Figure 2.5 Starvation treatment suppresses zVAD-induced cell death. (A) Serum 
withdrawal protects cell death induced by zVAD. L929 cells were treated with 10 or 
20 μM zVAD in full media or in FBS-free media for 24 hrs, the morphological 
changes of cells were recorded under a phase-contrast microscope (×200). (B) 
Quantification of cell death described in panel A. Cell viability was determined by the 
MTT test; the data were presented as the mean ± S.D. from 3 independent 
experiments (* p<0.05, student’s t-test, lower panel). (C) FBS-starvation induces 
autophagy. Cells were incubated in FBS-free media for 1, 6 and 12 hrs, and the cell 
lysate was subjected to western blotting. 
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Figure 2.6 Knockdown of Atg genes sensitizes zVAD-induced cell death. (A) 
Suppression of autophagy by knockdown of Atg5, Atg7 or Beclin 1 protein 
expression. L929 cells were transfected with scramble siRNA, or siRNA for mouse 
Atg5, Atg7 or Beclin 1 for 48 hrs followed by treatment with zVAD (10 μM) for 12 
hrs, cells were collected and lysed and the same amount of protein was subjected to 
western blotting. (B) Knockdown of Atg5, Atg7 or Beclin 1 sensitizes cells to 
zVAD-induced cell death. After transfection with siRNA oligos for 48 hrs, cells were 
treated with zVAD (10 μM) for 24 hrs. Representative images (×200) were shown to 
demonstrate the morphological changes of cell death. (C) Quantification of cell death 
using the PI exclusion assay. Cells were treated as described in panel C followed by 
the PI exclusion assay, and the percentages of the viable cells were shown in the bar 
chart. 
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Figure 2.7 Knockdown of Atg5, Atg7 or Beclin 1 abrogates the protective effects of 
starvation on zVAD-induced cell death. After transfection with various siRNA oligos 
for 48 hrs, cells were treated with 20 μM zVAD in FBS-free medium for 24 hrs, and 
cell death was determined by the PI exclusion assay. The R1 gated cells represented 
the viable cells and the percentage of viable cells was shown in each panel. 
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Figure 2.8 zVAD suppresses autophagy via inhibition of cathepsin enzymatic activity. 
(A) zVAD, but not IETD and DEVD, inhibits cathepsin B activity. After treatment 
with zVAD (10 μM), IETD (40 μM), DEVD (40 μM) or cathepsin inhibitors 
(E64d+pepstatin A, 20 μg/ml for each) for 12 hrs, cells were lysed in M2 buffer and 
the lysate was subjected to a cathepsin B activity assay. Data were presented as mean 
± S.D. from 3 independent experiments (** p<0.01, student’s t-test). (B) Cathepsin 
inhibitors sensitize cells to zVAD-induced cell death. Cells were treated with zVAD, 
IETD or DEVD with or without cathepsin inhibitors (as described in panel A) for 24 
hrs, and cell death was examined by morphological changes (×200, upper panel) and 
was quantified by the MTT test (lower panel). Data were presented as mean ± S.D. 
from 3 independent experiments (** p<0.01, student’s t-test). (C) Cathepsin inhibitors 
enhance the accumulation of LC3-II and p62 protein induced by zVAD. Cells were 
treated with zVAD (10 μM), with or without cathepsin inhibitors (as described in 
panel A) for 8 hrs and the cell lysate was subjected to western blotting to detect the 
LC3 and p62 protein levels. Quantification of LC3-II and p62 was performed using 
the Image J software and the values shown in the panel were the fold increase 
normalized to the control group. 















Figure 2.9 zVAD inhibits autophagosome maturation. (A) Degradation of GFP from 
the mRFP-GFP-LC3 protein in L929 cells under starvation conditions. L929 cells 
were transfected with the tfLC3 construct for 12 hrs and then incubated in EBSS for 
up to 2 hrs. The cells were examined using a confocal microscope and representative 
cells were selected and photographed at designated time points. (B) zVAD and 
cathepsin inhibitors block GFP degradation. After transfection with the tfLC3 
construct, cells were subsequently treated with zVAD (10 μM) or cathepsin inhibitors 
(as described in Figure 2.8) for 2 hrs in EBSS. The changes of both GFP and mRFP 
were examined and recorded using a confocal microscope and representative cells 
were selected and photographed. 







CHAPTER 3  
ACTIVATION OF THE PI3K-AKT-MTOR SIGNALING PATHWAY BY 
INSULIN PROMOTES NECROTIC CELL DEATH VIA SUPPRESSION OF 
AUTOPHAGY 
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3.1 Introduction  
Phosphoinositide-3 kinases (PI3Ks) are a family of enzymes that are capable of 
phosphorylating phosphatidylinositol (PtdIns) at 3’-hydroxyl group on the inositol 
ring. According to their specificity for the substrates and products, PI3Ks have been 
categorized into three classes, class I, II and III. Whereas the class III PI3K, also 
known as human vacuolar protein sorting 34 (hVps34), is constitutively active and 
able to generate PtdIns(3)P from PtdIns (Cantley, 2002; Wu et al., 2007; Yan and 
Backer, 2007), the class I PI3K has been found to be activated in response to various 
growth factors such as insulin (Lee et al., 2007). Upon activation, the class I PI3K 
catalyzes its favorite substrate, PtdIns(4,5)P2, to produce PtdIns(3,4,5)P3, which then 
triggers the downstream signaling cascade. As the key signaling molecule 
downstream of class I PI3K, Akt, also called protein kinase B (PKB), binds to 
PtdIns(3,4,5)P3 via its pleckstrin-homology (PH) domain and is phosphorylated by 
phosphoinositide-dependent kinase 1 (PDK1) at tyrosine 308. This phosphorylated 
Akt can be further phosphorylated at serine 473 by the mammalian target of 
rapamycin (mTOR) complex II, which results in its full activation (Jacinto et al., 2006; 
Sarbassov et al., 2005; Vanhaesebroeck and Alessi, 2000). Activated Akt finally leads 
to the activation of mTOR complex I via tuberous sclerosis complex (TSC) and Ras 
homolog enriched in brain (Rheb) (Garami et al., 2003; Inoki et al., 2003a; Inoki et 
al., 2002; Kwiatkowski, 2003).  
    Although the PI3K-Akt-mTOR pathway has been well-established as a critical 
signaling axis in cell growth, proliferation, and cell survival (Manning and Cantley, 
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2007), intriguingly, several lines of evidence suggests that this pathway could also be 
a pro-death signal, especially for necrotic cell death. For instance, it has been reported 
that the activation of PI3K and Akt sensitized the necrotic cell death in response to 
glucose deprivation or hypoxia in rat cardiomyocyte-derived H9c2 cells and mouse 
Lewis lung carcinoma (LLC) cells respectively (Aki et al., 2003; Hamanaka et al., 
2005). More recently, the PI3K-Akt-mTOR pathway was also demonstrated to 
promote cell death in apoptosis-defective cells under metabolic stress (Degenhardt et 
al., 2006). At present, the precise mechanisms responsible for the pro-death function 
of PI3K-Akt-mTOR axis still remain to be further elucidated.  
    Autophagy, or macroautophagy, refers to a highly conserved process by which 
cells “eat” themselves via sequestering and targeting bulk intracellular components 
for lysosomal degradation (Klionsky and Emr, 2000). To date, autophagy has been 
implicated into various physio-pathological processes, including tumorigenesis, 
development, cell death and cell survival (Huang and Klionsky, 2007; Klionsky, 
2007). There is a large body of evidence suggesting that autophagy may serve as a 
cell death mechanism under certain cellular scenarios and this autophagy-dependent 
cell death has been defined as “autophagic cell death” or “type II programmed cell 
death” (Baehrecke, 2005). Intriguingly, autophagy has also been shown as a 
pro-survival mechanism against cell death in response to a variety of stimuli 
including oxidative stress, metabolic stress and endoplasmic reticulum stress 
(Kroemer and Levine, 2008). 
    Recently we have shown that autophagy serves as a pro-survival mechanism in 
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the following necrotic cell death models: (i) zVAD-induced cell death in L929 cells 
(Wu et al., 2008a) and (ii) H2O2-induced cell death in DKO MEF (Huang et al., 2009). 
In this study, we aim to investigate the regulatory role of the PI3K-Akt-mTOR 
signaling axis in necrotic cell death. First, we found that insulin is capable of 
promoting necrotic cell death. Moreover, insulin is able to abolish the protective 
effects of starvation on necrotic cell death. Second, we demonstrated that the 
pro-death function of insulin is achieved through the activation of the 
PI3K-Akt-mTOR pathway. Finally, we provided evidence that insulin promotes 
necrotic cell death via suppression of autophagy. Hence, our findings reconfirm the 
pro-survival function of autophagy in necrotic cell death; also provide a novel insight 
for a better understanding of the intricate connections linking the PI3K-Akt-mTOR 
signaling pathway with cell death via modulation of autophagy.  
3.2 Materials and methods 
3.2.1 Reagents and antibodies  
    Pan-caspase inhibitor zVAD-FMK was purchased from BioMol (Plymouth 
meeting, PA). PI3K inhibitor (LY294002) was purchased from Calbiochem (San 
Diego, CA). Phospho-Akt (Ser 473), phospho-S6 ribosomal protein (Ser235/236), 
mTOR antibody were obtained from Cell Signaling (Beverly, MA). Anti-LC3 
antibody was obtained from Abgent (San Diego, CA). Anti-p62 antibody was from 
Abnova. Rapamycin, insulin, leucine, insulin-like growth factor 1 (IGF-1), Earles’s 
balanced salt solution (EBSS), N-methyl-N'-nitro-N-nitrosoguanidine, (MNNG), 
H2O2 and anti-α-tubulin antibodies were purchased from Sigma-Aldrich (St. Louis, 
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USA). 
3.2.2 Cell culture  
    L929 cells and Bax-/-Bak-/- double knockout mouse embryonic fibroblast cells 
(DKO MEF) were maintained in Dulbecco’s modified Eagle’s medium (Sigma) 
containing 10% fetal bovine serum (HyClone) and 1% penicillin-streptomycin 
(Invitrogen) in a 5% CO2 atmosphere at 37℃ .  
3.2.3 Detection of cell death/cell viability  
    The cell viability was detected by MTT test as described previously (Yang et al., 
1999). The results were presented as the relative cell viability comparing to the 
control group. In the mTOR knockdown experiment, propidium iodide (PI) exclusion 
assay coupled with flow cytometry was performed to quantify the percentage of 
viable cells (Yu et al., 2004). Briefly, cells were collected after treatments and were 
resuspended in PBS containing PI for incubation at 37℃  for 10 minutes. Ten 
thousand cells from each sample were scanned and analyzed with FACSCalibur flow 
cytometry (BD Bioscience) and CellQuest software.  
3.2.4 Plasmids and stable transfection  
    The mRFP-EGFP-LC3 expression vector (tfLC3), which have been described 
previously (Kimura et al., 2007), is provided by Dr. Tamotsu Yoshimori. The 
transfection was performed using Lipofectamine Plus reagent according to the 
manufacturer’s protocol (Invitrogen) and the transfected cells (with green 
fluorescence) were subjected to a stable transfection selection using G418.  
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3.2.5 Confocal microscopy  
    The tfLC3 stable transfected cells were subcultured to a coverglass slide 
chamber (Lab-Tek®, NUNC), after designated treatments, the cells were examined 
under confocal microscope (Olympus Fluoview 2000). 
3.2.6 Small interfering RNA  
    The mouse mTOR and nonspecific siRNA oligonucleotides (ON-TARGETplus 
SMARTpoolTM) were obtained from Dharmacon (Layfayette, CO). All siRNAs were 
transfected into L929 cells using the DharmaFECT 4 Transfection Reagent according 
to the manufacturer’s protocol.  
3.2.7 Western Blotting 
    At the end of designated treatments, cells were lysed in M2 lysis buffer (20 mM 
Tris at pH 7, 0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM 
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 20 mM glycerol phosphate, 1 
mM sodium vanadate and proteinase inhibitor cocktail). Equal amount of protein was 
fractionated on SDS-PAGE and transferred onto PVDF membrane (Bio-Rad). After 
blocked with 5% non-fat milk, the membrane was probed with designated first and 
second antibodies and developed with enhanced chemiluminescence method (Pierce) 
and visualized by Kodak Image Station 440CF (Kodak). The band density was 
quantified using ImageJ image processing program and normalized to that of the 
control group. 
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3.3 Results 
3.3.1 Insulin promotes cell death in necrotic cell death models  
    In our previous work, zVAD, a pan-caspase inhibitor, has been found to induce 
necrotic cell death in L929 cells where autophagy serves as a cell survival mechanism 
(Wu et al., 2008a). The similar protective role of autophagy against cell death has also 
been identified in H2O2-induced necrosis in DKO MEF (Huang et al., 2009). In this 
study we first examined the effects of PI3K-Akt-mTOR signaling axis triggered by 
insulin on zVAD-induced necrotic cell death in L929 cells. To our surprise, insulin 
dramatically and does-dependently promoted cell death in zVAD-treated L929 cells 
(Figure 3.1A, B) As MNNG, a DNA alkylating agent, had been reported to induce 
necrotic cell death (Ha and Snyder, 1999; Zong et al., 2004), we thus tested the effect 
of insulin on MNNG-induced cell death in L929 cells. As anticipated, MNNG 
induced necrosis in L929 cells, more importantly; the MNNG-induced necrosis was 
also enhanced by insulin (Figure 3.1C). To test whether the pro-death function of 
insulin is also applicable to necrosis in other cells, we examined its effect on 
H2O2-induced necrosis in DKO MEF cell death. Data in Figure 3.1D confirm that 
insulin acts similar pro-death function in DKO MEF cells. All these cells were 
cultured in full medium with the presence of 10% FBS. The concentration of insulin 
(200 nM) used in the study is within the range of most other studies in which the 
pro-proliferation and pro-survival function of insulin was demonstrated (Dudek et al., 
1997; Edderkaoui et al., 2007) and is sufficient to efficiently activate 
PI3K-Akt-mTOR signaling pathway indicated by phosphorylation of Akt and S6 
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ribosomal protein (S6) (Figure 3.1E).  
3.3.2 Insulin abolishes the protective effect of starvation on necrotic cell death 
   Previously, we have shown that starvation (by culturing cells in FBS-free medium) 
significantly suppresses zVAD-induced cell death in L929 cells (Wu et al., 2008a). 
Here we tested the effect of insulin on the protective effect of starvation on cell death 
by using two different modes of starvation: (i) by culturing cells in FBS-free medium 
and (ii) by culturing cells in EBSS. First, we found that addition of insulin totally 
abolished the protective effect on zVAD-induced cell death offered by FBS-free 
media (Figure 3.2A). Consistently, insulin was able to enhance the phosphorylation of 
Akt and S6 protein, indicating the re-activation of PI3K-Akt-mTOR signaling 
pathway in FBS-free media (Figure 3.2B). Next, we further investigated the effect of 
insulin on cell death in cells cultured in EBSS. As expected, starvation by EBSS 
showed perfect protection against zVAD-induced cell death (Figure 3.2C). Notably, 
only combined treatment of insulin with an amino acid (leucine) was found to restore 
cell death (Figure 3.2C), while insulin alone or leucine alone was insufficient to 
reinstate L929 cells to zVAD-induced cell death in EBSS (Figure 3.2C). It is 
important to note that, although insulin alone is able to evidently activate Akt in 
EBSS, it cannot activate mTOR without leucine, whereas the insulin plus leucine 
treatment dramatically re-activates mTOR in EBSS (Figure 3.2D).  
    However, in this study we were unable to test the effect of insulin on starvation 
in the H2O2-induced cell death in DKO MEF due to the fact that starvation itself 
(either in FBS-free media or in EBSS) effectively augmented H2O2-induced cell death 
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because there is enhanced level of oxidative stress in cells under starvation (Ollinger 
and Roberg, 1997). Likewise, starvation was also found to enhance MNNG-induced 
cell death (data not shown), possibly because that MNNG, similar as H2O2, induced 
necrosis by activation of PARP and depletion of ATP downstream of ROS (Huang et 
al., 2009; Zong et al., 2004).  
3.3.3 IGF-1, but not EGF, has a similar pro-death effect as insulin  
    To understand the molecular mechanism underlying the pro-death function of 
insulin, here we compared the effects of two different growth factors, insulin-like 
growth factor I (IGF-1) and epidermal growth factor (EGF) with that of insulin. We 
examined their effects on cell death when cells were cultured in EBSS. As shown in 
Figure 3.3A, IGF-1, but not EGF, when combining with leucine, acts similarly as 
insulin to reinstate L929 cells to zVAD-induced cell death in EBSS. Accordingly, 
insulin and IGF-1 were found to significantly activate Akt and mTOR, while EGF can 
only slightly activate this signaling pathway (Figure 3.3B), suggesting that the 
pro-death function of insulin and IGF-1 is related to activation of the mTOR function. 
We also tested two other amino acids, tyrosine and arginine for their effects on 
zVAD-induced cell death under starvation (cultured in EBSS) and found that both of 
them acted similarly as leucine (Figure 3.3C). These data suggest that the growth 
factors and amino acids are two essential components required for the activation of 
mTOR in EBSS, which then allows zVAD to induce necrotic cell death. Furthermore, 
that the growth factor (EGF) unable to dramatically activate mTOR fails to restore 
cell death again indicates that mTOR is the critical molecule for controlling cell death 
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downstream of PI3K-Akt signaling triggered by growth factors. 
3.3.4 Inhibition of PI3K-Akt-mTOR signaling pathway by chemical inhibitors 
abolishes the pro-death effect of insulin  
    Based on our data described above, it is believed that the pro-death function of 
insulin is probably mediated via the activation of PI3K-Akt-mTOR pathway. Here we 
examined whether inhibition of this pathway is able to mitigate the pro-death function 
of insulin. The first approach for such inhibition was to use a specific PI3K inhibitor, 
LY294002. As shown in Figure 3.4A and B, LY294002 completely blocked cell death 
in L929 cells treated with zVAD or MNNG, for which insulin could not reverse. 
Consistently, LY294002 was found to completely suppress the activation of the 
PI3K-Akt-mTOR axis in cells with or without the presence of insulin (Figure 3.4C).  
    The second approach was to use rapamycin, a specific mTOR inhibitor (Hartford 
and Ratain, 2007). Since we have shown previously that rapamycin is able to protect 
cell death via induction of autophagy (Huang et al., 2009; Wu et al., 2008a), we here 
tested the effect of insulin on cell death in the presence of rapamycin. As shown in 
Figure 3.5A, while the low concentration of rapamycin (0.1 nM) displayed no evident 
effects, the medium concentration of rapamycin (1.0 nM) was enough to partially 
ablated the pro-death effect of insulin on zVAD-induced cell death in L929 cells, and 
the high concentration of rapamycin (10 nM) was able to totally block cell death 
induced by zVAD plus insulin. Accordingly, the basal level and insulin-stimulated 
mTOR activation were dose-dependently inhibited by rapamycin (Figure 3.5B). 
Similar protective effects of rapamycin were also obtained in MNNG-treated L929 
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cells (Figure 3.5C) and H2O2-treated DKO MEF (Figure 3.5D and E). It is important 
to note that, although insulin enabled almost equal activation of Akt, its effects on 
mTOR activity was suppressed by rapamycin (Figure 3.5B and E), which is well 
correlated to the outcome of cell death (Figure 3.5A, C, and D), suggesting that the 
mTOR, not Akt, is the key effector molecule within the PI3K-Akt-mTOR pathway for 
promoting cell death in these necrosis models. 
3.3.5 Knockdown of mTOR mitigates the pro-death effect of insulin  
    Based on the data described above, it appears that mTOR is the key molecule to 
control the pro-death function of insulin. Here we employed the RNAi techniques to 
further investigate the role of mTOR in necrosis. Being consistent with the rapamycin 
data, knockdown of mTOR rescued zVAD-induced cell death in L929 cells (Figure 
3.6A). Moreover, mTOR knockdown dramatically mitigated the pro-death effect of 
insulin (Figure 3.6A). Notably, knockdown of mTOR severely impaired its function 
indicated by inhibition of the basal level and insulin-stimulated phosphorylation of S6 
without affecting the Akt activation (Figure 3.6B). In addition, we also tested the 
effect of mTOR knockdown in DKO MEF. As expected, knockdown of mTOR also 
protected the H2O2-induced cell death and mitigated the pro-death effect of insulin in 
DKO MEF cells (Figure 3.6C and D). Therefore, the results presented above provide 
important genetic evidence demonstrating that mTOR is the critical molecule in 
mediating the pro-necrosis function of insulin in necrotic cell death models tested 
here.  
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3.3.6 Insulin inhibits autophagy induced by starvation  
    We have previously established that autophagy serves as a cell survival 
mechanism in two necrosis models (Huang et al., 2009; Wu et al., 2008a). It is thus 
postulated that the pro-death function of insulin is achieved via suppression of 
autophagy. We therefore examined the effect of insulin on starvation-induced 
autophagy in L929 cells. As shown in Figure 3.7A, in starving cells (cultured in 
EBSS) there was a very low basal level of Akt-mTOR activation and enhanced level 
of autophagy (evidenced by increased LC3-II and reduced p62 in comparison to cells 
cultured in full medium). The tandem fluorescence conjugated LC3 (tfLC3) construct 
has been described as a useful tool to determine the dynamic process of autophagic 
influx (Kimura et al., 2007; Wu et al., 2008a). Here we used a stable cell line of L929 
cells in which tfLC3 is stably expressed. As shown in Figure 3.7B, in starving cells 
(cultured with EBSS) there were significant increase of autophagosome formation 
indicated by punctuation and aggregation of GFP-mRFP fluorescence. Moreover, the 
presence of the puncta with relative high level of mRFP fluorescence and lower level 
of GFP fluorescence indicates the maturation of autophagosome and the subsequent 
lysosomal degradation (Figure 3.7B, middle column). More importantly, addition of 
insulin and leucine in the starving cells markedly suppressed autophagy, based on the 
following observations: (i) reduction of LC3-II level and increase of the p62 protein 
level (Figure 3.7A), and (ii) decrease of the punctuation and aggregation of 
GFP-mRFP fluorescence (Figure 3.7B). As the addition of insulin and leucine 
effectively restored the mTOR activity (marked by increase of phospho-S6 protein 
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level, Figure 3.7A), it is thus believed that insulin and leucine are sufficient to 
suppress autophagy induced by EBSS via re-activation of PI3K-Akt-mTOR pathway.  
3.4 Discussion 
    To date, it is still debatable whether autophagy is a cell death or cell survival 
mechanism, or even just a bystander presented in dying cells (Kourtis and 
Tavernarakis, 2009; Kroemer and Levine, 2008; Levine and Yuan, 2005). It appears 
that the roles of autophagy in regulation of cell death are highly dependent on cell 
type and stimulus. Although zVAD-induced cell death in L929 cells was originally 
proposed to be autophagic cell death (Yu et al., 2004), our recent work has provided 
convincing evidence that autophagy serves as a cell survival mechanism and 
suppression of autophagy by zVAD contributes to cell death (Wu et al., 2008a). In 
this study, we further established the pro-survival function of autophagy in three 
necrosis models in two different cell types (zVAD and MNNG-treated L929 cells and 
H2O2-treated DKO MEF) by demonstrating that growth factors (insulin and IGF-1) 
are capable of promoting cell death via activation of the PI3K-Akt-mTOR signaling 
pathway and subsequent suppression of autophagy. Although it remains to be further 
studied whether the pro-death function of the activation of the PI3K-Akt-mTOR 
signaling pathway is also applicable to other necrosis models in other cell types, we 
believe that data from this study indeed provide a novel insight into the intricate 
connections linking the PI3K-Akt-mTOR signaling pathway with cell death via 
modulation of autophagy.  
    The pro-death function of insulin/IGF-1 is indeed intriguing and seems to be 
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paradoxical to the canonical view that the PI3K-Akt-mTOR signaling axis generally 
is a cell survival pathway. However, it is important to note that the pro-survival role 
of PI3K-Akt-mTOR signaling is mainly applicable for apoptosis (Manning and 
Cantley, 2007), while in the models used in this study it is necrotic cell death. 
Particularly, for zVAD treatment and in DKO MEF cells, the apoptotic pathway is 
abrogated either by the pan-caspase inhibitor, zVAD, or by genetic deletion of 
pro-apoptotic factors, Bax and Bak, which renders cells the preference for necrosis 
when exposed to lethal stimuli (Edinger and Thompson, 2004; Zong and Thompson, 
2006). Thus, our finding revealed a pro-death role of PI3K-Akt-mTOR axis specific 
for necrotic cell death. This is indeed in agreement with previous reports that 
activation of PI3K-Akt pathway drives cells to necrosis/non-apoptotic cell death in 
response to metabolic stress (Aki et al., 2003; Degenhardt et al., 2006).  
    One well-established view is that, along the signaling pathway triggered by 
growth factors, Akt is the major player implicated in its anti-death and pro-survival 
function (Cantley, 2002; Manning and Cantley, 2007). Intriguingly, our data suggest 
that the pro-death function of insulin is mainly achieved via mTOR, the molecule 
downstream of Akt, based on the following observations: i) Direct inhibition of 
mTOR by rapamycin or silencing mTOR is capable of inhibiting cell death in both 
models (Figure 3.5 and 3.6). ii) When cultured in EBSS, insulin alone is sufficient to 
activate Akt, but not mTOR and thus unable to promote cell death in L929 cells 
treated with zVAD. iii) Amino acids (leucine) are required for insulin to restore 
zVAD-induced cell death (Figure 3.2C) and re-activate mTOR (Figure 3.2D), while 
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they are dispensable for activation of Akt (Figure 3.2D). Such a finding is indeed 
consistent with a previous report that insulin alone, without amino acids, failed to 
activate mTOR when cells are cultured in PBS (Hara et al., 1998). These results thus 
demonstrated that the pro-death effect of insulin in our systems is not directly 
executed by Akt, but relies on mTOR activity.  
    At present, it still remains puzzling regarding the mechanisms underlying the 
pro-death function of PI3K-Akt-mTOR signaling pathway on necrosis. One 
explanation proposed by Toshihiko and his colleagues is that the activation of PI3K 
results in autophagic cell death (Aki et al., 2003). On the other hand, several other 
studies by White’s group suggest that activation of Akt helps to kill cells by inhibition 
of autophagy which plays a pro-survival function for cells under metabolic stress 
(Degenhardt et al., 2006; Karantza-Wadsworth et al., 2007; Mathew et al., 2007). It is 
evident that results from our studies support the latter notion. First of all, the growth 
factors such as insulin and IGF-1 have been well-established as autophagy 
suppressors by triggering PI3K-Akt-mTOR signaling activation (Klionsky and Emr, 
2000; Lum et al., 2005a; Vander Haar et al., 2007). Secondly, mTOR is probably the 
most well illustrated regulatory molecule for autophagy as its activation leads to 
suppression of autophagy at the initiation stage via the Atg1-Atg13 complex 
(Hosokawa et al., 2009; Jung et al., 2009; Kamada et al., 2000). Thirdly, our previous 
works have provided strong evidence showing that autophagy serves as a pro-survival 
function in these cell death models (Huang et al., 2009; Wu et al., 2008a). Taken 
together, data from this study present a model in which insulin, as a growth factor, 
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promotes necrotic cell death via activation of the PI3K-Akt-mTOR signaling pathway 
and subsequent suppression of autophagy.  
    The PI3K-Akt-mTOR signaling axis downstream of growth factors has long 
been recognized as a key pathway in tumor promotion and cancer development 
(Shaw and Cantley, 2006). For instance, many cancers are found to host 
lost-of-function mutations of certain inhibitory proteins of PI3K-Akt-mTOR pathway, 
such as PTEN and TSC, resulting in constitutive activation of this pathway (Bonneau 
and Longy, 2000; Carsillo et al., 2000). Recently, autophagy has been increasingly 
acknowledged as an anti-tumor mechanism (Chen and Karantza-Wadsworth, 2009). 
One observation supports such a notion is that mutations of autophagy specific genes 
are commonly happened in human malignancies and deletion of these genes could 
increase tumorigenesis in mouse model (Levine, 2007). It is initially to be at odd how 
autophagy, as a pro-survival mechanism, can inhibit tumorigenesis. One plausible 
explanation is that autophagy can protect cells from necrosis which will result in 
inflammatory responses in vivo and cause tumorigenesis (Degenhardt et al., 2006). 
Another appealing mechanism proposed is that autophagy is able to limit genomic 
instability and hence suppress tumorigenesis (Karantza-Wadsworth et al., 2007; 
Mathew et al., 2007; Mathew and White, 2007). Being in agreement with above 
views, it is likely that growth factors can serve to promote cancer development via 
enhanced necrotic cell death which is achieved through suppression of autophagy by 
activating the PI3K-Akt-mTOR pathway. It is believed that understanding such a 
connection bridging growth factors to tumorigenesis bears considerable significance 
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in development of novel strategies in cancer prevention and therapy. 
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Figure 3.1 Insulin promotes necrotic cell death in completed cell growth media. (A) 
Insulin enhances zVAD-induced necrosis in L929 cells. L929 cells were treated with 
insulin (200 nM) or insulin+zVAD (10 μM) for 24 hrs. Representative images were 
taken by a phase-contrast microscope (×200). Cell viability was measured using MTT 
test and the data were presented as mean ± S.D. from 3 independent experiments (** 
p<0.01, t-test). (B) Dose response of insulin on zVAD-induced necrosis. L929 cells 
were treated with zVAD or zVAD plus different concentrations of insulin (10, 100, 
and 200 nM) for 24 hrs, cell viability was examined using MTT assay (* p<0.05, ** 
p<0.01, t-test). (C) Insulin promotes MNNG-induced necrosis in L929 cells. L929 
cells were treated with MNNG (100 nM) or MNNG+insulin (200 nM) for 24 hrs, cell 
viability was determined as described in Panel A (** p<0.01, t-test). (D) Insulin 
promotes H2O2-induced necrosis in DKO MEF. DKO MEF cells were treated with 
insulin (200 nM) or insulin+ H2O2 (500 μM) for 24 hrs. Cell death was examined as 
described in Panel A (** p<0.01, t-test). (E) Insulin activates PI3K and mTOR in 
L929 and DKO MEF cells. L929 and DKO MEF cells were treated with insulin (200 
nM) for 2 hrs and the cell lysate were subjected to western blotting. 
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Figure 3.2 Insulin abolishes the protective effect of starvation on zVAD-induced 
necrotic cell death in L929 cells. (A) Insulin restores zVAD-induced cell death in 
L929 cells cultured in FBS-free media. L929 cells were treated with insulin (200 nM) 
or insulin+zVAD (10 μM) for 24 hrs in FBS-free media, the cell death was examined 
under microscope and by the MTT assay (** p<0.01, t-test). (B) Insulin reactivates 
PI3K and mTOR in FBS-free media. L929 cells were treated with insulin in FBS-free 
media for 2 hrs and the cell lysate were subjected to western blotting. (C) Insulin 
restores zVAD-induced cell death cultured in EBSS in the presence of leucine. L929 
cells were treated with zVAD (10 μM) in the presence of insulin (200 nM), leucine 
(0.2 mg/ml) or insulin+leucine in EBSS for 24 hrs, the cell death was examined as 
described in Panel A (**, ## p<0.01, t-test). (D) Insulin reactivates PI3K and mTOR in 
the presence of leucine. L929 cells were treated with insulin (200 nM), leucine (0.2 
mg/ml) or insulin+leucine in EBSS for 2 hrs and the cell lysate were subjected to 
western blotting. 
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Figure 3.3 Other growth factors and amino acids have a similar pro-death effect as 
insulin. (A) Insulin and IGF1, but not EGF, restore cell death induced by zVAD. L929 
cells were treated with zVAD (10 μM) for 24 hrs containing leucine (0.2 mg/ml), with 
or without combining with insulin, IGF-1 or EGF (200 nM). Cell death was 
determined using MTT assay (** p<0.01, t-test). (B) Effects of growth factors on 
activation of PI3K and mTOR when combining with leucine in EBSS. L929 cells 
were treated as designated using the same concentration as described in Panel A for 2 
hrs and the cell lysate was subjected to immunoblotting. (C) Other amino acids have 
similar effect as leucine. L929 cells were treated with insulin (200 nM) or 
insulin+zVAD (10 µM) in EBSS containing Leucine, tyrosine, or arginine (0.2 mg/ml) 
for 24 hrs. Cell death was examined under microscope (×200) 
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Figure 3.4 Inhibition of the PI3K activity abolishes the pro-death effect of insulin on 
zVAD-induced necrosis in L929 cells. (A) LY294002 blocks zVAD and 
zVAD+inuslin-induced cell death. L929 cells were pretreated with LY294002 (10 μM) 
for 30 mins, then were treated with zVAD (10 μM) or zVAD+insulin (200 nM) for 24 
hrs in full medium, and cell death was examined under microscope and by the MTT 
assay (** p<0.01, t-test). (B) LY294002 blocks MNNG and MNNG+inuslin-induced 
cell death. L929 cells were pretreated with LY294002 (10 μM) for 30 mins, then were 
treated with MNNG (100 nM) or MNNG+insulin (200 nM) for 24 hrs in full medium, 
and cell death was examined as described in Panel A (** p<0.01, t-test). (C) 
LY294002 abrogates insulin-activated PI3K and mTOR activation. L929 cells were 
pretreated with LY294002 (10 μM) for 30 mins, and then were treated with insulin 
(200 nM) for 2 hrs. Cell lysates were subjected to immunoblotting. 















































































































Figure 3.5 Inhibition of mTOR activity by rapamycin abolishes the pro-death effect 
of insulin. (A) Rapamycin protects zVAD and zVAD+insulin-induced cell death 
does-dependently. L929 cells were pretreated with rapamycin (0.1, 1.0 and 10 nM) 
for 30 mins and then were treated with zVAD (10 μM) or zVAD+insulin (200 nM) for 
24 hrs in full medium, and the cell death was examined by the MTT assay (** p<0.01, 
t-test). (B) Rapamycin inhibits insulin-induced activation of mTOR without affecting 
PI3K. L929 cells were pretreated with rapamycin (0.1, 1.0 and 10 nM) for 30 mins 
and then were treated with insulin (200 nM) for 2 hrs and the cell lysate were 
subjected to immunoblotting. (C) Rapamycin abrogates the pro-death effect of insulin 
on MNNG-induced cell death in L929 cells. L929 cells were pretreated with 
rapamycin (10 nM) for 30 mins and then were treated with MNNG (100 nM) or 
MNNG+insulin (200 nM) for 24 hrs, the cell death was examined by the MTT assay 
(** p<0.01, t-test). (D) Rapamycin abrogates the pro-death effect of insulin on 
H2O2-induced cell death in DKO MEF. DKO MEF were pretreated with rapamycin 
(10 nM) for 30 mins and then were treated with H2O2 (500 μM) or H2O2+insulin (200 
nM) for 24 hrs, the cell death was examined by the MTT assay (** p<0.01, t-test). (E) 
Rapamycin inhibits insulin-stimulated mTOR activation in DKO MEF cells without 
affecting PI3K. DKO MEF cells were pretreated with rapamycin (10 nM) for 30 mins 
and then were treated with insulin (200 nM) for 2 hrs. Cell lysate were subjected to 
immunoblotting. 


























































































Figure 3.6 Knockdown of mTOR mitigates the pro-death effect of insulin on necrosis. 
(A) Knockdown of mTOR protects zVAD and zVAD+insulin-induced cell death in 
L929 cells cultured in full medium. After transfected with mTOR and non-targeting 
(scramble) siRNA for 48 hrs, L929 cells were treated with zVAD (10 μM) or 
zVAD+insulin (200 nM) for 24 hrs. Cell death was examined under microscope and 
by PI exclusion assay (** p<0.01, t-test). (B) Knockdown of mTOR inhibits mTOR 
activation induced by insulin. After transfection for 48 hrs, L929 cells were treated 
with insulin (200 nM) for 2 hrs and the cell lysate were subjected to immunoblotting. 
(C) Validation of mTOR knockdown efficiency in DKO MEF cells. Cells were 
transfected with mTOR and non-targeting (scramble) siRNA for 48 hrs. (D) mTOR 
knockdown protects H2O2 or H2O2+insulin -induced cell death in DKO MEF cells. 
After transfection, the DKO MEF cells were treated with H2O2 (500 μM) or 
H2O2+insulin (200 nM) for 24 hrs, the cell death was examined under microscope (×
200) and the PI exclusion assay (** p<0.01, t-test). 
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Figure 3.7 Insulin suppresses autophagy induced by starvation. (A) Insulin 
suppresses autophagy induced by EBSS. L929 cells were incubated in EBSS for 30 
mins, followed by treated with leucine (0.2 mg/ml), insulin (200 nM) or 
insulin+leucine for 2 hrs. Cell lysate were subjected to immunoblotting. (B) Insulin 
suppresses autophagosome formation in EBSS. L929 cells stably transfected with the 
tfLC3 construct were incubated in EBSS with or without insulin+leucine for 2 hrs. 
The cells were examined using a confocal microscope and representative cells were 
selected and photographed (×600).  







CHAPTER 4  
zVAD-INDUCED NECROPTOSIS IN L929 CELLS DEPENDS ON 
AUTOCRINE PRODUCTION OF TNFα MEDIATED VIA THE 
PKC-MAPKs-AP-1 PATHWAY 
                                                            120 
4.1 Introduction  
    Programmed cell death (PCD) refers to a type of cell death which is executed 
through defined biochemical events and is known to play a critical role in health and 
diseases. Based on the morphological and biochemical features, PCD can be 
classified into three categories: apoptosis, autophagic cell death, and necrosis 
(Kroemer et al., 2009). The autophagic cell death has been described as a 
non-apoptotic cell death that is caused by excessive induction of autophagy, which 
presumably can be blocked by suppression of the autophagic pathway (Levine and 
Yuan, 2005; White, 2008). In contrast, necrosis may occur when the cell’s ability to 
produce ATP is impaired (Zong and Thompson, 2006). Among several types of 
necrotic cell death described in the literature, necroptosis is initiated by engagement 
of death-receptors with their corresponding ligands, such as tumor necrosis factor-α 
(TNFα) and Fas ligand (Degterev and Yuan, 2008). 
    TNFα is a pleiotropic pro-inflammatory cytokine that is capable of triggering 
multiple signaling pathways to regulate various physiological and pathological 
cellular processes. One important biological function of TNFα is to induce apoptosis 
via the extrinsic pathway (Micheau and Tschopp, 2003). On the other hand, TNFα has 
also been demonstrated to trigger programmed necrosis, or necroptosis, in a limited 
group of cell lines, such as mouse fibrosarcoma L929 cells, Jukart cells, and mouse 
embryonic fibroblasts (MEFs) (Fiers et al., 1999; He et al., 2009; Holler et al., 2000; 
Lin et al., 2004; Vercammen et al., 1997). The execution of necroptosis requires the 
kinase activity of receptor-interacting protein 1 (RIP1) and can be blocked by the 
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RIP1 kinase inhibitor, necrostatin-1 (Chan et al., 2003; Festjens et al., 2007; Holler et 
al., 2000; Lin et al., 2004). At present, how RIP1 controls the necrotic pathway is 
largely unknown. One possibility is that RIP1 may promote intracellular ROS 
production and JNK activation via activation of Nox1 NADPH oxidase (Kim et al., 
2007b). Recently, RIP3 has been identified as another crucial player in TNFα-induced 
necrotic cell death by interacting with RIP1 (Cho et al., 2009; He et al., 2009; Zhang 
et al., 2009). In TNFα-mediated necroptosis, there is one intriguing observation: 
blockage of caspase cascade by either chemical inhibitors or overexpression of a viral 
caspase inhibitor (CrmA) greatly promotes the cell death (Vandenabeele et al., 2006; 
Vercammen et al., 1998a). The exact mechanisms underlying such a sensitization 
effect are not known. As caspase-8 has been shown to cleave RIP1 in TNFα signaling 
(Lin et al., 1999), one possibility is that suppression of the caspase cascade would 
enhance the RIP1 protein stability and then promote RIP1-mediated necroptosis.  
    Among many types of caspase inhibitors, zVAD-fmk is probably the most 
commonly-used pan-caspase inhibitor. Interestingly, although zVAD has been 
demonstrated to be of low cytotoxicity to most of cell lines in vitro (Van Noorden, 
2001), it can induce robust necrotic cell death in certain cell lines, particularly in 
L929 cells (Wu et al., 2008a; Yu et al., 2004). Such necrosis was originally 
recognized as an autophagic cell death evidenced by the observations that there was a 
massive accumulation of the autophagic markers in the dying cells and the cell death 
was protected by disruption of Atg7 (Yu et al., 2004). However, our earlier works 
have provided compelling evidence showing that zVAD-induced cell death in L929 
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cells is not autophagy-dependent; instead, autophagy plays a protective role for cell 
survival (Wu et al., 2008a; Wu et al., 2009a). Therefore, the pro-death signaling in 
zVAD-mediated necrosis remains to be identified.  
    In the present study, we demonstrate that autocrine TNFα is required for 
zVAD-induced necrotic cell death in L929 cells. Furthermore, zVAD-mediated 
autocrine production of TNFα is achieved via activation of the PKC-MAPKs-AP-1 
signaling pathway. Data from this study thus provide new insights into the molecular 
mechanisms underlying zVAD-induced necroptosis, an important form of PCD with 
increasing understanding of its biological significance in health and diseases. 
4.2 Materials and Method 
4.2.1 Reagents and antibodies  
    The zVAD-fmk and DEVD-cho were purchased from BioMol. The BocD-fmk, 
QVD-oph, IETD-fmk, IETD-oph, and bisindolylmaleimide I (PKCi) were purchased 
from Calbiochem. The antibodies against caspase-8 (4927), caspase-3 (9662), 
PARP-1 (9542), c-Jun (9162), RelB (4922), phosphor-ERK (thr202/tyr204) (9101), 
phosphor-c-Jun (ser73) (9164), and phosphor-PKC substrate (2261) were all obtained 
from Cell Signaling. The Anti-phosphor-JNK (Thr183/Tyr185) (44-682G) was 
obtained from Biosource. The anti-RelA (SC-8008) and anti-IKKα (SC-7218) 
antibodies were from Santa Cruz. The Atg5 antibody (CAC-TMD-PH-AT5) was from 
Cosmo Bio Co. LTD. The anti-RIP3 antibody was obtained from ProSci (2283). The 
anti-IKKβ (05-535) antibody was from Upstate. The Beclin 1 antibody (612112) was 
from BD Transduction LaboratoriesTM. The TNFα neutralizing antibody 
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(AF-410-NA), and TNFR1 blocking antibody (AF-425-PB), mouse TNFα and TRAIL 
were purchased from R&D. The 12-O-tetradecanoylphorbol 13-acetate (TPA), 
actinomycin D (ActD), cycloheximide (CHX), SP600125, PD98059, and 
anti-α-tubulin and anti-LC3B (L7543) antibodies were purchased from 
Sigma-Aldrich. XENP1595, the DN-TNF against soluble TNFα was kindly provided 
by Dr. Szymkowski DE (Xencor). 
4.2.2 Cell culture  
    L929 cells, WT, Atg5-/-, and Tet-off Atg5 MEFs were maintained in Dulbecco’s 
modified Eagle’s medium (Sigma) containing 10% fetal bovine serum (HyClone) and 
1% penicillin-streptomycin (Invitrogen) in a 5% CO2 atmosphere at 37C.  
4.2.3 Detection of cell death  
    The cell death was detected by (i) morphological changes examined under the 
microscope and (ii) the propidium iodide (PI) exclusion assay coupled with flow 
cytometry to quantify the percentage of viable cells, as described previously (Wu et 
al., 2008a). Briefly, cells were trypsinized and collected after designated treatments 
and were resuspended in PBS containing PI for incubation at 37C for 10 minutes. 
Ten thousand cells from each sample were scanned and analyzed with FACSCalibur 
flow cytometry (BD Biosciences) and CellQuest software.  
4.2.4 siRNA  
    The nonspecific siRNA oligonucleotides and siRNA oligonucleotides targeting 
mouse caspase-8, FADD, RIP3, c-Jun, IKKα, IKKβ, RelA, and RelB 
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(ON-TARGETplus SMARTpoolTM) were all obtained from Dharmacon (Layfayette, 
CO). All siRNAs were transfected into L929 cells using the DharmaFECT 4 
Transfection Reagent according to the manufacturer’s protocol. 
4.2.5 Transfection and luciferase reporter assay  
    For CrmA transfection, cells grown in 24-well plates were transfected with 
CrmA and EGFP plasmids (10:1) using Lipofectamine and Plus reagent (Invitrogen) 
according to the manufacturer's instruction. For AP-1 luciferase assay, cells grown in 
24-well plates were transfected with AP-1-Luc and Renilla plasmids (100:1) using 
Lipofectamine and Plus reagent (Invitrogen) according to the manufacturer's 
instruction. Twenty-four hours after transfection, cells were treated as indicated in 
each figure legend. The AP-1 luciferase activity was measured and normalized 
against the Renilla luciferase activity using a Dual-Luciferase(R) Reporter Assay kit 
(Promega) on a Glomax 96 Microplate Luminometer (Promega). 
4.2.6 Reverse transcription-PCR  
    RNA was extracted with the RNeasy kit (Qiagen). One microgram of total RNA 
from each sample was used as a template for cDNA synthesis with a QuantiTect 
Reverse Transcriptase Kit (Qiagen). An equal volume of cDNA product was used in 
the PCR performed using the TopTaq Master Mix Kit (Qiagen). The mouse TNFα and 
GAPDH primers were purchased from R&D. The PCR reaction conditions were set 
according to the protocol coming with primers (R&D). The PCR products were 
resolved using an agarose gel containing GelRedTM Nucleic Acid Gel Stain 
(Biotium), and exposed using a Kodak Image Station 440CF (Kodak). The band 
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density was quantified using ImageJ image processing program and normalized to 
that of the control group. 
4.2.7 Measurement of autocrine TNFα in culture medium by ELISA  
    Cells grown in a 10-cm dish were washed with PBS twice, then were incubated 
in freshly-prepared medium and treated as described in the figure legends. The 
culture media were collected and the concentration of TNFα was determined by a 
Mouse TNF-alpha/TNFSF1A Quantikine ELISA Kit (R&D) following the instruction 
from the manufacturer. 
4.2.8 Western blotting  
    Cells were lysed in M2 lysis buffer (20 mM Tris at pH 7, 0.5% NP-40, 250 mM 
NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM dithiothreitol, phosphatase inhibitor 
cocktail (Pierce) and protease inhibitor cocktail (Roche). Equal amount of protein 
was fractionated on SDS-PAGE and transferred onto PVDF membrane (Bio-Rad). 
After blocked with 5% non-fat milk, the membrane was probed with designated first 
and second antibodies and developed with enhanced chemiluminescence method 
(Pierce) and visualized by Kodak Image Station 440CF (Kodak). 
4.3 Results 
4.3.1 zVAD and BocD, but not QVD, induce necrosis in L929 cells 
    zVAD is a well-established general caspase inhibitor and has been widely used 
to block apoptosis. Intriguingly, earlier reports, including one from our own 
laboratory, have demonstrated that zVAD alone is able to efficiently induce necrotic 
                                                            126 
cell death in a selected group of cell types, particularly in L929 cells (Wu et al., 2008a; 
Yu et al., 2004). In this study, we first asked whether other caspase inhibitors possess 
the similar activity as zVAD for induction of necrosis. As shown in Figure 4.1A, 
among an array of caspase inhibitors tested, only zVAD-fmk and BocD-fmk were 
able to induce evident cell death in L929 cells. Interestingly, QVD-oph, another 
pan-caspase inhibitor which has been reported to be more efficient and of 
broader-spectrum than zVAD and BocD for caspase inhibition (Chauvier et al., 2007), 
was unable to induce cell death (Figure 4.1A). The effectiveness of all these caspase 
inhibitors was confirmed by their inhibitory effects on TRAIL-induced cleavage of 
caspase-8, caspase-3, and PARP-1 in L929 cells (Figure 4.1B).  
In an earlier report, the killing ability of zVAD was attributed to its caspase-8 
inhibition effect (Yu et al., 2004). In this study, we further examined this by 
overexpression of CrmA, a viral protein known to specifically inhibit caspase-8 (Ray 
et al., 1992). As shown in Figure 4.1C, overexpression of CrmA (indicated by 
co-transfected GFP fluorescence) in L929 cells led to no cell death, while CrmA 
greatly enhanced cell death in the cells treated with exogenous TNFα, being 
consistent with earlier observations (Vercammen et al., 1998a). Furthermore, 
knockdown of caspase-8 or FADD did not kill L929 cells (Figure 4.1D), while 
effectively suppressed TRAIL-induced caspase-3 and PARP-1 cleavage, and 
apoptosis (Figure 4.1D). Taken together, all these findings clearly suggest that 
inhibition of caspase-8 alone is not sufficient for zVAD to induce cell death in L929 
cells.  
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4.3.2 zVAD-induced necrotic cell death requires de novo protein synthesis 
    To further understand the mechanisms underlying zVAD-induced cell death, we 
then tested whether de novo gene transcription and protein synthesis are required for 
such cell death. As shown in Figure 4.2A, actinomycin D (ActD) or cycloheximide 
(CHX) offered perfect protection against zVAD-induced cell death. These results thus 
suggest that zVAD-induced necrotic cell death requires de novo gene transcription 
and protein synthesis.  
    Another interesting and accidental finding is that the volume of cell culture 
medium affects zVAD-induced cell death. As shown in Figure 4.2B, when L929 cells 
were cultured in different volume of medium containing the same final concentration 
of zVAD (10 μM), the cell death was found to be mitigated by increasing medium 
volume. In contrast, alterations of medium volume did not affect cell death induced 
by exogenously administered TNFα (Figure 4.2B). It is thus possible that some newly 
synthesized proteins are secreted into the medium to trigger the cell death signaling 
pathway. 
4.3.3 zVAD-induced cell death is RIP1- and RIP3-dependent 
    It has been well-established that RIP1 plays a critical role in TNFα-induced 
necroptosis and that necrostatin-1, as a specific RIP1 kinase inhibitor, can suppress 
necroptosis induced by TNFα (Degterev et al., 2008). In this study, necrostatin-1 was 
found to be effective in suppressing cell death induced by zVAD, similar to that 
induced by TNFα, but not in MNNG-induced necrosis which has been reported to be 
mediated by PARP-1 overactivation (Figure 4.2C) (Zong et al., 2004). On the other 
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hand, RIP3 has recently been identified as a key modulator in TNFα-induced 
necroptosis (Cho et al., 2009; He et al., 2009; Zhang et al., 2009). Here we also tested 
whether RIP3 is involved in zVAD-induced cell death. As shown in Figure 4.2D, 
knockdown of RIP3 significantly reduced cell death induced by zVAD or TNFα, 
while with no effect on apoptosis induced by TRAIL. It is thus believed that 
zVAD-induced cell death is similar to TNFα-induced necroptosis involving both RIP1 
and RIP3.  
4.3.4 zVAD promotes autocrine production of TNFα 
    L929 cells are well known to produce a variety of cytokines, including TNFα 
(Vercammen et al., 1995). Moreover, autocrine TNFα has been recently recognized as 
a critical signal for the induction of apoptosis in response to Smac-mimetics or IAP 
antagonists (Petersen et al., 2007; Varfolomeev et al., 2007; Vince et al., 2007). Based 
on the data shown above, we hypothesized that autocrine TNFα is involved in 
zVAD-induced necrotic cell death. We thus tested the effect of zVAD on autocrine 
production of TNFα in L929 cells. We first measured the basal level of secreted 
TNFα in culture medium in untreated cells using ELISA. As shown in Figure 4.3A, a 
very low level of TNFα (around 3 pg/ml) was detected in the medium. Compared to 
the basal level, the autocrine TNFα markedly increased upon zVAD treatment for 8 
hrs (Figure 4.3B). The drop of TNFα concentration at 24 hr-time point was probably 
due to cell death as shown earlier. Meanwhile, pretreatment with CHX totally 
abrogated the production of TNFα (Figure 4.3B). It is thus clear that zVAD is capable 
of promoting the autocrine production of TNFα in L929 cells. Next, we checked 
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TNFα mRNA level using RT-PCR to determine whether zVAD augmented autocrine 
TNFα at the transcriptional level. As shown in Figure 4.3C, there was a higher level 
of TNFα mRNA in zVAD-treated cells than that in control cells. More importantly, 
both zVAD and BocD, but not QVD, enhanced the transcription of TNFα (Figure 
4.3C). Accordingly, only zVAD and BocD, but not QVD, led to the increase of 
autocrine TNFα in the medium (Figure 4.3D). Such findings are also consistent with 
the pattern of cell death induced by these caspase inhibitors as shown in Figure 4.1A.  
4.3.5 Blockage of TNFα signaling suppresses zVAD-induced necroptosis 
    To test whether zVAD-induced autocrine production of TNFα is required for 
induction of cell death, we first intercepted the TNFα signaling by blocking TNFα 
receptor 1 (TNFR1) using a TNFR1 blocking antibody. Notably, this antibody 
dose-dependently suppressed zVAD-induced cell death (Figure 4.4A). As expected, 
this antibody also prevented exogenous TNFα-induced cell death, without showing 
any protection against TRAIL-induced apoptosis in L929 cells (Figure 4.4A). 
Moreover, a TNFα neutralizing antibody that specifically neutralizes the TNFα ligand 
in culture medium also ablated zVAD-induced cell death dose-dependently (Figure 
4.4B). Likewise, the TNFα neutralizing antibody protected cell death induced by 
exogenously applied TNFα, but not TRAIL (Figure 4.4B). In attempt to seek further 
supporting evidence, we next utilized XENP1595, a DN-TNF protein against soluble 
TNFα as reported previously (Steed et al., 2003; Zalevsky et al., 2007). As shown in 
Figure 4.4C, XENP1595 offered perfect protection against cell death induced by 
zVAD and exogenous TNFα. Consistently, silencing TNFα also protected 
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zVAD-induced necrosis in L929 cells (Figure 4.4D). Collectively, these data clearly 
demonstrate that zVAD-induced necrotic cell death in L929 cells is necroptosis that 
depends on the secreted autocrine TNFα. Remarkably, such findings are consistent 
with a recent report in which autocrine TNFα was identified, through a RNAi library 
screening, to be required for zVAD-induced cell death in L929 cells (Hitomi et al., 
2008). 
4.3.6 NF-κB pathway is not involved in zVAD-induced autocrine production of 
TNFα, but plays a protective role during zVAD-induced necroptosis 
    It is known that both canonical and non-canonical NF-κB pathways are 
implicated in producing autocrine TNFα in cancer cells (Varfolomeev et al., 2007; 
Vince et al., 2007). Here we further investigated whether NF-κB pathway is involved 
in zVAD-induced TNFα production and subsequent necroptosis. To understand the 
role of NF-κB pathway in zVAD-induced cell death, we silenced IKKβ and IKKα 
using siRNA. The IKKβ and IKKα knockdown efficiency was shown in Figure 4.5A. 
Disruption of the canonical NF-κB pathway by targeting IKKβ blocked 
TNFα-triggered IκBα degradation (Figure 4.5B) and markedly sensitized L929 cells 
to zVAD-induced cell death (Figure 4.5D), whereas silencing the non-canonical 
pathway by targeting IKKα mitigated basal and zVAD-induced p100 processing 
(Figure 4.5C) and also slightly enhanced cell death (Figure 4.5D), suggesting a 
pro-survival function of both the canonical and non-canonical NF-κB pathways in 
zVAD-mediated necroptosis. To further confirm such a protective role of NF-κB, we 
next disrupted the canonical and non-canonical NF-κB pathways by directly silencing 
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their key components, RelA and RelB, respectively. The knockdown efficiency is 
shown in Figure 4.5E. Knockdown of RelA greatly, whereas knockdown of RelB 
slightly, sensitized L929 cells to necroptosis induced by zVAD (Figure 4.5F), being 
consistent to the data from knockdown of IKKβ and IKKα (Figure 4.5D). Finally, we 
found that knockdown of RelA or RelB failed to block the autocrine production of 
TNFα (Figure 4.5G). It is thus believed that neither the canonical nor the 
non-canonical NF-κB pathway contributes to zVAD-induced TNFα transcription, and 
both NF-κB pathways generally act as a pro-survival mechanism to ablate 
zVAD-induced cell death.  
4.3.7 AP-1 activity is required for zVAD-induced TNFα production and cell 
death 
    In addition to NF-κB, another important transcription factor, activating protein-1 
(AP-1), has been implicated in TNFα transcription (Barthel et al., 2003; Das et al., 
2009; Tsytsykova et al., 2007). In this part of our study, we attempted to elucidate the 
possible role of AP-1 in zVAD-mediated autocrine production of TNFα and 
subsequent necroptosis. As c-Jun is one of the essential components of AP-1 (Karin et 
al., 1997), we first examined the effects of c-Jun knockdown on AP-1 activity, TNFα 
transcription and cell death. The knockdown efficiency was shown in Figure 4.6A. 
Silencing of c-Jun significantly ablated AP-1 luciferase activity in the cells treated 
with zVAD (Figure 4.6B) and reduced TNFα mRNA transcription (Figure 4.6C). As 
expected, knockdown of c-Jun dramatically suppressed zVAD-induced cell death in 
L929 cells (Figure 4.6D). Therefore, this set of data strongly implies that AP-1 is 
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responsible for zVAD-stimulated TNFα transcription. 
4.3.8 zVAD-induced AP-1 activation is mediated by JNK and ERK 
    Next, we sought to explore the upstream signaling pathways mediating 
zVAD-induced AP-1 activation, focusing on MAPKs. First, zVAD treatment was 
found to activate c-Jun (Figure 4.7A). Second, zVAD was able to enhance the 
phosphorylation of JNK and ERK, the two important MAPKs upstream of AP-1 
(Figure 4.7A). Since TNFα is also known as a activator of MAPKs and c-Jun;(Devin 
et al., 2003; Karin et al., 1997) it is thus possible that the activation of JNK, ERK, and 
c-Jun is triggered by autocrine TNFα, but not by zVAD per se. To exclude this 
possibility, we treated the cells with TNFα neutralizing antibody to block the secreted 
TNFα function and found that zVAD was still capable of activating JNK, ERK and 
c-Jun (Figure 4.7B), suggesting that zVAD-activated MAPKs and c-Jun is 
independent of autocrine TNFα. On the other hand, it is noteworthy that the activation 
of JNK, ERK, and c-Jun was slightly weaker when the secreted TNFα was 
neutralized (Figure 4.7B), indicating that the autocrine TNFα may further activate 
MAPKs and c-Jun. To test whether JNK and ERK are the upstream molecules 
mediating AP-1 activation upon zVAD treatment, we next utilized two chemical 
inhibitors, SP600125 (SP) and PD98059 (PD), to inhibit JNK and ERK activation, 
respectively. As shown in Figure 4.7C, these two inhibitors almost completely 
abrogated zVAD-induced phosphorylation of JNK and ERK, as well as that of c-Jun. 
As a result, they blocked zVAD-induced AP-1 activation as determined by the AP-1 
luciferase assay (Figure 4.7D). As expected, these inhibitors dramatically suppressed 
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the autocrine production of TNFα (Figure 4.7E) and eventually offered perfect 
protection against zVAD-induced necroptosis in L929 cells (Figure 4.7F). Therefore, 
data from this part of study clearly demonstrate that the MAPKs-mediated AP-1 
activation is required for zVAD-induced TNFα production and subsequent 
necroptosis. 
4.3.9 PKC plays a critical role in zVAD-mediated MAPKs-AP1 activation, TNFα 
production, and cell death 
    After establishing the role of MAPKs (JNK and ERK) in zVAD-induced TNFα 
transcription and production, here we sought to find the upstream mechanism 
mediating zVAD-induced MAPKs activation. It has been well established that protein 
kinase C (PKC) is one of the important signals upstream of MAPKs (Eferl and 
Wagner, 2003). Therefore, we examined whether zVAD is able to activate MAPKs 
via PKC. First, zVAD was found to evidently activate PKC, similar to the effect of 
TPA, as determined by phosphorylation of the total PKC substrate (Figure 4.8A). A 
PKC inhibitor (PKCi, bisindolylmaleimide I) was able to completely inhibit both 
reactions. Importantly, TPA enhanced, whereas PKCi effectively suppressed, 
zVAD-induced phosphorylation of JNK, ERK, and c-Jun (Figure 4.8B), suggesting 
that PKC acts upstream of JNK and ERK, leading to AP-1 activation. Consistently, 
TPA was found to promote TNFα transcription and secretion (Figure 4.8C and D). 
Moreover, TPA further enhanced, while PKCi almost completely blocked, the 
zVAD-induced TNFα transcription and secretion (Figure 4.8C and D). As expected, 
TPA markedly increased, while PKCi perfectly protected against, zVAD-induced cell 
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death. Interestingly, TPA and PKCi modulated exogenously administered 
TNFα-induced necroptosis in an opposite pattern to their effects on zVAD-induced 
necroptosis (Figure 4.8E), being consistent with an earlier report in which TPA was 
found to mitigate TNFα-induced necrosis (Byun et al., 2006). These results suggest 
that activation of PKC can enhance zVAD-induced necroptosis via promoting 
autocrine production of TNFα, without affecting the downstream TNFα signaling 
pathways.   
In order to further understand the involvement of PKC in zVAD-induced 
necroptosis as demonstrated above, we compared the effects of different pan-caspase 
inhibitors on PKC activation. As anticipated, zVAD and BocD, but not QVD, were 
capable of activating PKC, as well as JNK, ERK and c-Jun (Figure 4.9A). This result 
prompted us to test whether activation of PKC would affect the effect of QVD on 
L929 cells. Interestingly, TPA indeed effectively turned QVD into a cell killer (Figure 
4.9B). It is noteworthy that the caspase-3 inhibitor, DEVD, was still unable to induce 
cell death in the presence of TPA (Figure 4.9B), indicating that inhibition of certain 
caspases by QVD, but not by DEVD, is critical for such cell death. Similarly, TPA 
was also effective for induction of necroptosis in cells with knockdown of caspase-8 
(Figure 4.9C), while knockdown of caspase-8 per se is not cytotoxic. Such 
observations thus suggest that both autocrine TNFα and inhibition of the caspase 
cascade, including caspase-8 inhibition, are required for necroptosis induced by 
zVAD and BocD. 
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4.3.10 zVAD sensitizes TNFα-induced necroptosis in L929 cells 
    As shown above, it appears that both autocrine TNFα and caspase inhibition are 
required for zVAD-induced necroptosis. To further understanding why caspase 
inhibition is required, we first examined the zVAD effect on autocrine TNFα 
production in another cell line, the macrophage RAW264.7 cells, because in which 
the TNFα production can be easily monitored by immunoblotting. As shown in Figure 
4.10A, zVAD, similar as TPA, dramatically promoted autocrine production of TNFα, 
more importantly, we found the similar results in RAW264.7 cells that only zVAD 
and BocD, but not QVD, activated c-Jun and enhanced TNFα production (Figure 
4.10B). However, albeit significant increase of TNFα production, zVAD only induced 
marginal necroptosis in RAW264.7 cells (Figure 4.10C). It has been reported that 
zVAD is able to greatly sensitize TNFα- and FasL-induced necrosis in L929 cells 
(Vercammen et al., 1998a), we suspected that such sensitization effect is critical. 
Consistently, we also observed that, in the presence of zVAD, TNFα showed a much 
greater cytotoxicity to L929 cells (Figure 4.11A), while zVAD did not show evident 
effect on TNFα-induced necrosis in RAW264.7 cells (Figure 4.11B). Of note, the 
TNFα of a concentration resembling the autocrine production (10 pg/ml) was found 
not cytotoxic, but induced robust cell death in the presence of zVAD (Figure 4.11A). 
It is thus clear such a sensitization effect is also critical for zVAD-induced necroptosis 
in L929 cells, in addition to promoting autocrine production of TNFα. 
4.3.11 Defect in autophagy enhances AP-1 activity 
    In Chapter 2 and 3, we have demonstrated that autophagy plays a protective role 
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during zVAD-induced necrosis but without knowing the underlying mechanism. After 
we established that such cell death is indeed necroptosis depending on autocrine 
production of TNFα, we set up experiments to investigate how autophagy can 
mitigate zVAD-induced necroptosis. First, we found that induction of autophagy by 
starvation and rapamycin did not provide an evident protection against exogenous 
TNFα-induced necroptosis (Figure 4.12A), suggesting that autophagy may exert its 
protective function upstream of autocrine TNFα. Next, starvation and rapamycin were 
found capable of inhibiting zVAD-induced c-Jun activation (Figure 4.12B). Strikingly, 
in Atg5-/- MEF cells that is deficient in autophagy evidenced by disappearance of 
LC3 I to II conversion (Figure 4.12C), we found that the basal level and 
zVAD-induced c-Jun activation was much higher than that in WT MEF. To further 
confirm this finding, we utilized the DOX-mediated Tet-off Atg5 MEF cells, which 
were generated by reconstituting the Atg5-/- cells with a DOX-suppressible WT Atg5 
expression vector (Hosokawa et al., 2006). Similarly, when the Atg5 expression was 
blocked by DOX pretreatment, zVAD induced c-Jun activation was enhanced (Figure 
4.12D). Remarkably, knockdown of Atg5 and Beclin 1 in L929 cells also led to 
higher basal and zVAD-induced activation of c-Jun (Figure 4.12E) while enhanced 
zVAD-induced necrosis (Figure 2.6A and B). We found that, using the Tet-off Atg5 
MEF system, removal Atg5 resulted in higher AP-1 activity in response to zVAD and 
TPA, but not to TNFα (Figure 4.12F). Therefore, all these data imply that autophagy 
may suppress AP-1 activity, leading to lower autocrine production of TNFα and 
consequently ablating zVAD-induced necroptosis. 
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4.4 Discussion 
    In recent years, necrotic cell death has been increasingly appreciated as an 
important form of PCD. In contrast to apoptosis, the molecular mechanisms 
underlying necrosis is much less understood. Necrosis usually occurs in cells when 
the apoptosis machinery is suppressed or absent. zVAD-induced necrotic cell death is 
among several necrosis models established so far. In this study, we identified 
autocrine TNFα as the missing pro-death signal in zVAD-induced necrotic cell death 
or necroptosis. Such a finding is indeed consistent with a recent report in which 
TNFR1 and autocrine TNFα were found to be crucial for zVAD-induced necrosis in 
L929 cells (Hitomi et al., 2008). It is known that endogenously produced TNFα can 
be secreted into the extracellular environments or exists as a membrane-bound form, 
both of which are able to trigger downstream signaling, leading to cell death (Kresse 
et al., 2005; Locksley et al., 2001). Notably, our data suggest that zVAD-induced 
necroptosis in L929 cells is predominantly executed by the secreted soluble TNFα, 
based on following observations: (i) the TNFα neutralizing antibody, which can only 
neutralize the soluble TNFα in medium, attenuated zVAD-induced cell death (Figure 
S3b) and (ii) blocking the soluble TNFα by the DN-TNF protein offered perfect 
protection against zVAD-induced cell death (Figure 4.4C).  
    The major aim of this study is to understand the molecular mechanisms 
underlying zVAD-induced autocrine production of TNFα. It is known that the TNFα 
promoter region contains both NF-κB and AP-1 responsive elements (Baud and Karin, 
2001). In cancer cells treated with the IAP antagonists, autocrine TNFα is produced 
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via both the canonical and non-canonical NF-κB pathways (Varfolomeev et al., 2007; 
Vince et al., 2007). Here we show that zVAD mainly utilizes the AP-1 pathway, but 
not the NF-κB pathway, to promote TNFα transcription (Figure 4.5 and 4.6). Notably, 
such a notion is also supported by the finding in which, by using RNAi library 
screening, Jun, but not NF-κB components, was identified as one of the critical 
players involved in zVAD-induced necrosis in L929 cells (Hitomi et al., 2008). 
Moreover, we demonstrate that zVAD-induced AP-1 activation in L929 cells is 
mediated by activation of MAPKs including JNK and ERK (Figure 4.7). These data 
are indeed consistent with recent reports that TNFα expression was regulated by JNK 
(Das et al., 2009) or ERK (Ding et al., 2009). Therefore, it appears that the 
transcriptional machinery for TNFα expression is cell type and stimulus specific.  
    One important finding in this study is that PKC acts upstream of MAPKs to 
promote TNFα production in response to zVAD. The PKC family is an important 
group of proteins with diverse functions in many cellular processes such as cell 
proliferation, differentiation and cell death (Mackay and Twelves, 2007). Among the 
three pan-caspase inhibitors tested in this study (zVAD, BocD and QVD), their effects 
on PKC activation, autocrine production of TNFα, and induction of cell death are 
highly correlated. Moreover, when combining with caspase inhibition, the typical 
PKC activator, TPA, was found to induce necroptosis in L929 cells (Figure 4.9B, 
4.9C). Among the three groups of PKC, TPA is able to activate both the conventional 
 and  and novel (, ,  and  isoforms of PKC (Newton, 1995). Therefore, future 
work should include the identification of the exact isoforms of the PKC involved in 
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zVAD-induced TNFα production and cell death. Another important and intriguing 
question would be how zVAD activates PKC. It appears that the activation of PKC is 
not related to caspase inhibition since QVD fails to activate PKC. On the other hand, 
zVAD and BocD have been reported to possess non-specific inhibitory effect toward 
other proteases such as cathepsins, while QVD does not (Chauvier et al., 2007). It is 
thus possible that PKC activation might be due to the off-target effect of zVAD and 
BocD.  
Although zVAD has been shown in this study to promote TNFα transcription 
and production, the autocrine level is still very low (around 10 pg/ml) (Figure 4.3B). 
Exogenous TNFα of such a concentration was found not cytotoxic (Figure 4.11B). 
Moreover, zVAD was found to promote autocrine production of TNFα as well as cell 
death in other cell line such as RAW264.7, but at a much lesser extent (Figure 4.10A, 
B, and C). Remarkably, when combining with zVAD, exogenous TNFα could induce 
necroptosis in L929 cells with a much faster kinetics and at a much lower 
concentration (Figure 4.11A and B), being consistent with an earlier report 
(Vercammen et al., 1998a). Such a striking sensitization effect of zVAD on 
TNFα-induced necroptosis cannot be found in RAW264.7 cells (Figure 4.11C). 
Therefore, it is believed that zVAD performs a dual role to induce necroptosis in 
L929 cells: (i) to promote autocrine production of TNFα, and (ii) to sensitize L929 
cells to TNFα-induced necroptosis, most probably via suppression of caspase activity. 
Such understandings also help explain the fact that only a restricted number of cell 
types are sensitive to zVAD-induced necroptosis. In addition, not all cells are 
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equipped with autocrine production of TNFα and the necroptosis machinery (such as 
RIP3) (He et al., 2009). At present, there is some evidence linking caspase 
suppression with promotion of necroptosis, based on an earlier report that RIP1, the 
key kinase in TNFα-mediated necroptosis, is cleaved by caspase-8 (Lin et al., 1999). 
This notion is also supported and strengthened by the following observations from 
this study: (i) although TPA alone and QVD alone were not cytotoxic, combined 
treatment of TPA and QVD was able to kill the cells efficiently (Figure 4.9B); and (ii) 
TPA alone was capable of inducing necroptosis when caspase-8 is silenced (Figure 
4.9C). Thus far, the detailed mechanism underlying this sensitization effect requires 
further investigations.  
As demonstrated in our earlier reports that autophagy plays a cell survival role in 
zVAD-induced necrosis (Wu et al., 2008a; Wu et al., 2009b), we thus investigated the 
possible mechanism of autophagy for protecting such cell death. First, we found that 
starvation or rapamycin did not offer evident protection against TNFα- or 
TNFα+zVAD-induced necroptosis in L929 cells (Figure 4.12A), suggesting the 
pro-survival role of autophagy during zVAD-induced necroptosis may be achieved 
via modulation of autocrine production of TNFα. Strikingly, we found more 
activation of c-Jun in Atg5-/- MEF than that in WT MEF (Figure 4.12C and 4.12D); 
moreover, knockdown of Atg5 and Beclin 1 in L929 cells also enhanced 
zVAD-induced c-Jun activation (Figure 4.12E). Consistently, the AP-1 activity was 
higher in Atg5-/- MEF than that in WT MEF (Figure 4.12F). Unfortunately, due to 
technical difficulties, we failed to detect the autocrine production of TNFα in MEF 
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cells and the difference in zVAD-induced TNFα production in the L929 cells with 
knockdown treatment was not convincing. Nevertheless, we believe these data are 
good indications suggesting an unexpected role of autophagy in promoting autocrine 
production of TNFα via upregulation of AP-1. Indeed, this hypothesis has been 
supported by a recent study in which loss of allelic Beclin 1 leads to more TNFα 
production and secretion in mice livers and liver tumor cells (Mathew et al., 2009). 
    Targeting caspase has been developed as a therapeutic approach to inhibit 
pathological apoptosis in vivo. However, the success of anti-apoptotic therapies has 
been limited in mammalian cells and one possible reason is that the cells may 
undergo necrosis in the absence of apoptotic pathway (Degterev and Yuan, 2008; 
Vandenabeele et al., 2006). Such a hypothesis is underscored by two very recent 
studies: the programmed necrosis in vivo was shown to implicate in the defense 
against vaccinia virus infection (Cho et al., 2009) and cerulein-induced acute 
pancreatitis is resulted from massive necrosis in vivo (He et al., 2009). Interestingly, 
in both models, the necrosis was triggered by endogenous TNFα. As a potent 
pan-caspase inhibitor, zVAD has been applied to various animal models to suppress 
the apoptotic responses (Emamaullee et al., 2007; Nussbaum and Whitton, 2004). 
Recently, zVAD was reported to improve the therapeutic outcomes of radiation on 
tumor xenograft (Moretti et al., 2009). It remains to be further determined whether 
the observed therapeutic effect of zVAD in vivo is due to caspase inhibition and 
suppression of apoptosis or due to promotion of autocrine production of TNFα and 
induction of necroptosis.  
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    Taken together, data from this study suggest that a group of caspase inhibitors 
represented by zVAD are capable of inducing programmed necrosis or necroptosis via 
the following two orchestrated pathways: (i) promotion of autocrine production of 
TNFα via PKC-MAPKs-AP-1 signaling pathway, and (ii) Sensitization of 
TNFα-induced necroptosis probably via inhibition of the caspase cascade, as 
illustrated in Figure 4.13. It is of interest to further examine whether zVAD or other 
caspase inhibitors possess similar effects on other cell types, especially in human 
cancer cells. 
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Figure 4.1 Caspase inhibition is not sufficient for zVAD to induce necrosis. (A) 
Effects of various caspase inhibitors on cell death. L929 cells were treated with 
zVAD-fmk (10 μM), QVD-oph (20 μM), BocD-fmk (10 μM), IETD-fmk (20 μM), 
IETD-oph (20 μM), and DEVD-cho (100 μM) for 24 hrs. Cell death was examined 
under microscope (×200) for morphological changes (upper panel) and quantified by 
SD from 3 
independent experiments). (B) Effects of caspase inhibitors on TRAIL-induced 
caspase and PARP-1 activation. L929 cells were pretreated as described in panel a for 
1 hr, followed by treatment with TRAIL (20 ng/ml) for 8 hrs. Cell lysate was 
subjected to western blotting. (C) Overexpression of CrmA is not sufficient to induce 
cell death in L929 cells. Cells were co-transfected with CrmA and EGFP (10:1), 24 
hrs later, cells were treated with TNFα (10 ng/ml×6 hrs) or remained untreated for 
another 24 hrs (Ctrl), cell death were examined under a fluorescence microscope 
(×400). Cell death was quantified by counting the dead cells with green color (with a 
morphology of rounded or floated) in randomly selected 100 green cells (data were 
presented as mean±SD from 3 independent experiments). (D) Caspase-8 and FADD 
knockdown are not sufficient for inducing necrosis. Knockdown of caspase-8 and 
FADD effectively block TRAIL-induced caspase activation (left). L929 cells were 
transfected with scramble, caspase-8, and FADD siRNA, 48 hrs later, cells were 
transfected with these three siRNA for the second round and allowed for growth for 
another 48 hrs, followed by treatment with TRAIL (20 ng/ml) for 8 hrs. Cell lysate 
was subjected to immunoblotting. Knockdown of caspase-8 and FADD are not 
cytotoxic and successfully inhibit TRAIL-induced apoptosis (right). L929 cells were 
transfected with siRNAs as described in Panel a, followed by treatment with TRAIL 
(20 ng/ml) for 24 hrs, viable cells were determined by PI exclusion assay (data were 
presented as mean±SD from 3 independent experiments). 

























































































Figure 4.2 zVAD-induced necrosis requires de novo protein synthesis. (A) De novo 
protein synthesis is required for zVAD-induced cell death. L929 cells were pretreated 
with CHX (10 μg/ml) or ActD (5 μg/ml) for 30 mins, followed by treatment with 
zVAD (10 μM) for 24 hrs. The cell death was examined under microscope and by PI 
exclusion assay. (B) Volume of culturing medium affects zVAD-induced cell death. 
L929 cells were treated with different volumes of culturing medium (300 μl, 600 μl, 
and 1000 μl per well for 24 well-plates) containing the same concentration of zVAD 
(10 μM) or TNFα (10 ng/ml) for 24 hrs. The cell death was examined as described in 
panel A. (C) zVAD-induced necrosis requires RIP1 kinase activity. L929 cells were 
treated with zVAD (10 μM × 24 hrs), TNFα (10 ng/ml × 8 hrs), and MNNG (100 nM 
× 24 hrs) with or without necrostatin-1 (30 µM). Cell death was examined under a 
microscope (× 200). (D) zVAD-induced necrosis in L929 cells is RIP3 dependent. 
L929 cells were transfected with scramble and RIP3 siRNA, 48 hrs later, cells were 
treated with zVAD (10 μM×24 hrs), TNFα (10 ng/ml×8 hrs) and TRAIL (20 
ng/ml×24 hrs) as indicated: Left panel, the effectiveness of RIP3 knockdown. Right 
panel: cell death determined by PI exclusion assay. 
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Figure 4.3 zVAD promotes autocrine of TNFα. (A) Basal level of TNFα secreted in 
culturing medium in untreated cells. L929 cells were incubated in fresh media for up 
to 24 hrs, and the secreted TNFα in the medium was determined by ELISA. (B) 
zVAD enhances autocrine TNFα production in culturing medium. L929 cells were 
incubated in fresh medium containing zVAD (10 μM) or zVAD+CHX (10 μg/ml) for 
up to 24 hrs. The TNFα level was measured as described in panel a. (C) zVAD and 
BocD, but not QVD, promote TNFα transcription. L929 cells were treated with zVAD 
(10 μM), QVD (20μM), and BocD (10 μM) for 6 hrs, the TNFα mRNA level was 
determined by RT-PCR. (D) zVAD and BocD, but not QVD, promote autocrineTNFα 
production. L929 cells were treated as described in panel c in fresh medium for 8 hrs, 
The secreted TNFα level was measured by ELISA. 
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Figure 4.4 Blockage of TNF signaling pathway prevents zVAD-induced cell death. 
(A) TNFR1 blocking antibody suppresses zVAD-induced cell death. L929 cells were 
pretreated with TNFR1 blocking antibody at designated concentrations for 1 hr, 
followed by treatments of zVAD (10 μM), TNFα (10 ng/ml), and TRAIL (20 ng/ml) 
for 24, 8, and 24 hrs, respectively. The cell death was detected as described in Figure 
1a. (B) TNFα neutralizing antibody decreases zVAD-induced cell death. L929 cells 
were pretreated with TNFα neutralizing antibody at designated concentrations for 1 hr, 
followed by treatments as described above. (C) XENP1595, a DN-TNF protein 
protects against zVAD-induced cell death. L929 cells were pretreated with 
XENP1595 at designated concentrations for 30 min, followed by treatment with 
zVAD (10 μM) and TNFα (10 ng/ml) for 24 and 8 hrs, respectively. The cell death 
was determined as described in Figure S1b. (D) Knockdown of TNFα mitigates 
zVAD-induced cell death. TNFα knockdown was performed and the effectiveness 
was validated in upper panel. The cells with knockdown of TNFα were treated with 
zVAD (10, 20 μM) and TNFα (5, 10 ng/ml) for 24 and 8 hrs, cell death was 
determined by PI exclusion assay. 






































































































Figure 4.5 NF-κB pathway plays a protective role in zVAD-induced cell death. (A) 
Knockdown of IKKα and IKKβ in L929 cells performed as described in Materials 
and Methods. (B) Effects of knockdown of IKKα and IKKβ on TNFα-induced IκBα 
degradation. After knockdown, the cells were treated with TNFα (1 ng/ml) for 
indicated time and cell lysate was subjected to western blotting. (C) Effects of 
knockdown of IKKα and IKKβ on zVAD-induced p100 processing. After knockdown, 
the cells were treated with zVAD (10 μM) for indicated time and cell lysate was 
subjected to western blotting. (D) Effects of knockdown of IKKα and IKKβ on 
zVAD-induced cell death. After knockdown of IKKα and IKKβ, cells were treated 
with zVAD (10 μM) for 24 hrs, and cell death was measured by the PI exclusion 
assay (data were presented as mean±SD from 3 independent experiments). (E) 
Knockdown of RelA and RelB in L929 cells as described in Materials and Methods. 
(F) Effects of knockdown of RelA and RelB on zVAD-induced cell death. Cells with 
knockdown of RelA and RelB were treated and the cell death was measured as 
described in panel b. (G) Effects of knockdown of RelA and RelB  on autocrine 
TNFα production. Cells with knockdown of RelA and RelB were treated with DMSO 
or zVAD (10 μM) for 8 hrs, secreted TNFα was determined by ELISA. 





























































1.0    1.5    0.4   0.3
 
 
Figure 4.6 Knockdown of c-Jun blocks zVAD-induced autocrine TNFα production 
and necroptosis (A) Validation of c-Jun knockdown efficiency. L929 cells were 
transfected with scramble and c-Jun siRNA, after 48 hrs, the cell lysates were subject 
to immunoblotting. (B) Knockdown of c-Jun abrogates zVAD-induced AP-1 
luciferase activity. Knockdown of c-Jun was performed as described in panel a, cells 
were transfected with the AP-1 and Renilla luciferase vectors for another 24 hrs and 
then were treated with zVAD (10 μM) for additional 10 hrs. The AP-1 luciferase 
activity was measured as described in Figure 6c. (C) Knockdown of c-Jun abolishes 
zVAD-induced TNFα transcription. Knockdown of c-Jun was performed as described 
in panel a, followed by treatment with zVAD (10 μM) for 6 hrs. TNFα mRNA level 
was determined by RT-PCR. (D) Knockdown of c-Jun blocks zVAD-induced cell 
death. Knockdown of c-Jun was performed as described in panel a, followed by 
treatment with zVAD (10 μM) for 24 hrs. Cell death was determined using PI 
exclusion assay. 
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Figure 4.7 zVAD-induced TNFα transcription is depending on the MAPKs-AP-1 
signaling pathway. (A) zVAD activates JNK and ERK. L929 cells were treated with 
zVAD (10 μM) for up to 6 hrs. Cell lysate was subjected to western blotting. (B) 
zVAD activates MAPKs and c-Jun in the presence of TNFα neutralizing antibody. 
Cells were pretreated with TNFα neutralizing antibody (2.0 μg/ml) for 1 hr, followed 
by treatment with zVAD as described in panel a, cell lysate was subjected to western 
blotting. (C) MAPKs inhibitors suppress zVAD-induced c-Jun phosphorylation. L929 
cells were treated with zVAD (10 μM) with or without the presence of SP600125 (20 
μM) or PD98059 (20 μM) for 6 hrs, and cell lysate was subjected to immunoblotting. 
(D) MAPKs inhibitors suppress zVAD-stimulated AP-1 luciferase activity. L929 cells 
were transfected with luciferase vectors for 24 hrs, and cells were then treated as 
described in panel c for 10 hrs, the AP-1 activity was measured by the luciferase assay. 
(E) MAPKs inhibitors block zVAD-induced autocrine TNFα production. L929 cells 
were incubated in fresh medium and were treated as described in panel c for 8 hrs, the 
TNFα protein level in the culturing medium was determined by ELISA. (F) MAPKs 
inhibitors protect zVAD-induced cell death. L929 cells were treated as described in 
panel c for 24 hrs, and cell death was measured by PI exclusion assay. 
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Figure 4.8 Critical role of PKC in zVAD-induced MAPKs-AP-1 activation, autocrine 
of TNFα and necroptosis. (A) zVAD activates PKC. L929 cells were treated with 
zVAD (10 μM) for up to 6 hrs, with or without the presence of PKCi (1 μM). TPA (80 
nM×1 hr) was used as a positive control. PKC activation was determined by the 
phosphorylation of PKC substrates using immunoblotting. (B) Effects of TPA and 
PKCi on zVAD-induced activation of JNK and ERK. L929 cells were treated with 
zVAD, TPA or PKCi as indicated for 6 hrs, and cell lysate was subjected to 
immunoblotting. (C) Effects of TPA and PKCi on zVAD-induced TNFα transcription. 
Cells were treated as described in panel b for 6 hrs, TNFα mRNA level was 
determined by RT-PCR. (D) PKC activation contributes to zVAD-induced autocrine 
TNFα production. L929 cells were treated as described in panel b for 8 hrs, 
concentration of the TNFα protein level in the medium was determined by ELISA. (E) 
PKC activation enhances zVAD-induced cell death but suppresses TNFα-induced cell 
death. L929 cells were treated with zVAD (10 μM×24 hrs) or TNFα (1 ng/ml×8 hrs) 
with or without the presence of PKCi (1 μM) or TPA (80 nM). Cell death were then 
determined by PI exclusion assay. 















































Figure 4.9 Promotion of autocrine of TNFα combining with caspase-8 inhibition 
induces cell death in L929 cells. (A) zVAD and BocD, but not QVD, activate the 
PKC-MAPK-AP-1 signaling pathway. L929 cells were treated with zVAD (10 μM), 
QVD (20 μM), or BocD (10 µM) for 6 hrs, and cell lysate was subjected to 
immunoblotting. (B) QVD, when combining with TPA, induces cell death. L929 cells 
were treated with zVAD (10 μM), QVD (20 μM) or DEVD (100 μM) with or without 
the presence of TPA (80 nM) for 24 hrs, and cell death was quantified as described in 
Figure 3b. (C) TPA induces cell death in caspase-8 knockdown cells. L929 cells were 
transfected with scramble or caspase-8 siRNA, 48 hrs later, cells were treated with 
TPA (80 nM) or zVAD (10 μM) for 24 hrs, cell death was determined by PI exclusion 
assay.  
































Figure 4.10 zVAD promotes autocrine production of TNFα but induces marginal cell 
death in RAW264.7 cells. (A) zVAD and TPA promote autocrine production of TNFα 
in RAW264.7 cells. RAW264.7 cells were treated with TPA (80 nM) and zVAD (20 
μM) for 8 hrs, the cell lysate was subjected to immunoblotting. (B) zVAD and BocD, 
but not QVD, promote autocrine production of TNFα. RAW264.7 cells were treated 
with zVAD (20 μM), QVD (40 μM), or BocD (20 µM) for 8 hrs, and cell lysate was 
subjected to immunoblotting. (C) RAW264.7 cells were treated with zVAD (20 μM) 
with or without the presence of TNFα neutralizing antibody (2.0 μg/ml) for 24 hrs, 
cell death was determined by PI exclusion assay. 
 






























































0            2            4          8           12        24        hrs
 
 
Figure 4.11 zVAD greatly sensitizes TNFα-induced necrosis in L929 cells but not in 
RAW264.7 cells. (A) L929 cells were treated with zVAD (10 μM), TNFα (10 ng/ml), 
or zVAD+TNFα for 2, 4, 8, and 12 hrs. Cell death was determined by PI exclusion 
assay. (B) L929 cells were treated with zVAD (10 μM), TNFα (10 pg/ml), or 
zVAD+TNFα for 2, 4, 8, 12, and 24 hrs. Cell death was determined by PI exclusion 
assay. (B) RAW264.7 cells were treated with zVAD (20 μM), TNFα (10 ng/ml), or 
zVAD+TNFα for 24 hrs. Cell death was determined by PI exclusion assay. 
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Figure 4.12 Effects of autophagy on activation of AP-1. (A) Starvation and 
rapamycin cannot block TNFα- or TNFα+zVAD-induced necroptosis. L929 cells 
were treated with TNFα (10 ng/ml × 8 hrs), or zVAD (10 μM × 24 hrs), or 
TNFα+zVAD (8 hrs) in full culture medium (Ctrl), or in EBSS, or in the presence of 
rapamycin (10 nM). Cell death was examined under microscope (×200). (B) 
Starvation and rapamycin inhibit zVAD-induced c-Jun activation. L929 cells were 
treated with zVAD (10 μM) in full medium, or in FBS free medium, or in the 
presence of rapamycin (10 nM) for 6 hrs. (C) Increase of c-Jun activation in Atg5-/- 
cells. WT and Atg5-/- MEFs were treated with zVAD (20 μM) for 1, 3, and 6 hrs, or 
in the presence of PD for 6 hrs. (D) Increase of c-Jun activation in Atg5 Tet-off cells. 
Tet-off Atg5 MEF cells were treated with or without DOX for 5 days, then were 
treated with zVAD (20 μM) for 8 hrs. (E) Knockdown of Atg5 and Beclin 1 enhance 
c-Jun activation. L929 cells were transfected with scramble, Atg5, or Beclin 1 siRNA, 
48 hrs later, cells were treated with zVAD (10 μM) for 8 hrs. (F) Defect in autophagy 
enhances AP-1 activity. Tet-off Atg5 MEF cells were treated with zVAD (10 μM), 








Figure 4.13 Illustration of the signaling pathways for zVAD-induced necroptosis. 
Both promotion of autocrine production of TNFα via the PKC-MAPKs-AP-1 
signaling pathway and suppression of caspase activation to stabilize RIP1 are 
required for necroptosis induced by zVAD. 
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GENERAL DISCUSSIONS AND CONCLUSIONS 
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Autophagy refers to an evolutionarily conserved cellular process in which bulk 
cytosolic proteins and organelles are sequestered by autophagosomes and delivered to 
lysosomes for degradation (Klionsky and Emr, 2000). Such a catabolic process has 
been shown to possess various biological functions and participate into diverse 
physiological and pathological processes, which is manifested by its critical 
implications in a variety of diseases (Mizushima et al., 2008). One of the important 
biological functions of autophagy is to regulate PCD. Therefore, a better 
understanding of the regulatory role of autophagy in PCD may provide deeper 
insights into the molecular mechanisms underlying the autophagy-associated 
diseases. 
The role of autophagy in PCD is still highly controversial. On one hand, the 
cytoprotective role of autophagy in PCD has been supported by numerous studies 
from yeast to mammal. On the other hand, there is evidence suggesting that 
autophagy may also act as a death mechanism to promote apoptosis or even trigger a 
non-apoptotic cell death named autophagic cell death (Kroemer et al., 2009). Thus far, 
the autophagic cell death is still a subject of argument. Examining the literature 
carefully, in many cases the evidence linking autophagy as a cell death mechanism is 
frequently circumstantial and appears inadequate (Kroemer and Levine, 2008). The 
zVAD-induced necrotic cell death in L929 cells has been originally proposed as 
autophagic cell death in mammalian cells (Yu et al., 2004) and has been frequently 
cited as a proof of autophagic cell death in the literature. At present, the exact nature 
and the underlying mechanism of autophagic cell death is still obscure and requires 
                                                            165 
further investigations.  
 The main objective of this study is to investigate the regulatory role of 
autophagy in necrosis. By using multiple necrosis models, we have (i) identified the 
pro-survival role of autophagy during zVAD-induced necrosis; (ii) established the 
pro-death function of insulin in necrosis via suppression of autophagy; and (iii) 
identified the autocrine TNFα as the cell death signal for zVAD to induce necroptosis 
in L929 cells that is mediated by the PKC-MAPKs-AP-1 pathway. Data from this 
study thus provided new insights into the regulatory role of autophagy in necrosis and 
the molecular mechanisms underlying zVAD-induced necrosis in L929 cells. 
5.1 Autophagy plays a pro-survival role in zVAD-induced necrosis  
zVAD, a pan-caspase inhibitor, can induce robust necrotic cell death in a number 
of cells, particularly in mouse fibrosarcoma L929, and such cell death was established 
as an autophagic cell death (Yu et al., 2004). However, after we systematically 
re-examined these models as described in Chapter 2 and 3, we concluded that 
autophagy indeed acts as a cell survival strategy during this necrosis. The logic basis 
of our thought is if this is an autophagic cell death, upregulation of autophagy should 
further enhance cell death while downregulation of autophagy should suppress cell 
death. However, our data clearly showed that the upregulation of autophagy by 
starvation and rapamycin protected zVAD-induced cell death in L929 cells as well as 
U937 cells (Figure 2.3, 2.4, and 2.5); on the other hand, suppression of autophagy by 
pharmacological inhibitors, chloroquine or pepstatin A plus E64d, both of which 
block autolysosomal degradation, greatly enhanced cell death (Figure 2.3, 2.4, and 
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2.8). Intriguingly, knockdown of Atg5, 7, and Beclin 1 also sensitized L929 cells to 
zVAD-induced necrosis (Figure 2.6), which is directly contradictory to the earlier 
report in the same system (Yu et al., 2004). The exact reason for such a discrepancy is 
not known. Remarkably, in separated experiments, knockdown of these genes was 
found to ablate the protective effects of starvation on cell death (Figure 2.7), which 
can serve as a control consistently showing that the knockdown of these genes 
promoted cell death. All these data thus clearly demonstrated a cytoprotective role of 
autophagy in zVAD-induced necrosis. The protective role of autophagy in 
zVAD-induced necrosis in L929 cells was further supported and strengthened by the 
follow-up study presented in Chapter 3. In this study, insulin and IGF-1 were found to 
enhance zVAD-induced cell death and capable of abrogating the protective effect 
provided by starvation (Figure 3.1, 3.2, and 3.3). Moreover, compelling evidence 
suggested that such effects of insulin and IGF-1 depend on mTOR activity, but not 
Akt (Figure 3.5 and 3.6). Finally, we established that the pro-death function of insulin 
was exerted via suppression of autophagy by activation of class I PI3K-Akt-mTOR 
axis (Figure 3.7). Collectively, it is clear that zVAD-induced necrosis in L929 cells is 
not an autophagic cell death; instead, autophagy serves as a cell survival strategy. In 
addition to zVAD-induced necrosis, autophagy also contributes to cell survival in 
other two necrosis models including MNNG-induced necrotic cell death in L929 cells 
and H2O2-induced necrosis in DKO MEF cells (Chapter 3).  
5.2 zVAD inhibits autophagy via suppression of cathepsin activity 
Paradoxically, in zVAD-treated cells, a large number of autophagosomes and a 
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significant accumulation of LC3 II can be observed (Chapter 2), which is consistent 
with the original report (Yu et al., 2004). Based on the dynamic nature of autophagy 
process, we realized that the accumulation of these autophagic markers can result 
from either increase of the autophagic flux or decrease of the autolysosomal 
degradation. On the other hand, zVAD has been proven possessing off-target effects 
to inhibit other proteases such as cathepsins (Chauvier et al., 2007; Schotte et al., 
1999). Cathepsins are a group of proteases that function to break down the autophagic 
cargoes within autolysosomes (Klionsky and Emr, 2000). As expected, we found that 
zVAD potently suppressed cathepsin activity in L929 cells, which implies that zVAD 
can block the exit of autophagy, leading to the accumulation of autophagic markers. 
This hypothesis was supported by analyzing the lysosomal degradation using the 
mRFP-GFP-LC3 construct. Therefore, it is believed that the accumulation of 
autophagic markers is due to the blockage of autophagy rather than induction of 
autophagy. Therefore, caution must be exercised to interpret the data of accumulation 
of autophagic markers, which is not sufficient to demonstrate an induction of 
autophagy but may also be an outcome of blockage of autophagy at the late stage. 
Such a notion has been highlighted in a number of recent reviews (Kroemer and 
Levine, 2008; Mizushima et al., 2010; Scarlatti et al., 2009). 
One intriguing and unclear question is whether zVAD nevertheless induced the 
influx of autophagy. Induction of autophagy is subjected to regulations by an 
extremely complicated signaling networks, thus, it is possible that zVAD may 
stimulate autophagy via certain signaling pathways. For example, it has been reported 
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that ROS is involved in zVAD-induced necrosis in L929 cells (Yu et al., 2006a) and 
the increase of intracellular ROS may induce autophagy (Azad et al., 2009). On the 
other hand, although zVAD can block autophagy via suppression of cathepsin activity, 
it cannot target all cathepsins (Chauvier et al., 2007; Schotte et al., 1999), suggesting 
it may not completely disrupt the lysosome function and totally abrogate autophagy. 
This was evidenced by the observation that cathepsin inhibitors further enhanced the 
LC II conversion in the presence of zVAD, suggesting the inhibition of zVAD on 
cathepsins is not saturated, which allows the completion of a small amount of 
autophagic flux. The functional autophagy is believed to contribute to cell survival, 
particularly when further induced by starvation or rapamycin; and suppression of 
such autophagy by silencing Atg genes enhances cell death.  
5.3 Suppression of autophagy by activation of PI3K-Akt-mTOR axis promotes 
necrosis  
As discussed above, in these three necrosis models, insulin was found to 
enhance the necrosis via activation of the PI3K-Akt-mTOR signaling pathway 
(Figure 3.1). Strikingly, rapamycin, the specific mTOR inhibitor, rendered the cells 
resistance to cell death (Figure 3.5), suggesting the pro-death function of insulin 
depends on mTOR activity. Consistently, knockdown of mTOR protected 
zVAD-induced necrosis in L929 cells and H2O2-induced necrosis in DKO MEF 
(Figure 3.6). Given the critical role of mTOR in governing autophagy, we found that 
insulin inhibited autophagy when it activated mTOR (Figure 3.7). Therefore, this set 
of data indicated a pro-death role of growth factors such as insulin in necrosis via 
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suppression of autophagy.  
It appears intriguing that activation of Akt promotes cell death since it has been 
long recognized as a pro-survival molecule (Downward, 2004). However, it is 
important to note that the pro-survival role of PI3K-Akt-mTOR signaling is mainly 
applicable for apoptosis (Manning and Cantley, 2007), while in the models used here 
it is necrotic cell death. Thus, our finding revealed a pro-death role of 
PI3K-Akt-mTOR axis specific for necrotic cell death. This is indeed in agreement 
with previous reports that activation of PI3K-Akt pathway drives cells to necrosis in 
response to metabolic stress (Aki et al., 2003; Degenhardt et al., 2006).  
At present, it still remains puzzling regarding the mechanisms underlying the 
pro-death function of PI3K-Akt-mTOR signaling pathway on necrosis. One 
explanation proposed by Toshihiko and his colleagues is that the activation of PI3K 
results in autophagic cell death (Aki et al., 2003). On the other hand, several other 
studies by the group of Eileen White at University of Medicine and Dentistry of New 
Jersey suggest that activation of Akt helps to kill cells by inhibition of autophagy 
under metabolic stress (Degenhardt et al., 2006; Karantza-Wadsworth et al., 2007; 
Mathew et al., 2007). Results from our studies thus support the latter notion. First of 
all, the growth factors such as insulin have been well-established as autophagy 
suppressors by triggering PI3K-Akt-mTOR signaling activation (Klionsky and Emr, 
2000; Lum et al., 2005a; Vander Haar et al., 2007). Secondly, mTOR is probably the 
most well illustrated regulatory molecule for autophagy as its activation leads to 
suppression of autophagy at the initiation stage via the Atg1-Atg13 complex 
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(Hosokawa et al., 2009; Jung et al., 2009; Kamada et al., 2000). Thirdly, our previous 
works presented in Chapter 2 and another study from our lab (Huang et al., 2009) 
have provided strong evidence showing that autophagy serves as a pro-survival 
function in these cell death models. Taken together, data from this part of study 
showed that autophagy plays a pro-survival role in multiple necrosis models.  
5.4 Autocrine TNFα is the death signal in zVAD-induced necrosis 
Autophagy is a cell survival strategy during zVAD-induced necrotic cell death; 
thus an apparent question would be what the real death signal is to trigger the necrotic 
response. As mentioned above, the mitochondrial ROS burst might be a mediator. It 
was found that zVAD could enhance intracellular ROS production and a ROS 
scavenger (BHA) was able to block the zVAD-induced necrosis in L929 cells (Yu et 
al., 2006a). However, numerous signaling pathways are capable of promoting ROS 
production, which signal is the initial death trigger in this case?  
As shown in Chapter 4, we followed another strategy in attempt to explore the 
cell death mechanism in zVAD-induced necrosis in L929 cells. We first found that 
caspase inhibition alone is not sufficient to induce necrosis (Figure 4.1); such a 
finding is also direct contradictory to the early report in which caspase-8 inhibition 
suffice cell death (Yu et al., 2004). Silencing of caspase-8 or FADD, although 
successfully blocked TRAIL-induced apoptosis as well as caspase activation, was not 
cytotoxic to L929 cells up to 6 days with two rounds of knocking down (Figure 4.1). 
Such a finding was also supported by the observation that QVD, despite its efficient 
inhibition of TRAIL-induced apoptotic responses, was unable to trigger cell death 
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(Figure 4.1). Several other important observations were made and some of them were 
consistent with the original report (Yu et al., 2004), including: (i) de novo mRNA 
transcription and translation are required (Figure 4.2); (ii) RIP1 protein or its kinase 
activity is essential (Figure 4.2); (iii) RIP3, a newly identified player required for 
necroptosis (Cho et al., 2009; He et al., 2009; Zhang et al., 2009), is indispensible for 
induction of cell death (Figure 4.2). Based on these results, we hypothesized that 
zVAD-induced cell death is necroptosis, which means it is initiated by certain cell 
death ligands. We thus focused on TNFα because it is a well-known potent 
necroptosis inducer in L929 cells (Degterev et al., 2008; Vercammen et al., 1995). 
Because increasing of the volume of cell culture medium was found to mitigate 
zVAD-induced cell death (Figure 4.2), we believed that the secreted autocrine TNFα 
is the missing death signal. As what we expected, zVAD was able to promote TNFα 
production and blockage of TNFα signaling by various approaches offered significant 
protection against the cell death (Figure 4.3 and 4.4). Therefore, we answered the 
earlier question that autocrine TNFα is the real death mechanism in zVAD-induced 
necroptosis in L929 cells. Not surprisingly, this notion has been perfectly supported 
by a recent report, in which, via a RNAi library screening, the TNFR1 and autocrine 
TNFα were identified to be required for zVAD-induced necrosis in L929 cells 
(Hitomi et al., 2008).  
In addition, we found that zVAD was able to promote the autocrine production 
of TNFα at the transcription level, which is essential for induction of cell death 
(Figure 4.3). This is consistent with the observation that zVAD-induced necrosis 
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requires de novo gene transcription and translation (Figure 4.2) (Yu et al., 2004). 
Autocrine TNFα has been found to be induced in response to Smac-mimetics and IAP 
inhibitors (Varfolomeev et al., 2007; Vince et al., 2007). In these two studies, both the 
canonical and non-canonical NF-κB pathways were identified to control the TNFα 
transcription (Varfolomeev et al., 2007; Vince et al., 2007). However, we found that 
zVAD mainly utilized the AP-1 pathway to amplify TNFα while the NF-κB pathways 
still served as a pro-survival strategy (Figure 4.6 and 4.5). Interestingly, the RNAi 
library screening study also revealed that Jun, but not NF-κB components are 
required for zVAD-induced necroptosis in L929 cells (Hitomi et al., 2008). Moreover, 
JNK and ERK were identified as the upstream signals mediating zVAD-induced c-Jun 
activation (Figure 4.7). These results are also consistent with the original report that 
c-Jun and JNK activation is required for cell death (Yu et al., 2004). Providing that 
JNK, ERK, and c-Jun can be activated by TNFα (Devin et al., 2003; Karin et al., 
1997), it is thus possible that the JNK, ERK and c-Jun activation is the downstream 
events triggered by autocrine TNFα, but not zVAD per se. Further investigation 
clearly demonstrated that the JNK, ERK, and c-Jun were directly activated by zVAD, 
but not dependent on autocrine TNFα (Figure 4.7B). It is noteworthy that blockage of 
autocrine TNFα signaling could slightly decrease the JNK, ERK and c-Jun activation, 
indicating a positive feedback may exist to further enhance TNFα production by 
autocrine TNFα (Figure 4.7B). 
More importantly, we found that the JNK and ERK activation was mediated by 
PKC (Figure 4.8). zVAD was able to activate PKC, similar to the classical PCK 
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activator, TPA (Figure 4.8A); moreover, inhibition of PKC abolished zVAD-induced 
JNK, ERK, c-Jun activation (Figure 4.8B), and autocrine production of TNFα (Figure 
4.8C and 4.8D). Likewise, TPA alone also promoted autocrine production of TNFα 
and further enhanced zVAD-induced TNFα production (Figure 4.8C and 4.8D). 
Consistently, TPA was able to enhance, while inhibition of PKC perfectly suppressed, 
zVAD-induced necroptosis (Figure 4.8E). However, how zVAD activate PKC and 
which isoform of PKC is involved is still unclear. It appears that the activation of 
PKC is not related to caspase inhibition since QVD fails to activate PKC (Figure 
4.9A). On the other hand, zVAD and BocD (another pan-caspase inhibitor that can 
activate PKC and induce cell death) have been reported to possess non-specific 
inhibitory effect toward other proteases such as cathepsins, while QVD does not 
(Chauvier et al., 2007; Schotte et al., 1999). It is thus possible that PKC activation 
might be due to the off-target effect of zVAD and BocD. 
5.5 Dual role of zVAD during induction of necroptosis 
It is well-known that zVAD displays low or no cytotoxicity in most of cell lines 
in vitro (Van Noorden, 2001), why it can induces robust necroptosis in a limited 
group of cell lines, particularly in L929 cells?  
First, not all cells are equipped with the necroptosis signaling pathway, instead, 
only a small number of cell lines have been shown capable of undergoing necroptosis. 
For example, Jurkat cells with caspase-8 or FADD deficiency or in the presence of 
zVAD can undergo necroptosis in response to FasL or TNFα (Chan et al., 2003; 
Holler et al., 2000; O'Donnell et al., 2007); MEF cells are also competent for 
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induction of necroptosis when challenged with TNFα in the presence of zVAD (Byun 
et al., 2006). In contrast, many other cell lines such as HeLa and HepG2 cells lack the 
necroptosis machinery and thus caspase inhibition can rescue cell death and maintain 
long term survival (Zhang et al., 2004). Recent studies have shown that the RIP3, in 
addition to RIP1, is indispensible for induction of necroptosis; and its abundancy 
determines the cell’s ability for undergoing necroptosis (He et al., 2009; Zhang et al., 
2009). Among those necroptosis-competent cells, L929 cells have been widely 
employed to study necroptosis because, in this cell, robust necroptosis can be easily 
induced by TNFα (Vercammen et al., 1995). It is noteworthy that the necroptosis 
pathway normally will be triggered upon caspase inhibition (Declercq et al., 2009), 
suggesting the necroptosis pathway may represent a backup cellular demise route 
while the apoptosis acts as the default suicide pathway. However, L929 cells appear 
to utilize the necroptosis pathway as the first choice in response to TNFα 
(Vercammen et al., 1997). Thus far, the exact underlying mechanism remains to be 
elucidated. In short, equipment of the necroptosis pathway is the first premise for 
cells to be killed by zVAD. Secondly, the cells need to be capable of producing TNFα 
when stimulated with zVAD. Although the macrophage is the main source of 
endogenous TNFα production in vivo, several other cell lines are also capable of 
producing a low level of basal TNFα including lymphocytes, fibroblasts, neutrophils, 
endothelial cells, and several tumor cell lines (Vilcek and Lee, 1991). Moreover, 
whether zVAD can promote the autocrine production of TNFα in these cells is still an 
open question. Results from this study showed that zVAD dramatically promoted the 
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autocrine production of TNFα in macrophages (RAW264.7) but only induced 
marginal cell death (Figure 4.10). Therefore, certain other factors exist and contribute 
to zVAD-induced necroptosis in L929 cells.  
As presented in Chapter 4, although zVAD could promote TNFα transcription 
and production, the TNFα level is still very low (around 10 pg/ml, Figure 4.3B). 
Exogenous TNFα of such a concentration was found not cytotoxic (Figure 4.11B). 
Remarkably, when combining with zVAD, exogenous TNFα at such a concentration 
could induce necroptosis in L929 cells, but not in RAW264.7 cells (Figure 4.11), 
which is consistent with the earlier report (Vercammen et al., 1998a). Therefore, it is 
believed that zVAD performs a dual role to induce necroptosis in L929 cells: (i) to 
promote autocrine production of TNFα, and (ii) to sensitize L929 cells to 
TNFα-induced necroptosis. This notion is also supported and strengthened by the 
following observations from this study: (i) although TPA alone and QVD alone were 
not cytotoxic, combined treatment of TPA and QVD was able to kill the L929 cells 
efficiently (Figure 4.9B); and (ii) TPA alone was capable of inducing necroptosis 
when caspase-8 is silenced (Figure 4.9C). At present, the detailed mechanism 
underlying this sensitization effect is elusive. It has been reported that RIP1 can be 
cleaved by caspase-8 upon activation of the extrinsic apoptotic pathway (Lin et al., 
1999); thus inhibition of caspase may stabilize RIP1 and facilitate necroptosis. 
However, the importance of such a stabilization of RIP1 by caspase inhibition in 
promoting necroptosis is still questionable, because no evident reduction of RIP1 was 
observed in the complex with caspase-8 (He et al., 2009) and only a tiny amount of 
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RIP1 was cleaved by caspase-8 (Yu et al., 2004). Another hypothesis is that zVAD 
can directly interact with ANT in the mitochondria in response to TNFα and 
suppresses the ADP/ATP exchange, leading to generation of ROS and depletion of 
energy that result in necrotic cell death (Temkin et al., 2006). But this model fails to 
explain how CrmA sensitizes TNFα-induced necroptosis in L929 cells (Vercammen et 
al., 1998a). To elucidate the mechanism underlying the great sensitization effect on 
TNFα-induced necroptosis will be an interesting topic for future work. 
5.6 The mechanisms for autophagy to protect necrosis 
The results presented in Chapter 2, 3, and 4 demonstrate a cytoprotective role of 
autophagy against necrosis; however, how autophagy fulfill this task is largely 
unknown.  
In Chapter 4, we conducted experiments in attempt to elucidate the mechanism 
underlying the protective function of autophagy on zVAD-induced necroptosis. First, 
we found that starvation or rapamycin did not offer evident protection against TNFα- 
or TNFα+zVAD-induced necroptosis in L929 cells (Figure 4.12A), suggesting the 
pro-survival role of autophagy during zVAD-induced necroptosis may be achieved 
via modulation of autocrine production of TNFα. Strikingly, we found a higher level 
of activated c-Jun in Atg5-/- MEF than that in WT MEF (Figure 4.12C and 4.12D); 
moreover, knockdown of Atg5 and Beclin 1 in L929 cells also enhanced 
zVAD-induced c-Jun activation (Figure 4.12E). Consistently, the AP-1 activity was 
higher in Atg5-/- MEF than that in WT MEF (Figure 4.12F). Unfortunately, due to 
technical difficulties, we failed to detect the autocrine production of TNFα in MEF 
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cells and the difference in zVAD-induced TNFα production in the L929 cells with 
knockdown treatment was not convincing. Nevertheless, we believe that these data 
indicate an unexpected role of autophagy in promoting autocrine production of TNFα 
via upregulation of AP-1. Recently, autophagy has been found to implicate in 
regulation of cytokine production and secretion (Virgin and Levine, 2009). The cells 
with defects in autophagy can produce more proinflammatory cytokines such as 
IL-1β, IL-18 (Jounai et al., 2007; Saitoh et al., 2008; Tal et al., 2009). Such an 
anti-inflammatory function of autophagy has been proposed to link autophagy 
deficiency with tumorigenesis (Mathew and White, 2007) and immune disorders such 
as Crohn’s disease (Klionsky, 2009). Therefore, our preliminary data may provide a 
clue that autophagy can protect cell death by suppressing the autocrine production of 
TNFα. Indeed, this hypothesis has been supported by a recent study in which loss of 
allelic Beclin 1 leads to more TNFα production and secretion in mice livers and liver 
tumor cells (Mathew et al., 2009). 
Unlike apoptosis that is an ATP-consuming suicide process, necrosis is believed 
to be an outcome resulted from cellular energy depletion evidenced by the 
observation that necrosis can be experimentally reproduced by disrupting the cell’s 
ability to produce ATP (Zong and Thompson, 2006). Therefore, it appears reasonable 
that, by recycling cytosolic contents, autophagy can provide essential backup energy 
and nutrients for maintaining cell viability. This notion has been supported by a report 
that autophagy contributes to cell survival by maintaining the intracellular ATP level 
in Bax/Bak DKO MEFs in response to growth factor withdrawal (Lum et al., 2005a). 
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However, whether autophagy mitigates necrosis by providing energy recycling in the 
models in this study is unclear and requires further investigation. 
5.7 Conclusions 
In this study, we investigated the role of autophagy in necrosis using multiple in 
vitro necrosis models including zVAD-induced necroptosis in L929 cells, 
MNNG-induced PARP-1-mediated necrosis in L929 cells, and H2O2-induced 
PARP-1-mediated necrosis in Bax/Bak-/- DKO MEF cells. The study consists of 
following four parts: (i) to study the role of autophagy in zVAD-induced necroptosis; 
(ii) to investigate the regulatory role of PI3K-Akt-mTOR signaling axis in modulation 
of autophagy and necrosis; (iii) to elucidate the cell death mechanism during 
zVAD-induced necroptosis. The major findings are: 
1. Autophagy plays a cell survival role during zVAD-induced necrosis in L929 
cells. 
 Induction of autophagy protects zVAD-induced necrosis in L929 cells. 
 Suppression of autophagy enhanced zVAD-induced necrosis in L929 
cells 
 zVAD suppresses autophagy via suppression of lysosomal function by 
inhibition of cathepsins enzyme activity 
2. Activation of PI3K-Akt-mTOR axis promotes necrosis in several necrosis 
models via suppression of autophagy. 
 Insulin enhances necrosis in these models in full growth medium 
 Insulin and amino acid abrogate the protective effect of starvation on 
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necrosis in these models 
 The pro-death function of insulin and amino acids depends on 
activation of mTOR and subsequent suppression of autophagy 
3. PKC-MAPKs-AP-1 mediated autocrine production of TNFα is the death 
mechanism in zVAD-induced necroptosis in L929 cells 
 zVAD-induced necrosis in L929 cells is necroptosis that depends on 
autocrine TNFα 
 zVAD promotes autocrine production of TNFα at transcription level 
 AP-1, but not NF-κB, mediates zVAD-induced TNFα transcription 
 zVAD-induced AP-1 activation is mediated by JNK and ERK 
 PKC mediates zVAD-induced JNK and ERK activation 
 zVAD plays a dual role in mediating necroptosis in L929 cells 
 Defects in autophagy enhances AP-1 activity 
Taken together, we demonstrated in this study that autophagy plays a 
cytoprotective role in zVAD-induced necroptosis as well as in two PARP-1-mediated 
necrosis models. Consistently, we provided compelling evidence showing that 
insulin-leucine is able to promote necrosis via activation of PI3K-Akt-mTOR 
pathway and consequent suppression of autophagy. More importantly, we identified 
the zVAD-promoted autocrine production of TNFα as the cell death signal in 
zVAD-induced necroptosis, and the TNFα production is mediated by 
PKC-MAPKs-AP-1 pathway. Finally, we provided a clue indicating that autophagy 
may mitigate zVAD-induced necroptosis via suppression of AP-1 activity. These 
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major findings are illustrated in Figure 5.1. At present, the exact role of autophagy in 
cell death is still not fully elucidated. Therefore, data from this study provide some 
novel insights into the intricate relationship between autophagy and cell death, in 
particularly necrotic cell death, a form of PCD has been increasingly appreciated of 
its implications in human health and diseases. 
 
 
Figure 5.1 Autophagy promotes cell survival during necrosis and autocrine TNFα 
mediates zVAD-induced necrosis in L929 cells 
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